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Abstract 
 Germinal center (GC) responses are responsible for the protection provided by 
immunizations but can also drive autoimmunity. B and T cells collaborate in the GC to 
target the same antigen (Ag) to inform B cell differentiation; however, the properties of 
Ags differ substantially in autoimmunity and foreign-Ag driven immunity. Currently, it is 
not well understood how properties of the Ag itself influence the initiation or progression 
of GC responses, limiting our ability to develop effective vaccinations and predict the 
progression of autoimmune responses. The purpose of this thesis is to assess how GC 
responses initiate and progress when immunizing with an autoAg relative to a model 
foreign-Ag. It was hypothesized that autoreactive GCs would be relatively short-lived and 
less productive than foreign-Ag driven GCs due to limiting properties of the autoAg. To 
address this hypothesis, we developed a modular protein expression system to purify 
large amounts of myelin oligodendrocyte glycoprotein (MOG), a commonly targeted 
autoAg in Multiple Sclerosis (MS), and streamlined the modification of the MOG 
protein’s properties. Relative to immunization with a model foreign-Ag, immunization 
with MOG induces a short-lived GC that collapses early forming a large numbers of 
memory B cells. Memory B cells generated from the MOG-induced GC are capable of 
participating in secondary GCs, however, these memory cells are short-lived resulting in 
a short window in which MOG-specific memory B cells can be engaged. The progression 
of the MOG-induced GC is then shown to be limited by low T cell Ag-affinity. A 
possible explanation for how Ag-properties affect GC progression, is that Ag-properties 
influence how B and T cells communicate with each other. To address this hypothesis, 
reporters capable of monitoring the activation status of B and T cells were generated 
although, attempts to generate mice carrying these reporters were unsuccessful. Overall, 
these results confirm that properties of Ags affect the progression of GC responses and 
that the MOG-induced GC is limited by properties of the MOG autoAg. These results 
have important implications for future vaccine design but also gives insight into how 
autoreactive B cells may expand in MS. 
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Chapter 1  
1 Introduction 
 Our bodies are exposed to pathogens every day of our lives requiring the 
combined efforts of the innate and adaptive immune systems to control infections. In the 
modern world, the control of infectious diseases such as smallpox and polio has been 
greatly facilitated through the use of vaccinations that induce protective antibody 
responses by stimulating B cells from the adaptive immune system. Vaccinations are 
invaluable in modern healthcare (1) yet there are still many diseases, such as human 
immunodeficiency virus and malaria, that we have difficulty generating effective B cell 
responses against due to insufficient understanding of how the immune system adapts 
itself to properties of the immunizing antigen(s) (Ag) (2, 3).  
 Nonetheless, while the promotion of B cell responses may be beneficial in the 
context of immunity against pathogens, it is problematic in the context of autoimmunity. 
Indeed, the induction of B cell responses needs to be regulated heavily as B cells can 
target Ags within our own bodies, known as autoAgs, resulting in the development and 
progression of autoimmune diseases (4). Typically, the B cell’s contribution to disease 
has been attributed to the production of autoantibodies that facilitate the destruction of 
host tissue. However, evidence of B cells playing additional roles beyond antibody 
production have created a great deal of interest in understanding how new subsets of B 
cells are generated and how they influence ongoing autoimmune responses (5). Thus, not 
only is there a need to better understand how B cell responses develop towards 
pathogens, but a better understanding of factors that limit B cell responses directed 
against our own bodies is required. In this thesis, I will address both of these needs by 
investigating the basic rules that inform B cell differentiation in immune responses 
directed towards a model autoAg and a model foreign-Ag. 
1.1 B and T cells in immunity and autoimmunity 
 I will start by discussing the essential properties of B cells that define how these 
cells participate in immune responses and how this may change in autoimmunity. In 
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addition, I will similarly discuss another cell of the immune system, called a T cell, as the 
B cell responses I will be studying in the thesis involve a necessary collaboration of these 
two cells types (this will be discussed in more detail later). 
1.1.1 The generation and function of Ag-specific receptors on B and T cells 
         As B and T cells develop in the bone marrow and thymus, respectively, they 
rearrange genomic DNA through a random process to generate unique receptors specific 
to each of these cells (6, 7). For B cells, they recombine DNA to generate a B cell 
receptor (BCR) that is unique to each B cell clone. The BCR can be used to capture or 
target a specific Ag, which can consist of any unique 3-dimensional (3-D) surface that 
can be recognized by a BCR (8, 9). The recognition of Ags using the BCR is essential for 
B cells to act as antigen presenting cells (APCs) and antibody secreting cells (ASCs) and 
it is through these functions that the B cell contributes to immunity.  
 T cells similarly generate T cell receptors (TCRs) that are again unique to 
particular T cell clones and recognize a specific Ag (8). However, unlike B cells, they do 
not recognize Ag directly, instead they require APCs to collect and process full-length 
proteins into smaller fragments, often referred to as peptides or peptide fragments. These 
small peptide fragments are then loaded onto a specialized protein complex called the 
major histocompatibility complex (MHC). The peptide is loaded into a binding cleft on 
the MHC where molecular interaction between the MHC and peptide determine the 
efficiency of peptide loading (10). Once loaded, the peptide can be recognized in the 
binding cleft by TCR molecules. Classically, αβ-T cells (that rearrange α and β TCR 
chains) have been divided in CD4+ and CD8+ T cells that recognize Ag presented on 
MHC class II and MHC class I molecules, respectively (11). The ability of T cells to 
recognize Ags through their TCR is essential for T cells to participate in the immune 
response by either coordinating the activity of other cells (12, 13) or by acting as 
cytotoxic cells to kill their targets (14). Although there are additional subsets of T cells 
beyond αβ CD4+ T cells, for the purposes of this thesis, I focus on these T cells as they 
are the primary drivers of B cell responses (15). 
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 Collectively, the B and T cell repertoires of Ag-specificity can recognize an 
almost unlimited number of Ags (16). Although this is highly beneficial for the immune 
system’s ability to recognize pathogens, this is also problematic as many of the BCRs and 
TCRs generated also recognize autoAgs and can participate in autoimmunity. To limit 
autoimmunity, the immune system has several systems that act on B and T cells during 
development (central tolerance) that shape the peripheral B and T cell repertoires. One 
important mechanism for controlling autoreactive B and T cell responses is to limit the 
production of B and T cells that recognize autoAgs with high Ag-affinity, a key property 
of BCRs and TCRs that influences several aspects of B and T cell biology. Antigen-
affinity is a measure of how strongly a BCR or TCR forms a physical contact with its 
target Ag. Antigen-receptor affinity affects not only the capacity of B and T cells to 
execute their effector functions (17, 18), but of key interest to this thesis, it also affects B 
and T cell activation and differentiation (17, 19). Thus, it is likely that the cumulative Ag-
affinities of the B and T cell receptors available in the periphery of the body can in large 
part influence how an immune response initiates and progresses. Indeed, the idea that Ag-
receptor affinity affects the progression of B cell responses will be addressed in this 
thesis. In this next section, I will discuss how tolerance mechanisms bias the peripheral 
autoreactive B and T cell repertoires towards lower Ag-affinities and why this would not 
occur for foreign-Ag specific B and T cell repertoires. 
1.1.2 The influence of tolerance on autoreactive B and T cell receptors 
 As B and T cells progress through their development, they undergo a process 
known as negative selection that is responsible for purging autoreactive B and T cells (6, 
20). Upon presentation of autoAgs during negative selection, developing B and T cells 
respond by triggering tolerance pathways that affect B and T cells differently. The fate of 
B cells upon recognizing an autoAg is to undergo receptor editing, wherein the BCR 
locus undergoes additional recombination events in an attempt to generate a new BCR 
that no longer recognizes autoAgs (21). In the event that a B cell cannot recombine and 
generate a non-autoreactive BCR, the B cell is induced to undergo apoptosis (22). Central 
tolerance of B cells successfully eliminates the vast majority of autoreactive B cells (6, 
23, 24), however, approximately 20-40% of the peripheral B cell repertoire remains 
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autoreactive (25) although they typically recognize autoAgs with a low Ag-affinity (25, 
26). Additionally, many of the leftover autoreactive B cells are anergic (a state of reduced 
responsiveness to Ag-receptor signaling) (27). Anergic B cells typically have a shorter 
life-span than non-anergic B cells leading to increased bias against the persistence of 
autoreactive cells (28-30). Altogether, central tolerance eliminates high-affinity 
autoreactive B cells thereby biasing the peripheral autoreactive B cell repertoire to B cells 
of low enough Ag-affinity to pass through central tolerance. 
 Similarly, autoreactive T cells undergo negative selection by exposure to autoAg 
in the thymus. In turn, the fate of an autoreactive T cell is determined by its Ag-affinity 
(31). T cells that recognize autoAgs with high-affinity are induced to undergo apoptosis, 
T cells that have low-affinity for autoAgs are unaffected, and T cells recognizing autoAgs 
with intermediate-affinity are induced to become regulatory T (Tregs) cells (32). 
Regulatory T cells are important as these intermediate-affinity cells would normally 
potently induce autoimmune disease but are instead, functionally programed to become a 
subset of T cells that potently inhibits autoimmune responses (33, 34). Overall, central 
tolerance of T cells effectively removes higher-affinity autoreactive T cells that would 
otherwise potently induce autoimmune disease by either deleting or converting them into 
regulatory cells, leaving a relatively smaller pool of low-affinity autoreactive T cells. 
 As foreign-Ags are not expressed in organs where B and T cells are developing, 
tolerance mechanisms do not appreciably affect the Ag-affinities of foreign-Ag specific B 
and T cell repertoires. Thus, a major difference between foreign-Ag specific and autoAg-
specific B and T cells, is the abundance of high-affinity B and T cells in the foreign Ag-
specific repertoire (35). Based upon the bias of autoreactive B and T cells towards low 
Ag-affinities, and given that Ag-affinity affects B and T cell activation, it is likely that 
the low Ag-affinities of autoreactive B and T cells will limit any immune response 
directed against protein autoAgs. Thus, I hypothesize that B cell responses, in the form of 
germinal center (GC) responses that are dependent on collaboration between B and T 
cells, will be short-lived and generally less productive than foreign-Ag induced GC 
responses as a result of the low Ag-receptor affinities of autoreactive B and T cells. 
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1.2 B cell responses in Multiple Sclerosis 
 Despite tolerance mechanisms limiting the capacity of autoreactive B and T cells 
to participate in autoimmune responses, it is still possible to engage these cells to do so. 
In this section, I will describe the autoimmune disease MS that incorporates autoreactive 
B and T cells into its pathology. 
1.2.1 Multiple Sclerosis and experimental autoimmune encephalomyelitis 
 Multiple Sclerosis is an autoimmune disease where the myelin sheath surrounding 
neurons in the central nervous system (CNS) is targeted for destruction by the immune 
system. Damage to the CNS results in cognitive and physical disabilities that vary 
depending on the region of the brain or spinal cord that has been damaged (36). Studies 
looking for genetic signatures associated with MS have identified predominantly genes 
that are associated with the immune system suggesting the immune system plays a key 
role in the initiation of MS (37). Historically, MS has been thought of as a CD4+ T cell 
mediated autoimmune disease as the induction of a myelin-specific CD4+ T cell response 
is the minimum requirement to induce CNS autoimmunity in animals (38). Collectively, 
animal models of CNS autoimmunity are known as experimental autoimmune 
encephalomyelitis (EAE) (39). Typically, EAE is induced by immunizing animals with 
short peptide fragments corresponding to immunodominant CD4+ T cell epitopes derived 
from one of three major components of the myelin sheath: MOG, proteolipid protein, and 
myelin basic protein. The disease course of EAE follows a predictable course of 
ascending paralysis in mice and is characterized by the infiltration of T cells, B cells, and 
various myeloid cells near regions of demyelination in the spinal cord and brain (40). As 
MS research has evolved additional cells beyond CD4+ T cells have emerged as 
important mediators of disease including cells of the myeloid lineage, CD8+ T cells and, 
of key interest to this thesis, B cells.  
1.2.2 Role of the B cell in Multiple Sclerosis 
 B cells had originally been thought to be of limited importance to disease 
progression because the induction of a CD4+ T cell response was the minimum 
requirement to induce EAE and B cell-deficient mice develop worse EAE than wild type 
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mice (41). These results were misleading however, as B cell deficient mice develop 
worse EAE as a result of lacking IL-10/IL-35 expressing regulatory B (Breg) cells that 
potently inhibit T cell responses (42-44). Interest in B cells in MS was reignited when the 
depletion of B cells in MS patients using an anti-CD20 antibody was shown to be one of 
the most effective treatments for MS currently available (45, 46). Indeed, although Bregs 
can be found in MS patients (47), it is now clear that the B cell compartment is overall 
pro-inflammatory in MS and animal models (48, 49). Interestingly, CD20 is expressed on 
all human B cell subsets except antibody-secreting plasma cells and the therapeutic 
benefit of the anti-CD20 monoclonal antibodies occurs before any decrease in serum 
antibody levels suggesting that non-plasma cell B cells may be the primary contributor to 
MS (50, 51).  
 Engaging B cells to participate in immune responses directed against protein Ags, 
such as those that are targeted in MS, typically occurs by inducing a GC, a structure that 
normally forms in secondary lymphoid organs such as the spleen, peyers patches, or 
lymph node (LN) (52). Within the GC, B cells can acquire high-affinity BCRs by 
mutating their genomes, in particular the BCR locus, using enzymes such as activation-
induced cytidine deaminase and uracil-DNA glycosylase in combination with DNA 
repair pathways to mutate nucleotides in the BCR locus, a process known as somatic 
hypermutation (SHM) (53). Nucleotide changes within the BCR then translate into amino 
acid changes in the BCR that can affect the BCRs ability to bind Ag. Activation-induced 
cytidine deaminase is also involved in another process where B cells undergo 
immunoglobulin class-switch recombination (CSR) where IgM and IgD BCR isotypes 
are switched for IgG, IgE, and IgA BCR isotypes (54). Class-switching is important as 
BCR isotype affects the effector functions of secreted antibodies and also affects Ag-
induced signaling through the BCR (55-57). Overall, the GC supports these two 
processes leading to the production of high-affinity and class-switched B cell subsets that 
contribute to potent long-term immunity (58). Thus, if B cells are being engaged in an 
Ag-specific manner in MS, we would expect that there should be evidence of myelin-
specific B cells that have undergone CSR and SHM.  
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 In support of the idea that myelin-specific B cells are stimulated in MS, high-
affinity MOG-specific IgG antibodies can be found in the serum of 67% of early onset 
pediatric MS patients (59) and 20-42% of MS patients later in disease (60-62). 
Furthermore, at the later stages of disease, IgG-antibodies directed against other myelin-
Ags are commonly seen (63, 64). As these antibodies are class-switched and of high-
affinity, this is highly suggestive that the plasma cells that generated these antibodies 
were derived from GCs. Myelin-specific B cells have also been seen to contribute to EAE 
in several different models. The contribution of myelin-specific B cells to EAE is 
partially through antibodies (65), however, it is clear that myelin-specific B cells also 
contribute to the initiation and progression of EAE independently of antibody secretion 
(49, 66, 67). Thus, there is evidence of myelin-specific GCs occurring in MS and there is 
evidence of myelin-specific B cells contributing to the pathology of EAE suggesting 
myelin-specific B cells in MS may also contribute to MS pathology. 
 Germinal centers directed against myelin-Ags could potentially occur within the 
deep cervical LNs as they are connected to the lymphatic drainage of the brain and thus, 
make autoAgs available to autoreactive B and T cells (68-70). Consistent with the idea 
that B cell responses in the deep cervical LNs are contributing to MS pathology, there is 
evidence that clonally expanded B cells in the deep cervical LNs are clonally related to B 
cells found within the CNS of MS patients (71, 72). In particular, analysis of SHM in B 
cells derived from the deep cervical LNs, peripheral blood, and cerebral spinal fluid of 
MS patients identified B cell clones that were derived from the same GC. Thus, beyond 
there being evidence of myelin-specific GCs in MS, there is also evidence of GCs 
occurring outside of the CNS that are generating Ag-experienced B cells that are entering 
the CNS.  
 A key assumption in the literature is that the B cell clonal relationships found 
between the periphery and the CNS are due to myelin-specific B cells proliferating in the 
periphery and entering the CNS. However, despite the evidence suggesting that GC-
derived myelin-specific B cells contribute to the pathology of MS, no study to date has 
characterized how a GC response directed against a myelin autoAg would initiate or 
progress. Furthermore, as no one has studied myelin-specific GC responses, we also do 
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not have a good understanding of what immune cells are generated from myelin-specific 
GCs or the properties of those cells. Indeed, based upon what is known about B and T 
cell activation and the properties of autoreactive B and T cells (section 1.1), it is likely 
that a GC directed against a myelin-autoAg will not progress in the same fashion as 
foreign-Ag induced GCs. In this thesis, I address this need by studying GC responses 
directed against the myelin protein, MOG, which is commonly used to induce EAE. In 
the next sections, I will describe what is currently known about GCs and how Ag-
properties affect GCs. 
1.3 Germinal center responses 
 The initiation and progression of GC responses has been classically defined in 
context of GCs in LNs or the spleen. Germinal center responses proceed similarly in LNs 
and the spleen despite being structurally different (73, 74). However, the experiments in 
this thesis focus exclusively on LNs and thus, I will only describe the GC response in the 
LN. Lymph nodes are found throughout the body where they collect excess lymph from 
surrounding tissues and process pathogens/debris/Ags that filter through the LN to 
activate Ag-specific B and T cells (75) (Figure 1.1). Lymph nodes have a thick outer 
capsule that forms a conduit for incoming lymph in conjunction with the subcapsular 
sinus. Lymph filters through the subcapsular sinus into the B cell follicle that is located 
just below the subcapsular sinus (73). B cells reside in the B cell follicle where they can 
interact with Ags draining through the B cell follicle through a variety of mechanisms 
that will be described in more detail in section 1.3.1. Below the B cell follicles, CD8+ and 
CD4+ T cells reside in the T cell zone that serves as the site of initial T cell activation. 
Then, at the absolute center of the LN, are the medullary cords where macrophage and 
plasma cells/plasmablasts reside. After lymph has passed through these sites, it is 
collected in the efferent lymphatic duct and flows through the lymphatic system until it 
connects back to circulating blood through the thoracic duct (75). These microstructures 
are essential in directing B and T cells during immune responses and these structures will 
be discussed in detail in the following sections. 
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Figure 1.1. Summary of developing germinal center responses. 
Immune responses in LNs start when mature Ag-presenting dendritic cells and soluble 
Ags flow into the LN. (A) The Ag-specific T cell response is initiated through 
interactions with mature Ag-presenting dendritic cells (76). (B) The B cell response is 
initiated when B cells engage their Ag with their BCR, resulting in their activation (77). 
(C) When these two events occur, approximately 1 day post-immunization, activated B 
cells and pre-T follicular helper (pre-TFH) cells will migrate to the periphery of the B cell 
follicle and form cognate interactions (78). These cognate interactions are responsible for 
driving B cell differentiation into memory B cells, antibody-secreting plasmablasts, and 
differentiation into GC B cells as well as finishing TFH cell differentiation. (D) 
Approximately 4 days post-immunization, TFH cells and GC B cells then migrate into the 
B cell follicle and seed a new GC where they again form cognate interactions. These 
interactions are responsible for GC maintenance and differentiation of GC B cells into 
antibody-secreting plasma cell subsets (E) and memory B cells which can participate in 
secondary GC responses if induced to do so (F) (79). 
 
  
10 
 
 
 
  
11 
 
 
1.3.1 The initiation of B and T cell responses 
 At the initiation of immune responses, Ags flow into LNs through lymphatic 
vessels which permeate surrounding tissues. Once Ag has arrived at the LN, it can diffuse 
across the subcapsular sinus through small pores that allow small Ags to cross this layer. 
Alternatively, B cells can actively collect Ag by extending membrane projections into 
small channels carrying lymph through the B cell follicle (80). Larger Ags can be 
actively collected in LNs by subcapsular sinus macrophage that shuttle complement 
associated Ag from the subcapsular sinus into the B cell follicle (81). Moreover, dendritic 
cells (DCs) that have collected Ag from the periphery of the body can exocytose whole 
Ag into the B cell follicle (82). Through the BCR, B cells can recognize soluble Ags 
directly in extracellular fluid (Figure 1.1B) or can recognize Ag deposited on specialized 
follicular dendritic cells (FDCs), which collect Ags and are found at the center of the B 
cell follicle (83). The FDC is important at this early stage of the immune response as they 
retain Ags for long periods of time and can also collect insoluble or low affinity Ags that 
B cells may have more difficultly responding to (84).  
 B cell receptor recognition of Ags results in the activation of B cells, culminating 
in gene expression changes and altered surface expression of co-stimulatory molecules 
that are important for the next stage of the B cell response, the pre-GC time point (see 
section 1.3.2). This next stage of the B cell response is initiated when B cells upregulate 
CCR7, a chemokine receptor, which directs cells to migrate towards the T cell zone as a 
result of the expression of the CCL19 and CCL21 ligands by follicular reticular cells in 
the T cell zone (85, 86). Additionally, B cells upregulate EBI2, a chemotactic receptor 
that directs cells towards the periphery of the B cell follicle (87, 88) due to the expression 
oxysterols at the periphery of the B cell follicle (89). This change in chemotactic receptor 
expression ultimately directs B cells to move towards the border of the B cell follicle and 
T cell zone where B cells await a cognate T cell partner to continue their differentiation 
(77). 
 The T cell response occurs simultaneously with the B cell response. However T 
cells are activated through an entirely different process. T cell responses are initiated by 
resident DCs that collect Ags in the periphery of the body. Upon encountering a pathogen 
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and/or a signal indicating danger/tissue damage, DCs will begin to differentiate into 
mature DCs. These DCs continue to mature and their activation commences as they 
migrate from the periphery of the body into draining LNs and localize to the T cell zone 
where they present Ags on MHC molecules to T cells (76). If a CD4+ T cell recognizes 
one of the Ag peptides being presented on the DC, the T cell and the DC will form a 
stable and long-lived interaction that is responsible for inducing T cell proliferation and 
instructing T cell differentiation (Figure 1.1A) (90). The differentiation of CD4+ T cells is 
instructed by a combination of cytokines and T cell Ag affinity that influence the choice 
to become the various T helper subsets such as T helper 1, T helper 2, T helper 17 cells 
and other T cell subsets (91-93). One of these other subsets, the pre-TFH cell, is essential 
for the initiation and maintenance of the GC response and thus, is of the greatest 
importance to this thesis (15). Pre-TFH cells undergo a transcriptional reprogramming as 
part of their differentiation involving the expression of the transcription factor, Bcl6, a 
key regulator directing TFH cell differentiation. The expression of Bcl6 is essential for 
expressing the co-stimulatory receptors and ligands that are of critical importance to the 
next stage of the immune response, the pre-GC time point (94). Similar to B cells, pre-
TFH cells also modify their expression of chemokine receptors by upregulating CXCR5, a 
chemokine receptor that directs cells towards the B cell follicle (88) as a result of 
CXCL13 expression by follicular stromal cells and FDCs in the center of the B cell 
follicle (95). Ultimately, this results in their localization to the border of the B cell follicle 
and the T cell zone (78, 96). Once activated B cells and pre-TFH cells meet at the B cell 
follicle-T cell zone border, the pre-GC time point begins. 
1.3.2 The pre-germinal center time point 
 The pre-GC time point occurs approximately 1-1.5 days post-immunization and 
begins once activated B cells begin to form physical interactions with pre-TFH cells. 
During this time point, cognate B and T cells interact via their MHC class II and TCR 
molecules, co-stimulatory/co-inhibitory receptors, and a variety of integrins whose 
signaling is incorporated into decisions that result in cell differentiation, proliferation, or 
initiation of cell death. For a more detailed description of these receptors and the timing 
of their expression, see section 1.8. Interactions between B and T cells occur along the 
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border between the B cell follicle and the T cell zone up to a region between B cell 
follicles known as the interfollicular zone (78) (Figure 1.1C). Pre-GC interactions 
between B and T cells are typically long-lived in nature, potentially lasting hours in 
length (78, 97). During these interactions signals are exchanged between cognate B and T 
cells that are essential for the pre-TFH cells to fully differentiate into T follicular helper 
(TFH) cells, which are responsible for GC maintenance once they form (98). In addition to 
TFH cell differentiation, pre-GC B-T interactions have a profound effect on the way that 
the B cell response will progress. 
 At the pre-GC stage, B cells can differentiate into several different B cell subsets: 
low-affinity short-lived plasmablasts, GC-independent memory B cells, and GC B cells. 
Short-lived plasmablasts are a type of ASC that are responsible for generating low-
affinity IgM antibodies early in the immune response to help with infections, before high-
affinity antibodies are generated later in the GC. Whereas short-lived plasmablasts 
contribute to the early immune response, memory B cells contribute to long-term 
immunity. Memory B cells cease proliferation and become quiescent once differentiated 
and instead acquire a naïve-like phenotype and rejoin the circulating B cell pool (99, 
100). If there is a second challenge with the same Ag, memory B cells can be stimulated 
to participate in secondary responses by quickly differentiating into plasma cells or GC B 
cells, accelerating the development of secondary GCs and quickly reinforcing antibody 
titers (100) (Figure 1.1F). The differentiation of GC B cells marks the end of the pre-GC 
phase as upon differentiation they migrate into the B cell follicle, along with TFH cells, 
and are responsible for seeding the GC (78, 101, 102). (Figure 1.1D).  
1.3.3 The germinal center 
 The GC is an organized collection of cells, predominantly GC B cells, TFH cells, 
FDCs, and other minor populations of cells which form at the center of B cell follicles. 
From the GC, several B cell subsets are generated: GC-derived memory B cell subsets, 
plasma cells, and long-lived plasma cells (58). The GC is an environment optimized for 
inducing SHM and CSR within GC B cells for the purposes of driving GC B cells to 
acquire high-affinity class-switched BCRs (53, 103). Thus, a GC B cell’s affinity for Ag 
and their BCR isotype is not fixed in a GC.  
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 However, inducing CSR and SHM can generate non-functional BCRs or BCRs 
that recognize their Ag with a lower-affinity (104, 105). Thus, CSR and SHM in GC B 
cells needs to be complemented by selective pressure to expand functional high-affinity B 
cell clones and eliminate low-affinity or non-functional B cell clones. This is the role 
played by the TFH cell. Much like the pre-GC time point, it is physical interactions 
between GC B cells and TFH cells within the GC that are responsible for selecting GC B 
cells to continue in the GC and for directing B cell fate choices. Unlike pre-GC B and T 
cell interactions however, GC interactions are much shorter in nature but are nonetheless 
essential for GC maintenance (78, 106). These interactions are ultimately what controls 
the GC response as a whole and in the following sections I will describe how T cells 
influence the fate choices B cells make during GC responses. Furthermore, I will discuss 
the properties of GC B cells, ASCs, memory B cells, and TFH cells in more detail. 
1.4 Germinal center B cells 
 GC B cells are distinguished from naive B cells or memory B cells based upon 
their expression of the following markers in mice: GC B cells are Bcl6+, CD38low, 
CD95high, GL-7+, and IgD- (107). Properties associated with GC B cells include relatively 
high levels of apoptosis, high levels of proliferation, and active SHM. Below, I will 
describe in more detail how GC B cells are maintained in immune responses and factors 
influencing their differentiation. 
1.4.1 The light and dark zones of the germinal center 
 GC B cells exist in two major phases, a light zone (LZ) phase and a dark zone 
(DZ) phase (Figure 1.2A). These structures are essential and unique as the disruption of 
either of these structures impacts GC maintenance, SHM, and the production of B cell 
subsets (108). The LZ of the GC is where FDCs are found and TFH cells concentrate 
(109). In this zone, GC B cells are referred to as centrocytes and compete with each other 
for the limiting resource in the GC, Ag, which is concentrated on FDCs (110). The ability 
of a particular centrocyte to obtain Ag is determined by their affinity for Ag. The 
acquisition of Ag leads to centrocytes internalizing and processing Ag for presentation on 
MHC class II molecules (17). The amount of Ag presented by centrocytes is directly 
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proportional to the interaction time they secure with TFH cells and by extension the 
amount of costimulatory signaling they receive from TFH cells (111-113). Receiving TFH 
cell signals are important for influencing the differentiation of GC B cells (this will be 
further discussed in subsequent sections), but also because TFH cell signals are 
responsible for selecting centrocytes to enter the DZ of the GC. To enter the DZ, GC B 
cells upregulate the chemokine receptor CXCR4 that binds the chemokine CXCL12 
secreted by follicular reticular cells in the DZ (108, 114). The presence of CXCL12 in the 
DZ attracts CXCR4+ GC B cells, which are now referred to as centroblasts. Once in the 
DZ, centroblasts downregulate surface BCRs and costimulatory molecules before 
undergoing SHM and CSR (58).  
 As centroblasts are mutating their BCRs, they are also undergoing extensive 
proliferation (115, 116). The number of rounds of proliferation and the length of time that 
a centroblast stays in the DZ are thought to be influenced by their interactions with TFH 
cells that occurred in the LZ (115, 117). As the length of time in the DZ is directly 
proportional to the amount of SHM a centroblast will undergo (115), the retention in the 
DZ of the GC is advantageous for acquiring a high-affinity BCR. Additionally, as 
centroblasts proliferate, they are also under pressure to undergo apoptosis (118), a 
process that is thought to be inhibited through signals acquired from the TFH cell (111). 
Class-switch recombination also occurs in the DZ of the GC and, although CSR does not 
affect the Ag-affinity of a BCR, switching to other BCR isotypes can modify intracellular 
signaling in B cells and can affect the fate choices and competitiveness of B cells in the 
GC (56, 119, 120). Thus, a combination of SHM and CSR can influence the 
competitiveness of individual B cell clones.  
 After a period of time, the centroblast will complete its proliferation and will 
begin expressing its newly mutated BCR and costimulatory molecules, while 
downregulating CXCR4 allowing it to enter the LZ of the GC where it will again 
compete for Ag. This process of continuously cycling between the LZ and DZ of the GC 
is generally known as the cyclic re-entry model of the GC. Overall, the combination of 
selection pressures to enter the DZ, apoptosis, and proliferation serve to expand the 
population of high-affinity B cell clones over continuous rounds of LZ-DZ transitions 
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ultimately resulting in a slow progression in the GC towards higher-affinity B cells (79) 
(Figure 1.2B). Indeed, the starting affinity of B cells entering the GC can increase by a 
million fold by the end of the GC (121, 122) where these high-affinity B cell clones 
typically become the primary B cell clone in the GC when they emerge (123). As GC B 
cells are the precursor to all other GC-derived B cell subsets, and GCs can potentially 
continue for months (124, 125), retention and expansion of a particular B cell clone 
within the GC will lead to that particular B cell clones progeny dominating the products 
of a GC as it continues. This is further complicated as certain subsets of B cells emerge 
from the GC at different times. Memory B cells emerge from the GC first, with optimal 
memory B cell production typically lasting ~22 days post-immunization; thereafter 
plasma cell differentiation tends to be favored (126). Consequently, retention in the GC 
not only affects the continued production of a particular B cell clone, but also the 
differentiation of that clone into particular B cell subsets that are favored in the later 
portions of the GC response. 
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Figure 1.2. B cell differentiation and selection in the light and dark zones of the germinal 
center. 
(A) GC B cells in the LZ of the GC are in constant competition with one another to 
acquire Ag sequestered on FDCs (110). Germinal center B cells that do not acquire Ag do 
not secure interactions with TFH cells and persist in the LZ promoting memory 
differentiation (127). B cells that successfully compete for Ag and interact with TFH cells 
will be selected to transition into the DZ of the GC (111) or alternatively may begin 
plasmablast/plasma cell differentiation if they receive strong BCR signaling (128). GC B 
cells that transition into the DZ upregulate CXCR4 and downregulate surface receptors 
associated with B and T cell interactions (58, 108). Once in the DZ, B cells begin to 
proliferate at an increased rate (115) and may also undergo apoptosis depending on their 
resistance to apoptosis determined by T cell help acquired in the LZ (118). As this is 
occurring, GC B cells that survive mutate their BCR through SHM and CSR in an 
attempt to generate a new higher-affinity and class-switched BCR before transitioning 
back to the LZ (58). The transition back to the LZ is associated with the downregulation 
of CXCR4, upregulation of costimulatory molecules and their newly mutated BCR. (B) 
The fates of low, medium, and high-affinity GC B cells in the GC are summarized based 
upon the model provided above.  
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1.4.2 Germinal center B cell differentiation 
 The GC status of B cells is a temporary and unstable state that is maintained by 
the expression of the master transcription factor, Bcl6 (129). As GC B cells are an 
intermediate, the eventual fate of a GC B cell is death or differentiation that is determined 
by the expression of transcription factors. The expression of Bcl6 suppresses Blimp-1 
expression, where Blimp-1 is the master transcription factor directing plasma cell 
differentiation, and thus secures the GC B cell identity (130, 131). GC B cell 
differentiation is not thought to be directly antagonistic with memory B cell 
differentiation as the expression of Bach2, a transcription factor that has recently 
emerged as an important driver in memory differentiation, is not directly antagonistic 
with Bcl6 (127).  
1.5 Memory B cells 
 The study of memory B cells in mice is complicated by the lack of a universal 
marker to differentiate memory B cells from naïve B cells (132). This is further 
complicated by a paucity of knowledge on B cell subsets as all non-plasma cell, non-GC 
B cell, and non-naïve B cells are grouped together as memory B cells. This is in part due 
to the definition of memory B cells typically used in studies: a B cell that has participated 
in a B cell response that has since acquired a quiescent, naïve-like phenotype. True 
memory B cells, however, should also show evidence of: (1st), persistence over time; 
(2nd), attaining a quiescent state; (3rd), specificity for a known Ag; and lastly, the ability 
to respond in secondary immune responses (100). Thus, without a universal marker to 
identify all memory B cells in mice, demonstration of memory requires satisfying the 
above criteria. 
1.5.1 Memory B cell subsets 
 Historically, memory B cells have been defined as class-switched naïve-like B 
cells as class-switching only occurs after B cells have participated in an immune 
response, but also because it was easy to identify class-switched B cells. More recently it 
was discovered that many memory B cells are IgM+ (133) and indeed not all memory B 
cells require the GC as many differentiate before GC formation (126, 134). Studies 
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looking at the functionality of IgM+ vs IgG+ memory B cell subsets identified several 
differences between the two subsets (Table 1.1) and lead to the idea that memory B cell 
responses were controlled by their BCR isotype. However, recent studies grouping 
memory B cells based upon the expression of CD80 and PD-L2, have provided better 
predictive power than the usage of class-switching alone (135) (Table 1.1). Thus, 
although class-switching can be useful for predicting how conventional memory B cells 
will differentiate in secondary immune responses, new markers are providing a more 
refined view. 
 Relatively recently a subset of CD27+/- CD21- B cells, also known as 
Atypical/age/exhausted/autoimmune associated B cell (ABCs), have been identified in a 
variety of different chronic diseases such as rheumatoid arthritis (136), malaria (137), 
human immunodeficiency virus (138), cytomegalovirus (139), hepatitis C virus infections 
(140), and MS (141). Based on these papers, ABCs appear to be Ag experienced as they 
class-switched and are clonally related to standard memory B cells produced in GCs 
(137). Furthermore, ABCs tend to be polyreactive often recognizing self-Ags or are 
specific for Ags associated with the infectious agent or autoimmune disease (136, 138, 
140, 142). This subset is only beginning to be defined (Table 1.1) but appears to be a GC-
derived subset that can contribute to immune responses. 
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Table 1.1. Summary of memory B cell subsets and their functions. 
Subset Function and properties 
Naïve-like 
IgM+ 
Primarily enter the GC in secondary immune responses (143) unless their 
activation is suppressed by circulating IgG (102). Typically these cells are 
low affinity for Ag and have not undergone extensive SHM (129). A large 
portion of these cells are generated prior to GC formation (126). 
Class-
switched, 
IgD- IgM- 
IgG+ 
Primarily contribute to the GC and secondary plasma cell responses (143). 
Recruited into secondary immune responses preferentially over IgM+ 
memory B cells (144, 145). Typically these cells are higher affinity for 
their Ag have some SHM (129). Primarily GC derived (126). 
CD80- 
PD-L2- 
These cells primarily enter the GC in secondary immune responses 
regardless of isotype (135). These cells are mostly low-affinity and not 
class-switched. They are typically made early in the GC response (126). 
CD80+ 
PD-L2+  
These cells primarily differentiate into plasma cells in secondary immune 
responses regardless of isotype (135). Most of these cells are higher 
affinity and class-switched memory B cells. They are typically generated 
late in the GC response (126). 
CD80+/-        
PD-L2+/- 
These cells express either CD80 or PD-L2, but not both. They have a 
phenotype intermediate between double positive and double negative 
memory B cells (135). 
ABC Commonly express Tbet, CD11b, CD11c, and downregulate CD21 and 
CD23 (146, 147). Some cells with this phenotype can act as potent Ag-
specific APCs and are poorly responsive in secondary responses (136-
138, 148). Nonetheless, others have found that they can be serial 
transferred to give rise to new GCs and have stem like properties (149).  
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1.5.2 Memory B cell differentiation 
 Although the transcription factors responsible for programming the memory B 
cell identity are not well characterized, there is one notable transcription factor associated 
with memory B cells. Memory B cell differentiation tends to be favored by high 
expression of Bach2 in the GC (127, 150) where Bach2 is antagonistic to the expression 
of the master regulator of plasma cell differentiation, Blimp-1 (127). Nonetheless, both 
naïve B cells and memory B cells express Bach2. Thus Bach2 alone cannot be 
responsible for the memory B cell identity. Another possibility is that memory B cell 
differentiation may not be controlled entirely by transcription factors but also through 
epigenetics, an aspect still being characterized (151). B cells destined to differentiate into 
memory B cells in the GC tend to accumulate in the LZ of the GC as these B cells 
typically are not selected by TFH cells to transition into the DZ (108, 152). Indeed, low 
BCR Ag-affinity and, thus, a low capacity to compete for TFH cell help, favors memory B 
cell differentiation (127). Consistent with this, expression of Bach2 in GC B cells is 
inversely proportional to BCR Ag-affinity (127). Thus, a relative lack of T cell help tends 
to favor memory B cell differentiation.  
1.6 Plasmablasts and plasma cells 
 Classically, the primary function of plasmablasts/plasma cells, collectively 
referred to as ASCs, is to produce antibodies that neutralize, opsonize, or lyse their 
targets. Antibodies can differ in isotype where particular isotypes are specialized to 
interface with different immune effector mechanisms. Through the production of 
antibodies, ASCs can be responsible for completely abolishing infections, the prevention 
of infectious diseases, and autoimmunity (153, 154). Thus, ASCs represent an important 
subset of effector cells produced from the B cell response. 
 ASCs are identified using the CD138 marker (155) and can be broadly split into 
plasmablasts and plasma cells. Plasmablasts are an actively proliferating precursor to 
terminally differentiated plasma cells (156). While both plasmablasts and plasma cells 
make antibodies, plasma cells are more polarized towards effector functions as a result of 
expanding their endoplasmic reticulum to accommodate increased protein expression 
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(157). Unlike plasma cells, plasmablasts maintain expression of MHC class II, the BCR, 
and co-stimulatory molecules and retain the capacity to interact with T cells for 
proliferative and anti-apoptotic signals (156, 158, 159). Altogether, B cells initially 
differentiate into highly proliferative plasmablasts that can eventually terminally 
differentiate into non-proliferative plasma cells that are highly specialized toward their 
effector functions. 
1.6.1 Differentiation of plasmablasts and plasma cells 
 The fate decision to become a plasma cell originates in the B cell, decided by its 
BCR affinity, and is completed by the T cell, by influencing the proliferation vs cell 
death of plasmablasts (128, 160). In particular, differentiation of B cells into ASCs is 
favored by having a relatively high-affinity for Ag as this primes B cells to begin ASC 
differentiation but also leads to B cells securing additional T cell help through the 
presentation of additional Ag on MHC class II (112, 128). Indeed, when two populations 
of equal-affinity B cells are in competition, targeting Ag to one of the populations will 
cause the targeted population to secure more T cell help and increased representation in 
the ASC population as result of increased proliferation (128, 160, 161). B cells destined 
to become ASCs typically leave the LZ of the GC to undergo a brief period of 
proliferation in the DZ before these cells leave the GC altogether to become a part of the 
plasma cell pool (128). Differentiation into ASCs is induced by Blimp-1 (162-164) and 
by suppressing Bcl6 expression (165). Overall, the size of the plasma cell response is 
influenced by a combination of B cells choosing to differentiate into plasma cells based 
upon BCR-affinity, but also expansion based upon T cell signals. 
1.6.2 Subsets of plasmablasts and plasma cells 
 ASCs are generated from two major sources in the GC response: an initial burst 
prior to GC formation and throughout the ongoing GC (78, 156). Pre-GC ASC 
differentiation typically consists of low-affinity, primarily IgM plasmablasts that localize 
to the medullary cords of the LN via CXCR4 expression where they continue to produce 
antibodies until they apoptose or leave the tissue (99, 159, 166, 167). This population has 
typically been described as short-lived. However, a portion of these Pre-GC ASC give 
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rise to long-lived IgM+ plasma cells that localize to the spleen and bone marrow (101). 
From these locations, long-lived plasma cells can produce antibodies continuously over a 
long period of time and contribute to long-term immunity.  
 ASCs produced from the GC can be separated into plasma cells and long-lived 
plasma cells. Plasma cells derived from the GC localize to the medullary cords of the LN 
similarly to pre-GC-derived ASCs (167). Germinal center-derived long-lived plasma cells 
localize to the bone marrow where they are maintained as a niche (101). Long-lived 
plasma cells do not live indefinitely. Their niche in the bone marrow has a maximum 
capacity and as a result, some vaccinations require booster immunization to maintain 
long-lived plasma cell numbers (168). Germinal center-derived ASCs are important as 
both short and long-lived ASCs are more likely to be class-switched, have undergone 
substantial SHM, and recognize their Ag with high-affinity relative to pre-GC plasma 
cells (101). Overall, pre-GC and GC-derived ASCs have similar but not necessarily 
overlapping functions in the immune response. 
1.7 T follicular helper cells 
 T follicular helper cells were originally identified as a cell that accumulates in B 
cell follicles in autoimmune mice and was associated with excessive GC formation (169). 
Indeed, it is now clear that the maintenance of the GC response is critically dependent on 
TFH cells (170). TFH cells localize to the B cell follicle and concentrate in the LZ of the 
GC where they interact with GC B cells and direct their selection (171). TFH cells are 
typically identified through the expression of several different markers on CD4+ T cells: 
CXCR5+, PD-1+, ICOS+, GL-7+, Bcl6+ and low CD62L expression (172). 
1.7.1 Pre-T follicular helper cells 
 The differentiation of TFH cells is initiated through interactions between DCs and 
CD4+ T cells at the initiation of the immune response. T cells that begin to express Bcl6 
based on these interactions are known as pre-TFH cells. These cells have acquired most of 
the features of a TFH cell but they do not localize to the GC. Instead pre-TFH cells go 
towards the B cell follicle-T cell zone boundary where they form interactions with B cells 
(78, 172). These interactions are essential for GC formation, but, they are also required 
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for pre-TFH cells to finish their differentiation into mature TFH cells (78, 173). In addition 
to pre-TFH cell differentiation, memory TFH cells are also generated from early DC-T cell 
interactions. Memory TFH cell differentiation does not require B cell interactions as they 
enter the circulation shortly after interacting with DCs (94). As memory TFH cells 
circulate through secondary lymphoid organs, they can participate in secondary immune 
responses if their Ag is present (174). 
1.7.2 T follicular helper cells and their associated subsets 
 T follicular helper cells promote the GC response using cytokines such as IL-4, 
IL-9, IL-10, IL-21, and surface receptors to modify B cell differentiation (106, 150, 175-
177) (discussed in more detail in section 1.8). However, expression of these molecules 
can differ between individual TFH cells and thus, can differ in their capacity to provide T 
cell help. In particular, TFH cells found in the B cell follicle have a less polarized 
phenotype characterized by: lower expression of Bcl6, co-stimulatory molecules, and 
cytokine expression but normal PD-1 expression (178, 179). Indeed, if TFH cells are 
forced to localize to the B cell follicle, using mice deficient in CXCR5 and S1PR2, they 
are less capable of maintaining GC’s (178). Both follicular and GC TFH cells require 
interactions with B cells to maintain their phenotype as inadequate interaction with B 
cells causes T cells to lose their PD-1 high phenotype required for them to persist in the 
immune response (78, 170, 180).  
 Recently another population of T cells called T follicular regulatory (TFR) cells 
has also been defined. These cells express many of the same receptors and transcription 
factors as conventional TFH cells do. However, they also express FoxP3, the transcription 
factor driving regulatory cell identity (181). T follicular regulatory cells can originate 
from Tregs generated during T cell development (182) or naïve T cells can be induced to 
differentiate into TFR cells through immunization (183, 184). The differentiation of these 
cells is thought to be similar to TFH cell generation including the requirement for B-T 
interactions for their maintenance (94). T follicular regulatory cells have been described 
to inhibit GC responses by inhibiting both TFH cells (185) and GC B cells (186). Indeed, 
the ratio of TFH cells to TFR cells can affect GC progression where the maintenance of the 
TFH cell population is of critical importance (187). Of note, both the TFH cell and TFR cell 
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populations are dynamic and thus, the ratio of these cells can change over the course of 
the GC response (182, 183). Nonetheless, the role of the TFR cell in the GC is 
complicated as these cells are also responsible for producing IL-10 (175), a cytokine that 
promotes GC B cell survival (188), and thus may in some scenarios promote GCs (189). 
Overall, the TFR cell population plays an important role in suppressing autoimmunity 
(190) while in some scenarios, TFR cells can promote GC responses. 
1.8 B and T cell interactions 
 Throughout the GC the physical interaction between B and T cells is essential for 
the maintenance of the GC and the differentiation of B cells into the various B cell 
subsets. In these interactions, B and T cells exchange signals via secreted cytokines and 
ligation of surface receptors. The sum of these signals induce intracellular signaling 
cascades that ultimately influence B and T cell biology and will be discussed in detail 
here. 
1.8.1 Cellular identity and signal integration 
 The identity of cells, such as B or T cells, is determined by a set of core 
transcription factors that program their identity (191). Typically, these transcription 
factors are constitutively expressed in the nucleus and are responsible for continuously 
inducing the production of proteins associated with a cell’s particular identity. The 
identity of a cell can change if the expression of the core set of transcription factors 
changes. Changes in the expression of these transcription factors can occur by several 
mechanisms: (1st), signaling can drive the inactivation or degradation of core 
transcription factors (192); (2nd), induced expression of another core transcription factor 
may repress the expression of others (193); (3rd), and signaling may drive transcription 
factors normally based in the cytoplasm to enter and accumulate in the nucleus thereby 
changing the nuclear content of core transcription factors (130). Amongst these 
mechanisms, the controlled activation of cytoplasmic-based transcription factors to 
translocate in the nucleus is particularly important as they can act as hubs of signal 
integration. Indeed, by controlling their nuclear localization, positive and negative 
signaling from multiple different pathways can be summed together into one decision 
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(194, 195). Altogether, core transcription factors are responsible for programming 
cellular identity where the expression of core transcription factors can be modified 
through cellular signaling. 
 Two commonly used pathways in the immune system are the nuclear factor kappa 
B (NFκB) and nuclear factor of activated T cells (NFAT) pathways. The NFκB pathway 
is activated through either a canonical pathway or a non-canonical pathway that 
converges upon the activation of the IκB kinase complex. The IκB complex is responsible 
for directing the degradation of IκB proteins which normally retain NFκB proteins in the 
cytoplasm preventing them from being active (195). The NFAT pathway is activated by 
anything that raises intracellular Ca2+ levels to a sufficiently high level to activate 
calmodulin (196, 197). Upon binding Ca2+, calmodulin interacts with calcineurin, a 
phosphatase that removes phosphate groups from the regulatory domain of NFAT 
proteins, thereby exposing their nuclear localization sequence resulting in their 
localization to the nucleus. As these activating events are quite common across several 
immune signaling pathways (see Table 1.2), the activation of these transcription factors 
commonly coincides with B and T cell interactions. In addition to these pathways, the 
immune system uses other transcription factors such as the AP-1 complex, STAT 
proteins, or other factors to contribute to immune cell decisions; however, these will not 
be discussed in detail in this thesis. 
1.8.2 Receptors and cytokines influencing B cell differentiation 
 B and T cells use a number of surface receptors and cytokines to communicate 
with one another to influence the others differentiation and survival. These receptors and 
cytokines have been studied in great detail including the study of: the regulation of their 
expression over the course of the immune response, how signaling through these 
receptors and cytokines is transduced and integrated into common signaling pathways, 
and how they influence the GC response and the production of B cell subsets. Below, I 
have outlined the expression patterns and effects of receptors and cytokines known to 
affect the GC response (Table 1.2).  
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Table 1.2. Summary of the expression and functions of key signaling molecules affecting 
the germinal center response. 
T cell B cell Major 
Pathway(s) 
Effect on the GC 
FasL 
(activated T 
cells (198)) 
CD95 
(activated and 
GC B cells 
(198, 199)) 
Caspase-3, 7 
and 8 (200)) 
Mediates the selection of high-
affinity GC B cells and suppresses 
autoimmunity through the induction 
of apoptosis (201-203). 
CD40L 
(activated T 
cells (204)) 
CD40 (all B 
cells (204)) 
NFκB (205) Required for GC maintenance. 
Promotes B cell proliferation and 
resistance to cell death (111, 206, 
207). 
CD28 (all T 
cells (208)) 
CD80 CD86 
(activated and 
GC B cells 
(209)) 
NFAT, 
NFκB, PI3K, 
AP-1 (210) 
CD86 is required to initiate GC 
responses and CD80/CD86 maintain 
the GC and promote plasma cell 
differentiation (198, 211, 212). 
CTLA4 (TFH 
and TFR cells 
(186, 213)) 
CD80 CD86 Inhibits 
NFAT, 
NFκB, AP-1 
(214) 
Suppresses the expansion of TFH cells 
and GC B cells (186, 215, 216). 
ICOS 
(activated T 
cells (190, 
208)) 
ICOSL (all B 
cells (217)) 
NFAT, 
NFκB, PI3K, 
AP-1 (208) 
ICOS is required for TFH cell 
maintenance and contributes to the 
selection of high affinity B cells in 
the GC (218, 219). 
PD-1 (TFH 
and TFR cells 
(220, 221)) 
PD-L1 (Naïve 
and GC B 
cells (180)) 
Inhibits 
NFAT, 
Inhibits TFR cells (222), promotes 
plasma cell differentiation and GC B 
cell maintenance (223), and prevents 
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PD-L2 (GC B 
cells (222)) 
NFκB, PI3K, 
AP-1 (220) 
excessive accumulation of TFH cells 
in the GC (180). 
IL-4 (pre-TFH 
and TFH cells 
(224)) 
IL-4R 
(activated and 
GC B cells 
(224)) 
STAT6 (225) Promotes memory B cell 
differentiation, GC B cell survival, 
and SHM and CSR (224, 226-228). 
IL-9 (TFH 
cells (150)) 
IL-9R (GC B 
cells (150)) 
STAT1/3/5 
(229) 
Promotes memory B cell 
differentiation (150). 
IL-10 (TFH 
and TFR cells 
(175)) 
IL-10R (GC 
B cells (175)) 
STAT3 (230) Inhibits GC B cell apoptosis and 
promotes GC B cell proliferation 
(175, 188, 231). 
IL-21 (pre-
TFH and TFH 
cells (224)) 
IL-21R 
(activated and 
GC B cells 
(224)) 
STAT1/3 
(232) 
Promotes GC B cell proliferation and 
plasma cell differentiation at the 
expense of memory B cells (233, 
234). 
SLAM (pre-
TFH and TFH 
cells (235)) 
SLAM 
(Activated 
and GC B 
cells (235)) 
Integrins, 
NFκB (236) 
Promotes IL-4 production in TFH cells 
and plasma cell differentiation (237). 
CD84 (pre-
TFH and TFH 
cells (235)) 
CD84 
(Activated 
and GC B 
cells (235)) 
Integrins 
(238) 
Needed for optimal GC formation, 
optimal antibody responses, and TFH 
cell maintenance (235). 
Ly108 (pre-
TFH and TFH 
cells (235)) 
Ly108 
(Activated 
and GC B 
cells (235)) 
Integrins 
(238) 
Inhibits GC induction and 
maintenance by promoting short B-T 
interactions until this receptor is 
engaged (239). 
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1.9 Thesis overview 
 This thesis characterizes the progression of autoreactive GCs directed against 
MOG protein and establishes rules controlling its progression. This was accomplished by 
developing a new MOG expression system that can be easily manipulated to change the 
properties of the immunizing Ag. The primary goal of this thesis was to characterize the 
basic rules that control B cell differentiation in GC responses and to apply these rules to 
an autoimmune GC model that has a pathogenic B cell component. I hypothesized that B 
cells participating in GCs directed against an autoAg would make different fate choices 
relative to a standard model Ag and that T cells would control these fate choices. 
1.9.1 Chapter 2: Simple and Efficient Production and Purification of Mouse 
Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune 
Encephalomyelitis Studies 
 Herein, I describe the process of production and purification of the model autoAg 
I use throughout this thesis, mMOGtag protein. I show that mMOGtag protein obtains the 
correct 3-D conformation and can be recognized by MOG-specific B and T cells. I also 
show that mMOGtag protein is amenable to modification for experimental purposes by 
creating a new MOG protein that manipulates T cell Ag-affinity, called haMOGtag. Both 
mMOGtag and haMOGtag induce EAE through protein immunization including the 
incorporation of pathogenic B and T cells confirming that both induce adaptive immune 
responses that contribute to CNS demyelination. Overall, the mMOGtag expression 
system has proven to be an effective system for purifying large amounts of MOG protein 
making it possible to characterize how autoreactive B cell responses are initiated and how 
they contribute to EAE. 
1.9.2 Chapter 3: Autoreactive T cells preferentially drive differentiation of 
short-lived memory B cells at the expense of germinal center 
maintenance. 
 In this chapter, the tools developed in the previous chapter are used to determine 
whether B cell responses directed against an autoAg are different from those of a model 
foreign-Ag. I show that GCs directed against mMOGtag protein collapse early and instead 
form large numbers of memory B cells. While robust immune memory was generated in 
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the foreign-Ag driven GC response, in the form of memory B cells and long-lived plasma 
cells, MOG-specific memory B cells are short lived and few long-lived plasma cells are 
generated through mMOGtag immunization. Collapse of the autoreactive GC was largely 
under the control of the autoreactive T cells. However, GC collapse could be partially 
corrected when T cells were stimulated with a high-affinity T cell Ag. Despite clear 
evidence for T cell control of the GC response, autoreactive and foreign-Ag specific T 
cells did not differ in phenotype but rather, differed only by the absolute number of T 
cells controlling in the GC response. Altogether, this chapter characterizes the 
development of the anti-MOG GC response and shows that T cells are capable of 
influencing some aspects of the GC response, but not others.  
1.9.3 Chapter 4: Reporters for in vivo and in vitro monitoring of NFκB and 
NFAT signaling 
 For the final chapter, I describe the generation of fluorescent reporters capable of 
monitoring intracellular signaling in real-time for the purposes of understanding how 
signals are exchanged between interacting cognate pairs of B and T cells. I show that by 
combining a fluorescent marker of the nuclei of cells with fluorescently labelled NFκB or 
NFAT proteins, I can monitor intracellular signaling in living cells. Using the Clustered 
regularly interspaced short palindromic repeats (CRISPR)/Cas9 genomic editing tool, I 
show that I can edit mouse genomes to express my reporters but generation of a reporter 
mouse was unsuccessful. This issue was addressed by constructing a new reporter for 
NFAT activity that is compatible with conventional gene knock-in methods and will be 
used to generate a reporter mouse. Overall, this project demonstrates the potential of a 
reporter capable of determining the timing and kinetics of signal exchange between B and 
T cells during their interactions. 
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Chapter 2  
2 Simple and Efficient Production and Purification of Mouse 
Myelin Oligodendrocyte Glycoprotein for Experimental 
Autoimmune Encephalomyelitis Studies 
 Multiple sclerosis is a chronic inflammatory disease of the CNS, thought to occur 
as a result of autoimmune responses targeting myelin. Experimental autoimmune 
encephalomyelitis is the most common animal model of CNS autoimmune disease and is 
typically induced via immunization with short peptides representing immunodominant 
CD4+ T cell epitopes of myelin proteins. However, B cells recognize unprocessed protein 
directly, and immunization with short peptide does not activate B cells that recognize the 
native protein (240). As recent clinical trials of B cell-depleting therapies in MS have 
suggested a role for B cells in driving disease in humans, there is an urgent need for 
animal models that incorporate B cell-recognition of autoAg. To this end, I have 
generated a new fusion protein containing the extracellular domain of the mouse version 
of MOG as well as N-terminal fusions of a His-tag for purification purposes and the 
thioredoxin protein to improve solubility (mMOGtag). A tobacco etch virus (TEV) 
protease cleavage site was incorporated to allow, if desired, the removal of all tag 
sequences, leaving only the enriched MOG1-125 extracellular domain. Here, I describe a 
simple protocol using only standard laboratory equipment to produce large quantities of 
enriched mMOGtag or MOG1-125. This protocol consistently generates over 200 mg of 
mMOGtag protein. Additionally, the same purification protocol successfully purified a 
family of modified mMOGtag proteins, one of which is described in detail here, high-
affinity MOG (haMOGtag), which incorporates a high-affinity T cell epitope and is 
capable of stimulating potent MOG-specific T cell responses. Immunization with either 
mMOGtag, MOG1-125, or haMOGtag generates an autoimmune response that includes 
pathogenic B and T cells that recognize the native mouse MOG Ag. Furthermore, it was 
found that haMOGtag immunization potentiated EAE development. Together, this protein 
expression system has proven to be reliable and amenable to modification permitting the 
study of how B cells contribute to EAE and how manipulating B and T cells affects EAE 
development.  
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2.1 Introduction 
 MS is a human disease characterized by chronic inflammation and 
neurodegeneration of the CNS which is thought to be driven by an autoimmune response 
directed towards myelin. The loss of myelin and axons over time result in the gradual 
decline of cognitive and motor function (241). "Experimental Autoimmune 
Encephalomyelitis" is an umbrella term for animal models of autoimmune disease 
directed towards CNS myelin. Like human MS, EAE is typically characterized by 
immune cell infiltration of the CNS and, in some cases, demyelination (38). However, the 
degree to which any given EAE model resembles human MS in part depends on the 
species or strain used and on the complexity of the underlying anti-myelin autoimmune 
response.  
 Anti-myelin autoimmunity can be experimentally induced in several ways, but the 
most common method used today is to immunize mice with a short peptide of amino 
acids mimicking the immunodominant CD4+ T cell epitope of a myelin protein. This 
represents the minimum requirement to induce a pathogenic immune response. Perhaps 
the most common of these is a 21 amino acid peptide derived from myelin 
oligodendrocyte glycoprotein (MOG35-55), which is used to induce EAE in C57Bl/6 mice 
(242). However, for some experimental purposes it is desirable or even necessary to 
immunize with larger protein Ags and indeed there are several advantages to this over 
immunization with short peptides. First, due to MHC restriction, short peptides are 
usually only effective in a very limited number of animal strains, while larger protein Ags 
representing either the whole protein or a specific domain can be processed normally for 
presentation in multiple inbred mouse strains or even in different species (243). Second, a 
larger protein Ag is capable of inducing a more complex immune response by 
incorporating additional types of lymphocytes through Ag recognition of a broader array 
of epitopes, rather than limiting Ag recognition to a small population of CD4+ T cells 
responding to a single peptide. For example, B cells via their BCR interact directly with 
whole protein rather than processed peptides. We and others have shown that B cells 
activated by MOG35-55 immunization do not recognize whole MOG protein (240). Since 
34 
 
 
B cells were recently demonstrated to play a pathogenic role in human MS (244), EAE 
models that incorporate B cells in autoimmune pathology are increasingly important.  
 Despite the advantages of using larger protein Ags to induce EAE, there remain 
few commercially available sources for such proteins. Indeed, while short peptides like 
MOG35-55 can be synthesized very quickly and at a relatively low cost, the commercial 
options for MOG protein are limited and cost substantially more to purchase. Currently, 
there are several expression vectors available that research groups can use to generate 
MOG extracellular domain (MOG1-125). However, all of the expression systems that I 
have identified in the literature are based on older technologies that have since been 
replaced with more efficient expression systems (245). Further, most are based on rat or 
human MOG (246). For some investigations of autoimmunity in mice, an Ag based on 
the mouse MOG (mMOG) autoAg is preferable. In addition to the problems highlighted 
above, a new expression system would ideally be modular as this would allow for the 
manipulation of variables associated with the Ag. Indeed, several studies have made use 
of specific point mutations in Ags to manipulate B cell Ag-affinity (247, 248) as well as 
T cell Ag-affinity (249-251). Thus, a modular MOG expression system would permit an 
in depth characterization of how B and T cell Ag-affinity contributes to the progression 
and maintenance of the EAE autoimmune response. Finally, all expression vectors of 
MOG-based proteins that I have identified are fusion proteins containing additional 
amino acids to the MOG1-125 base (245, 252). These include a tag for purification and 
usually other sequences as well, many of which with a function I was unable to identify, 
which in some cases may need to be removed for experimental purposes. 
 To address these limitations, I generated a family of proteins based on the mouse 
MOG extracellular domain fused to a tag containing thioredoxin to combat the known 
insolubility of MOG protein (240). The tag sequence also contains a 6xHis sequence for 
purification and a TEV protease cleavage site that allows for the complete removal of all 
tag sequences, if desired. This is the only method that I am aware of that efficiently 
generates enriched MOG1-125 protein. To facilitate production of large amounts of 
protein, the MOG1-125 sequence was codon-optimized for bacterial expression and the 
mMOGtag fusion protein was inserted into the pET-32 expression system. Additionally, 
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the mMOGtag-pET-32a vector contains several restriction enzyme sites and is easily 
polymerase chain reaction (PCR) amplified permitting manipulation through cloning 
techniques. An example of this is given here through the production of ‘high-affinity’ 
mMOGtag (haMOGtag) Ag, which incorporates a high-affinity T cell epitope recognized 
by MOG-specific CD4+ T cells, allowing for the experimental manipulation of the CD4+ 
T cell response. Here, I show that I can produce and purify large quantities of mMOGtag 
protein, enriched MOG1-125, and haMOGtag using non-specialized equipment available to 
most immunology laboratories. I then show that these proteins are capable of inducing 
MOG-specific B and T cell responses in the context of EAE and that the haMOGtag Ag 
can manipulate MOG-specific T cell responses. 
 
2.2 Results 
2.2.1 A protocol for expressing mMOGtag protein 
 To develop a system with which I could produce large amounts of mMOG 
protein, I took advantage of the pET-32a protein expression system in BL21 E.coli. This 
was accomplished by inserting bacterial codon optimized mMOG extracellular domain 
(amino acids 1-125) sequence (based upon GenBank NM_010814.2) into the pET-32a 
vector along with an N-terminal TEV protease cleavage site. The mMOG1-125 and TEV 
protease sequences are expressed in frame with the proceeding sequences in the pET-32a 
vector including E.coli thioredoxin protein, an S-Tag, and a 6xHis tag to make the 
mMOGtag protein (Figure 2.1). 
 To make the mMOGtag protein, BL21 bacteria transformed with the pET-32a 
mMOGtag vector are induced to express mMOGtag with Isopropyl β-D-1-
thiogalactopyranoside (IPTG) overnight. This resulted in a substantial increase in 
mMOGtag expression as seen by the appearance of a 31.86 kilodalton (kDa) band on 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) after induction 
(TO/N) relative to pre-induction (T0) (Figure 2.2A and 2.2B). The BL21 bacteria are then 
lysed and pelleted to collect inclusion bodies primarily containing the mMOGtag protein 
(253). Inclusion bodies are then solubilized with guanidine, a chaototopic agent that 
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disrupts protein folding (254), to produce a crude solution of mMOGtag prior to 
purification (Figure 2.2B). The protein is then purified through four rounds of incubation 
with nickel resin, that can be used to purify His-tag labelled proteins (255), followed by 
elution to collect our 6xHis tag labelled mMOGtag protein. As guanidine prevents the 
mMOGtag protein from folding, dialysis is used to slowly remove guanidine from the 
purified protein allowing the protein to slowly fold into the correct 3-D protein 
conformation. Once folded, the protein is concentrated to 5 mg/ml using PEG3350 and 
PEG8000 to generate enriched and concentrated mMOGtag protein. Purity of mMOGtag 
protein was confirmed by SDS-PAGE (Figure 2.2B). 
 To determine whether the mMOGtag protein produced had acquired the correct 3-
D conformation, I took advantage of a mouse strain called the IgHMOG mouse, which 
expresses a heavy chain BCR that confers MOG specificity to B cells in this mouse 
(256). I hypothesized that if mMOGtag had acquired the correct conformation, it should 
preferentially bind to IgHMOG B cells over wild type C57Bl/6 B cells. Lymph node cells 
from either IgHMOG or C57Bl/6 mice were incubated with mMOGtag Ag, to label MOG-
specific B cells, then labelled with a secondary anti-His antibody and a tertiary anti-IgG1 
antibody. Binding of mMOGtag to B cells was then assessed by flow cytometry. As 
shown in Figure 2.2C, mMOGtag-specific B cells could be detected in both WT C57Bl/6 
mice and IgHMOG mice however mMOGtag preferentially bound to IgH
MOG cells, often 
labelling between 20-30% of the B cells in these mice well above the background level 
seen in the fluorescence minus one (FMO) control. 
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Figure 2.1. mMOGtag protein. 
Linear structure, and amino acid and DNA sequences of the mMOGtag fusion protein. The 
DNA sequence for the extracellular domain of mouse MOG (MOG1-125, lower sequence 
in blue) was codon-optimized for expression in bacteria (black). This sequence was 
synthesized and inserted into a vector to create an N-terminal fusion to a tag containing 
E.coli thioredoxin and an S-Tag to counteract the known insolubility of the MOG protein 
(253, 257), as well as a 6x His Tag for purification (258). A TEV protease cleavage site 
separates the MOG1-125 from the tag sequences. TEV-mediated cleavage between 
glutamine-164 and glycine-165 using an alternative consensus TEV cleavage site (258) 
results in removal of all non-MOG amino acids. 
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Figure 2.2. Purification of mMOGtag. 
(A) To generate mMOGtag protein, bacteria expressing the mMOGtag protein are grown to 
high densities then induced to express mMOGtag using IPTG. After an overnight culture, 
the bacteria are lysed and through a series of pelleting steps the protein fraction 
containing inclusion bodies, which contains mMOGtag, is extracted. mMOGtag is then 
purified from the crude protein fraction through four cycles of absorption onto charged 
nickel resin and elution of the mMOGtag protein. A portion of the pooled eluate is then 
taken for a Bradford assay to determine the yield of mMOGtag protein and the rest of the 
eluate is dialyzed into acetate buffer over the course of several days. Lastly, the protein is 
concentrated using PEG3350 and PEG8000 to a final concentration of 5 mg/ml based 
upon the yield of mMOGtag determined in the Bradford assay. (B) Shown are protein 
samples that were collected from various points across the protein purification procedure 
and analyzed by SDS-PAGE gel. T0= BL21 bacteria prior to protein induction, TO/N= 
BL21 bacteria post-induction of protein expression, Crude mMOGtag= Solubilized 
mMOGtag protein prior to protein purification, Enriched mMOGtag= mMOGtag protein 
after purification. (C) Binding of the mMOGtag protein to CD19
+ CD4- naive B cells from 
lymph nodes from either wild type C57Bl/6 mice or IgHMOG mice that express an 
immunoglobulin heavy chain specific for MOG protein (245, 256) was assessed using 
flow cytometry. mMOGtag-specific B cells were identified by staining LN cells with 
mMOGtag followed by a secondary anti-His tag antibody and a fluorescent tertiary anti-
IgG1 antibody. Staining of cells from C57Bl/6 or IgHMOG mice is shown along with a 
mMOGtag FMO control stain of IgH
MOG cells. The proportion of IgHMOG B cells binding 
mMOGtag protein is written above the gating displaying mMOGtag binding. 
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2.2.2 TEV protease can remove the tag sequence to generate enriched 
MOG1-125 that can be purified 
 As the tag sequence is derived from foreign-Ags, some experiments or protocols 
may have need of enriched MOG1-125 Ag. To accomplish this, I developed a protocol to 
remove all of the exogenous sequence associated with the mMOGtag Ag to make enriched 
MOG1-125 (summarized in Figure 2.3A). In this protocol, purified mMOGtag protein is 
dialyzied into TEV protease cleavage buffer then TEV protease is mixed with the 
mMOGtag protein to remove the tag sequence. After cleavage, the buffer is changed and 
the volume is reduced by dialysis. Then nickel resin is used to remove impurities from 
MOG1-125, namely the tag sequence, uncut mMOGtag, and the TEV protease. After four 
rounds of absorption onto nickel resin, the protein left in the original solution is then 
folded similarly to mMOGtag and concentrated to 2.24 mg/ml to be equimolar with 
mMOGtag at 5 mg/ml. As shown in Figure 2.3B, this protocol can be used to generate 
enriched MOG1-125 as seen by the prominent band at 14.28 kDa on an SDS-PAGE gel.  
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Figure 2.3. Generation of MOG1-125. 
(A) After collecting the mMOGtag eluate from the mMOGtag purification described in 
Figure 2.2A, the mMOGtag protein is dialyzed into TEV protease cleavage buffer. Once 
the dialysis is complete, TEV protease is added to the mMOGtag solution resulting in the 
cleavage of mMOGtag into the MOG1-125 protein and the associated tag sequence. The 
volume of the cleavage solution is then reduced and dialyzed into buffer B prior to 
protein purification. Impurities from the cleavage solution are removed by four 
successive rounds of absorption onto charged nickel resin and elution of the impurities 
ultimately resulting in a solution of enriched MOG1-125. The concentration of the MOG1-
125 protein is determined through a Bradford assay and the protein is folded over the 
course of several days through dialysis. Once dialysis is complete, the MOG1-125 protein 
is concentrated to 2.24 mg/ml using PEG3350 and PEG8000. (B) Shown are protein 
samples run on a SDS-PAGE gel demonstrating purification of MOG1-125. Enriched 
mMOGtag = mMOGtag protein prior to TEV cleavage, mMOGtag w/ TEV = Protein 
fraction that was collected after 72 hr of incubation of mMOGtag with TEV protease, 
Elution = Protein fraction that remained bound to the nickel resin during the MOG1-125 
purification protocol, Enriched MOG1-125 = MOG1-125 protein after purification. 
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2.2.3 Generation of haMOGtag, a variation of mMOGtag that alters T cell 
antigen affinity 
 In addition to studying the immune response induced against mMOG protein, the 
mMOGtag expression system provides a general platform to easily produce manipulated 
versions of the protein to investigate how properties of the immunizing Ag affect 
developing immune responses. For example, T cell affinity for Ag is a central component 
of T cell activation (19) but is not well characterized in the context of GCs. To this end, I 
have generated several variations of the mMOGtag Ag: a version based on the rat MOG 
protein (rMOGtag), a humanized version of mMOG that I call B cell dependent MOG 
(bMOGtag), and lastly a version that manipulates Ag-affinity called haMOGtag. Although 
the bMOGtag and rMOGtag Ags have been purified and validated, I will only focus on 
haMOGtag in this thesis. 
 The haMOGtag protein is based upon manipulating the mMOGtag Ag to 
incorporate a high-affinity T cell epitope, thereby altering the affinity of T cell 
recognition, by taking advantage of a common feature of TCRs known as polyreactivity 
(259) that is especially prevalent in autoreactive T cells (260). Polyreactivity is feature of 
TCRs where a single TCR molecule can recognize more than one Ag with different Ag-
affinities. Autoreactive TCRs, including TCRs that recognize the MOG35-55 peptide such 
as the 2D2 TCR, tend to bind peptide:MHC with relatively low affinity (261). However, 
analysis of the MOG35-55-specific 2D2 TCR revealed that it also recognizes a second 
peptide derived from amino acids 18-30 from the Neurofilament-M protein (NF-M18-30) 
(262), and in fact binds NF-M18-30 with higher affinity than it does MOG35-55 (261). Of 
note, this property is not just an artifact of the 2D2 TCR, as cross reactivity between 
MOG35-55 and NF-M18-30 is common in C57Bl/6 mice (263). The usage of polyreactivity 
to assess how T cell Ag-affinity affects immune responses is highly desirable because it 
involves stimulating the same T cell to different degrees. Other models that use different 
T cell clones to look at affinity will always have the confounding factor that the two T 
cells could simply be generally different beyond their affinity.  
 I took advantage of the polyreactivity of the 2D2 TCR to generate a modified 
mMOGtag Ag that incorporates amino acids 13-35 from NF-M, containing the NF-M18-30 
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epitope, in between the N-terminal tag and the TEV protease cleavage site in the original 
mMOGtag Ag (Figure 2.4A – referred to as haMOGtag). Incorporation of the haMOGtag 
pET-32a vector into BL21 bacteria and purification of the haMOGtag protein were both 
successful using our protocol as seen by the prominent 34.36 kDa band on an SDS-PAGE 
gel (Figure 2.4B). Enriched haMOGtag protein was further confirmed to have acquired the 
correct 3-D conformation as haMOGtag, much like mMOGtag, bound IgH
MOG B cells 
(between 20-25% of the IgHMOG B cells depending on the experiment) to a greater degree 
than wild type C57Bl/6 B cells (Figure 2.4C). 
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Figure 2.4. Structure and purification of the haMOGtag protein. 
(A) Schematic of the haMOGtag protein. The haMOGtag protein is structurally similar to 
the mMOGtag protein however amino acids 13-35 derived from NF-M were inserted 
inbetween the TEV protease site and the S-tag in the original mMOGtag protein. Below 
the amino acid sequence of NF-M13-35 and MOG38-50 are shown where the sequences 
highlighted in grey represent the minimal amino acid sequence required to induce 2D2 T 
cell responses (262) and amino acids highlighted in red represent amino acids that change 
between NF-M18-30 and MOG38-50. (B) Shown are protein samples that were collected 
from various points across the protein purification procedure and run on a SDS-PAGE 
gel. T0= BL21 bacteria prior to protein induction, TO/N= BL21 bacteria post-induction of 
protein expression, Crude haMOGtag= Solubilized haMOGtag protein prior to protein 
purification, Enriched haMOGtag= haMOGtag protein after purification. (C) Binding of the 
haMOGtag protein to CD19
+ CD4- naive B cells from LN’s from either wild type C57Bl/6 
mice or IgHMOG mice was assessed using flow cytometry. haMOGtag-specific B cells 
were identified by staining LN cells with haMOGtag followed by a secondary anti-his tag 
antibody and a fluorescent tertiary anti-IgG1 antibody. Staining of cells from C57Bl/6 or 
IgHMOG mice is shown along with a haMOGtag FMO control stain of IgH
MOG cells. The 
proportion of IgHMOG B cells binding haMOGtag protein is written above the gating 
displaying haMOGtag binding. 
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2.2.4 haMOGtag induces greater MOG-specific T cell responses relative to 
mMOGtag in vitro and in vivo 
 Having confirmed that I could produce both mMOGtag and haMOGtag, I sought to 
determine whether these proteins could induce different myelin-specific T cell responses. 
I hypothesized that haMOGtag would induce larger T cell responses based on higher-
affinity engagement of the TCR. To accomplish this, I set up an in vitro T cell stimulation 
assay where splenocytes from wild type C57Bl/6 mice were loaded with either mMOGtag 
or haMOGtag. Unloaded splenocytes were used as a negative control and splenocytes 
loaded with the model foreign-Ag nitrophenyl conjugated ovalbumin (NPOVA) were 
used as a positive control. Splenocytes were then incubated with Carboxyfluorescein 
succinimidyl ester (CFSE) labelled T cells from 2D2 (MOG specific T cells (264)) or 
OTII (OVA specific T cells (265)) mice. After three days of incubation, T cell 
proliferation was assessed by flow cytometry looking for CFSE dilution. All Ags induced 
proliferation of T cells relative to the no Ag control confirming that each Ag was capable 
of being properly presented (Figure 5A - left). Of the three Ags, NPOVA induced the 
greatest degree of proliferation with a large percentage of OTII T cells having undergone 
2, 3, and 4 cell divisions relative to 2D2 T cells incubated with either MOG-based Ag 
(Figure 2.5A). Proliferation induced with haMOGtag Ag was intermediate between that of 
NPOVA and mMOGtag where a greater proportion of T cells had undergone proliferation 
relative to mMOGtag (Figure 2.5A). Thus, in vitro haMOGtag was capable of inducing a 
larger 2D2 T cell response relative to mMOGtag. 
 To determine whether this was true in vivo, a similar assay was set up where 
CFSE labelled red fluorescent protein (RFP) positive 2D2 T cells were transferred into 
wild type C57Bl/6 mice. Mice were then immunized by flank injections with either 
mMOGtag or haMOGtag and T cell proliferation and differentiation in the draining 
inguinal LNs was assessed d2 and d3 post-immunization. Proliferation of 2D2 T cells as 
seen by CFSE dilution was greater at the d2 time point in haMOGtag immunized mice 
relative to mMOGtag however by the d3 time point these two populations were no longer 
different (Figure 2.5B and 2.5C). Thus, proliferation of MOG-specific T cells towards 
mMOGtag was not compromised but rather delayed.  
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Figure 2.5. haMOGtag induces greater MOG-specific T cell proliferation than mMOGtag 
(A) In vitro proliferation assay assessing T cell proliferation to NPOVA, mMOGtag, and 
haMOGtag. Splenocytes loaded with either NPOVA, mMOGtag, or haMOGtag were 
incubated with CFSE labelled OTII T cells (NPOVA) or 2D2 T cells (mMOGtag and 
haMOGtag) for three days. On the third day, CFSE dilution was assessed by flow 
cytometry. A representative FACS plot is shown on the left and the quantification of 
proliferation is shown on the right. Data is representative of three independent 
experiments with three technical replicates, error bars represent standard deviation. (B 
and C) CFSE labelled RFP+ 2D2 T cells were transferred into non-fluorescent C57Bl/6 
recipients then immunized in the flanks with mMOGtag or haMOGtag and CFSE dilution 
in RFP+ CD4+ CD8- CD19- T cells in the draining inguinal LN was assessed by flow 
cytometry on d2 (B) or d3 (C) post-immunization. (B and C) Data is based on one 
experiment. Error bars represent standard deviation for panels B (n=4 mMOGtag, n=3 
haMOGtag) and C (n=5 mMOGtag, n=4 haMOGtag). Comparisons between multiple 
groups were done using a one-way ANOVA with a Bonferroni correction and 
comparisons between single groups were done using a Student’s T-test, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
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2.2.5 mMOGtag and haMOGtag can both induce EAE incorporating anti-
myelin B and T cells 
 MOG proteins are commonly used for the induction of EAE where there is 
considerable interest in understanding how B cell responses contribute to EAE 
progression. To determine whether the mMOGtag and haMOGtag proteins can induce EAE 
with associated myelin-specific B and T cell responses, I transferred green fluorescent 
protein (GFP) positive IgHMOG B cells and RFP+ 2D2 T cells into non-fluorescent 
C57Bl/6 recipients then immunized the recipients with mMOGtag or haMOGtag via flank 
injections. On d0 and d2, pertussis toxin (PTX) was administered to promote EAE 
induction (266) and mice were scored daily based on disease severity. Mice immunized 
with either Ag were capable of developing EAE where haMOGtag immunized mice 
developed EAE with greater incidence (Figure 2.6A). Spinal cords taken from these mice 
demonstrated inflammation and demyelination within the CNS (Figure 2.6B). 
Furthermore, histological analysis of draining inguinal LNs of these mice showed that 
MOG-specific GFP+ B and RFP+ T cells could be seen within GCs confirming that these 
cells were activated through immunization and were actively participating in anti-myelin 
autoimmunity (Figure 2.6C).  
 To determine if haMOGtag immunization impacts the B cell antibody response, 
serum from the above mice were analyzed for circulating IgM and IgG anti-MOG1-125 
specific antibodies using an enzyme-linked immunosorbent assay (ELISA). No difference 
in either IgM or IgG anti-MOG antibodies were observed (Figure 2.6D). This finding was 
confirmed in a separate experiment where wild type C57Bl/6 mice were immunized with 
mMOGtag or haMOGtag to induce EAE. Then, the number of anti-MOG1-125 specific 
plasma cells in the draining inguinal LNs and bone marrow was assessed using an 
enzyme linked immuno-spot (ELISpot) assay. Equivalent numbers of IgM+ and IgG+ 
plasma cells were confirmed to be present in the draining inguinal LNs and bone marrow 
of mMOGtag and haMOGtag immunized mice (Figure 2.6E). 
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Figure 2.6. mMOGtag and haMOGtag both induce EAE incorporating myelin-specific B 
and T cells. 
(A-D) RFP+ 2D2 T cells and GFP+ IgHMOG B cells were transferred into non-fluorescent 
C57Bl/6 recipients then immunized with either mMOGtag or haMOGtag. Mice were 
injected with intraperitoneal (i.p.) PTX on d0 and d2 post-immunization and were scored 
daily to assess their physical disability. Then, d14 post-immunization the draining 
inguinal LNs and spinal cords were taken for histology and blood was taken to analyze 
the serum for anti-MOG1-125 antibodies. (A) Disease curves of mMOGtag and haMOGtag 
immunized mice are shown, the disease incidence for each group is shown on the legend 
(n=6 per group). Errors bars represent standard error of the mean (SEM). (B) Shown are 
representative histological sections of spinal cords from mMOGtag and haMOGtag 
immunized mice stained with the antibodies shown on the left and FluoroMyelin to stain 
myelin. (C) Shown are representative images of inguinal LNs from mMOGtag and 
haMOGtag immunized mice, LN sections were stained with IgD to outline the B cell 
follicle. (B and C) Scale bars represent 100 µm. (D) Serum from mMOGtag and 
haMOGtag immunized mice were analyzed for IgM and IgG anti-MOG1-125 antibodies. 
(E) C57Bl/6 mice were immunized with either mMOGtag or haMOGtag and injected with 
PTX i.p. d0 and d2 post-immunization. Day 18 post-immunization draining inguinal LNs 
and bone marrow were extracted and assessed for MOG1-125 specific IgM
+ or IgG+ 
plasma cells using an ELISpot assay. Data is representative of 1-3 independent 
experiments. A Student’s T-test was used for single comparisons. 
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2.3 Discussion 
 Here, I have described a protocol for the production of mMOGtag protein and how 
to generate enriched MOG1-125 from mMOGtag. This protocol is based both on standard 
His-tag based protein purification methods, as well as a previously described protocol for 
the generation of an older MOG-based protein (245). Previously we demonstrated that 
immunization with mMOGtag or MOG1-125 not only induces EAE with greater spinal cord 
inflammation and demyelination compared to the standard MOG35-55 peptide, but also 
that pathogenic IgHMOG B cells that recognize MOG protein are activated to produce a 
germinal center in response to mMOGtag or MOG1-125, but not to MOG35-55 (240). Thus, 
our mMOGtag protein successfully incorporates MOG-specific B cells into an immune 
response directed against the brain and spinal cord allowing us to study how autoreactive 
B cells differentiate and contribute to EAE. 
 One major difference between the mMOGtag protein described here and 
previously published forms of recombinant MOG protein is that these studies use the 
extracellular domain of human MOG protein (246, 247, 267). This is significant because 
mMOG and human MOG have different properties and induce different forms of EAE. In 
particular, human MOG induces a B cell dependent form of EAE (49) whereas rodent 
versions of MOG induce T-cell dependent EAE that is complemented by Ag-specific B 
cells (41, 240, 268). The change from T cell-dependent to B cell-dependent EAE can be 
attributed to a single amino acid change, a S42P mutation in the human MOG protein 
(268, 269). This mutation resides within the immunodominant MOG35-55 epitope (243) 
and induces delayed proliferation of MOG-specific T cells relative to MOG35-55 (data not 
shown). As T cell priming is less efficient in human MOG immunized mice, it is unclear 
whether studies using human MOG are inducing a potent enough T cell response for 
them to make a major contribution to EAE progression. Thus, one major advantage of the 
mMOGtag protein over the human MOG version is that T cells are unambiguously being 
primed with the endogenous autoAg, which leads to potent T cell responses that can drive 
inflammation.  
 The other form of MOG commonly used in EAE models is the extracellular 
domain of rat MOG protein. The rat MOG and mMOG proteins share the same MOG35-55 
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immunodominant epitope and both induce T cell-dependent EAE (41, 270). Although rat 
MOG and mMOG induce similar effector T cell responses, they do differ in Treg 
activation (271). In particular, rat MOG differs from mMOG at 6 amino acids that reside 
in subdominant T cell epitopes recognized by Treg cells, ultimately impacting their 
ability to respond to rat MOG. As a result of inefficient Treg activation, rat MOG induces 
more severe EAE than mMOG (271). Ideally, EAE models should not exclude regulatory 
processes that would normally be present in MS patients (272, 273), as overcoming these 
regulatory processes would be expected to be a part of the development of autoimmune 
disease. As a result, EAE induced with mMOG protein better recapitulates regulatory 
processes expected to be a part of MS. Nonetheless, rat MOG can still be useful 
experimentally to manipulate regulatory T cell responses. 
 In addition to manipulating Treg responses, I have also shown here that I could 
generate a version of the mMOGtag protein that manipulates Ag-affinity, haMOGtag, to 
promote MOG-specific T cell responses using a high-affinity T cell epitope recognized 
by MOG-specific T cells. In the EAE experiment described here, haMOGtag induced EAE 
with greater incidence relative to mMOGtag immunized mice, a finding that has been 
repeated several times. This may be related to my finding that 2D2 T cells proliferate 
faster in response to haMOGtag relative to mMOGtag consistent with previously published 
work showing faster signaling kinetics in 2D2 T cells stimulated with NF-M18-30 relative 
to MOG35-55 (261). It is therefore possible that stronger T cell responses are better at 
priming T cells to induce EAE where I may expect that inducing a weaker T cell response 
would reduce disease incidence. Indeed, we have previously shown that a version of our 
mMOGtag protein containing the S42P mutation described above, bMOGtag, that induces 
even slower kinetics of T cell activation relative to mMOGtag, cannot induce EAE 
through T cell stimulation alone whereas mMOGtag and haMOGtag can (268). This shows 
how our modular mMOGtag platform can be manipulated for experimental needs to 
answer basic questions about immunology and EAE induction. Indeed, in Chapter 3 of 
this thesis I will use the tools produced here to determine factors that limit the initiation 
and progression of GC responses directed against the MOG protein. 
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 In addition to the ability to manipulate the autoimmune B and T cell responses, 
the mMOGtag system is valuable as a system to identify and study MOG-specific B cells. 
The first way that this can be done is using the MOG1-125 Ag as a reagent for an ELISpot 
to identify MOG-specific plasma cells in a tissue. Indeed, here I was able to show that 
MOG1-125-specific plasma cells are found in draining LNs and bone marrow post-
immunization with mMOGtag. The mMOGtag Ag can also be used as a flow cytometry 
reagent to identify MOG-specific B cells. In the experiments shown in this chapter, 
MOG-specific B cells were identified by staining them with mMOGtag followed by a 
secondary anti-his antibody and a tertiary anti-mouse IgG1 antibody. This method has the 
flaw that it identifies IgG1+ B cells in addition to identifying mMOGtag-specific B cells. 
This can be addressed through direct conjugation of the mMOGtag protein to a 
fluorophore, thereby removing the need for the tertiary anti-IgG1 antibody, a method that 
we have validated previously (240) and will use in Chapter 3 of this thesis. Similar 
methods have been used to study GC responses induced with nitrophenyl (NP) 
haptenated proteins but, the NP system has one major advantage over our MOG based 
system, the ability to study antibody/BCR-affinity by manipulating the conjugation ratio 
of NP to protein to increase or decrease Ag-avidity (274). Thus, although mMOGtag is a 
useful tool for studying MOG-specific B cells and plasma cells, it does not have the same 
utility as previously established methods for studying GC responses to other Ags.  
 In summary, here I have described a simple protocol for producing and purifying 
large quantities of mMOGtag protein. Furthermore, the addition of a TEV protease 
cleavage site to our mMOGtag protein provides the opportunity to generate enriched 
MOG1-125 that can be used to identify MOG-specific antibodies in serum or detect MOG-
specific plasma cells. I have also shown that our expression system is modular by 
producing haMOGtag, an Ag that successfully manipulated the induction of EAE and the 
underlying T cell response by stimulating autoreactive T cells with a high-affinity T cell 
epitope. Furthermore, as both mMOGtag and haMOGtag are recognized and bound by anti-
myelin autoimmune B cells, EAE induced with these proteins incorporates myelin-
specific B cell-mediated contributions into their pathology. Therefore, this protein 
expression system allows us to not only begin to study how B cells contribute to EAE, 
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but also how manipulations of B cells or T cells modify how the underlying autoimmune 
response develops and by extension how EAE progresses. 
 
2.4 Materials and Methods 
2.4.1 Mice 
 C57Bl/6, 2D2 TCR-transgenic (264), SMARTA TCR-transgenic 
(4694;Tg(TcrLCMV)327Sdz/JDvsJ), and OTII TCR-transgenic mice 
(4194;Tg(TcraTcrb)425Cbn/J) were purchased from Jackson Laboratories, Bar Harbor, 
Maine. IgHMOG MOG-specific BCR knock-in mice (256) were received as a gift from Dr. 
H Wekerle. Mice expressing fluorescent proteins within all nucleated cells, either dsRed 
(RFP; 6051; Tg(CAG-DsRedpMST)1Nagy/J) under control of the β-Actin promoter or 
eGFP via the ubiquitin promoter (4353; Tg(UBCGFP)30Scha/J) were obtained from the 
Jackson Laboratory. Mice were housed in a specific pathogen-free barrier at the 
University of Western Ontario’s West Valley Barrier Facility (London, Ontario). All 
animal protocols (2011-047 and 2015-090) were approved by the Western University 
Animal Use Subcommittee. 
2.4.2 Antibodies used for flow cytometry or histology 
 The following antibodies were purchased from BD Biosciences (Franklin Lakes, 
New Jersey): anti-CD4-V450 and A647 (RM4-5), anti-CD19-BV711 (1D3), and anti-
IgG1-APC (A85-1). The following antibody was purchased from BioLegend (San Diego, 
California): anti-His Tag-purified (J099B12). The following antibodies were purchased 
from Thermo Fisher Scientific (Waltham, Massachusetts): anti-IgD-eF450 (11–26), anti-
CD3-FITC (145-SC11), and anti-CD4-PE-Cy5 (RM4-5). FluoroMyelin Red for myelin 
staining was purchased from Invitrogen (Carlsbad, California). 
2.4.3 Recombinant mMOGtag and haMOGtag vector design and purification 
 The mMOGtag insert was designed using SnapGene software (Chicago, Illinois) to 
include the following: a TEV cleavage sequence site (ENLYFQ/G), the extracellular 
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immunoglobulin domain of mouse MOG (residues 1–125), a TAA stop codon and BglII 
and EcoRI restriction sites added to the 5' and 3' ends, respectively. The mMOGtag insert 
sequence was codon optimized for bacterial protein expression in E. coli then synthesized 
in the pQE-12 vector (Celtek Genes, Franklin, Tennessee). The insert was then cloned 
into the pET-32a(+) vector containing the gene for thioredoxin (Novagen, Madison, 
Wisconsin) and then transformed into BL21 E. coli using standard transformation 
procedures(275).  
 A protocol for purification of mMOGtag protein was adapted from previous 
systems (245) and is described in more detail in a Jain et al. 2016 (276). pET-32a(+) 
mMOGtag BL21 E. coli were cultured in LB medium at 37 °C to an O.D. of 0.6, when 
protein expression was induced overnight with 1 mM IPTG. Bacterial cells were pelleted 
and suspended in lysis buffer (0.1 mg/mL hen egg lysozyme, 0.1% Triton-X (v/v) in 
PBS) then lysed to collect inclusion bodies. The inclusion body pellet was suspended in 
500 mM NaCl, 20 mM Tris–HCl, 5 mM imidazole, pH 7.9 (Buffer A) and incubated at 4 
°C, then denatured with the addition of 6 M guanidine (Buffer B). The protein suspension 
was centrifuged at 4 °C to collect the supernatant containing the solubilized proteins. 
Before protein absorption, His-Bind nickel resin (Novagen, Madison, Wisconsin) was 
prepared according to the manufacturer's instructions. Briefly, the nickel resin was 
washed and treated with distilled water and 100 mM NiSO4, then equilibrated with Buffer 
B. The solubilized proteins containing mMOGtag was incubated with the charged nickel 
resin in a standard 50 mL centrifuge tube at 4 °C. Following centrifugation, the 
supernatant was kept for further rounds of purification and mMOGtag was eluted from the 
pelleted resin with 500 mM imidazole, 500 mM NaCl, 6 M guanidine and 20 mM Tris–
HCl pH 7.9. Elutions were pooled and exchanged by overnight dialysis at 4 °C into the 
storage buffer containing 0.115% glacial acetic acid, 3 mM sodium acetate and 
concentrated with PEG3350 and PEG8000 to 5 mg/mL before storage at -80 °C. Unless 
otherwise stated, reagents were purchases from Bioshop (Burlington, Ontario). Protein 
expression and quantification were confirmed using standard SDS-PAGE and Bradford 
assay kits (Bio-Rad, Hercules, California) according to manufacturer’s instructions. 
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 To generate haMOGtag, the pET-32 mMOGtag vector was mutated by PCR using 
the following primers: 5'-
TCTTCTTTTTCTCGCGTTTCTGGTTCTCCGTCTTCTGGTTTTGAAAACTTGTATT
TCCAAGGACAGTTTCGCG 3' and the reverse primer 5'-
GCGAGAAAAAGAAGAACGGGTTTCGGTAACACGACGATATGCACCGGAGCC
ACCACCGGTAC 3'. The resulting vector was sequenced to confirm the insertion of the 
13-35 NF-M sequence (based on NCBI Reference Sequence: NP_032717.2) and 
transformed into BL21 bacteria for expression. Expression of the haMOGtag protein is 
similar to what was listed above for mMOGtag. However, haMOGtag was concentrated to 
5.394 mg/mL to be equimolar with mMOGtag. 
2.4.4 TEV protease cleavage of mMOGtag protein 
 Purified mMOGtag was dialyzed into 50 mM Tris–HCl, 0.5 mM EDTA and 5 mM 
2-Mercaptoethanol pH 8. Then, AcTEV protease (Thermo Fisher Scientific, Waltham, 
Massachusetts) was added to mMOGtag protein at a 1:20 ratio and incubated at room 
temperature for 72 hrs. The protein was then dialysed into pure water then concentrated 
with PEG8000 to a final volume of 35 mL. The protein was then dialyzed into buffer B 
and the tag, AcTEV protease, and uncut mMOGtag impurities were removed through 
incubation with charged nickel resin as described above. After four rounds of incubation 
with nickel, the original volume was then dialyzed into 0.115% glacial acetic acid and 
concentrated using PEG3350 and PEG8000 to 2.24 mg/ml before storage at -80 °C. 
Unless otherwise stated, reagents were purchases from Bioshop (Burlington, Ontario). 
Protein expression and quantification were confirmed using standard SDS-PAGE and 
Bradford assay kits (Bio-Rad, Hercules, California) according to manufacturer’s 
instructions. 
2.4.5 Adoptive transfer of B and T cells and immunization 
 Naïve Ag-specific T cells were isolated from RFP+ 2D2 mice and naïve Ag-
specific B cells were isolated from GFP+ IgHMOG mice as previously described (78). 
Briefly, LNs and spleens of RFP+ T cell and GFP+ B cell mice were dissociated and B 
and T cells were isolated using EasySep Negative selection Mouse B and T cell 
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Enrichment Kits (StemCell Technologies, Vancouver, Canada). Five million GFP+ 
IgHMOG B cells and 5 x 105 2D2 T cells were transferred i.v into C57Bl/6 or SMARTA 
recipients 2 days prior to immunization. Mice were immunized in each flank with 
equimolar amounts of the given Ag (250 μg mMOGtag and 270 μg haMOGtag) in 
complete freund’s adjuvant (CFA) and injected with 250 ng PTX on days 0 and 2 post-
immunization. Draining inguinal LNs were harvested at the indicated time points for 
analysis.  
2.4.6 Flow cytometry 
 Draining popliteal LNs were harvested from mice for flow cytometric analysis as 
previously described (78). Briefly, LN cell suspensions were blocked with an anti-Fcγ 
receptor, CD16/32 2.4G2 (BD biosciences, Franklin Lakes, New Jersey), in PBS 
containing 2% FBS before further incubation with the indicated antibodies. Dead cells 
were excluded by staining with either the Fixable Viability Dye eFluor506 or propidium 
iodide (Thermo Fisher Scientific, Waltham, Massachusetts). Flow cytometry was 
performed on a BD Immunocytometry Systems LSRII cytometer and analyzed with 
FlowJo software (Tree Star, Ashland, Oregon).  
2.4.7 Induction of EAE 
 Six to 8 week old mice were immunized s.c. on d0 at two sites on the hind flanks 
with a total of either 0.5 mg of mMOGtag or 0.54 mg of haMOGtag mixed 1:1 with 4 
mg/mL desiccated M. tuberculosis (H37 Ra) in incomplete freund’s adjuvant (Sigma-
Aldrich, St. Louis, Missouri). At the same time mice were also administered 250 ng of 
pertussis toxin (List Biological Laboratories, Campbell, California) i.p. and again on d2. 
Clinical disease was monitored daily and was scored according to standard conventions 
(277) as follows: 0, no clinical signs; 1, tail paralysis; 2, tail paralysis and hind limb 
weakness; 3, hind limb paralysis; and 4, complete hind limb paralysis and front limb 
weakness. Half points were given for intermediate scores. 
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2.4.8 Immunofluorescence histology 
 At the end of the experiment, spinal cords and inguinal LNs were extracted from 
mice and prepared as previously described (78). Briefly, spinal cords and LNs were 
extracted and incubated overnight in 1% paraformaldehyde (PFA), 95 mM L-Lysine, 10 
mM sodium periodate, pH 7.2 (Bioshop, Burlington, Ontario). Tissues were then 
incubated in solutions of increasingly concentrated sucrose until a final concentration of 
30% sucrose (Bioshop, Burlington, Ontario). Then, 5–9 evenly spaced spinal cord tissues 
spanning the lumbar to cervical regions were cut and frozen in OCT (Tissue-Tek, St. 
Torrance, California) media or directly frozen in OCT media for inguinal LNs. Serial 
cryostat sections (7 μm) were blocked in PBS containing 1% Bovine Serum Albumin, 
0.1% Tween-20 and 10% rat serum before proceeding with staining. Sections were 
mounted with ProLong Gold Antifade Reagent (Invitrogen, Carlsbad, California) and 
stored at −20 °C. Tiled images of whole spinal cord sections or inguinal LNs (20×) were 
imaged using DM5500B fluorescence microscope (Leica microsystems, Concord, ON, 
Canada). 
2.4.9 In vitro and in vivo T cell proliferation assays 
 RFP+ OTII or 2D2 CD4+ T cells were enriched through negative selection as 
described above. Splenocytes of wild type C57Bl/6 mice were depleted of red blood cells 
using ACK lysis buffer (Thermo Fisher Scientific, Waltham, Massachusetts). The cells 
were then transferred into 10% FBS RPMI with L-glutamine (Thermo Fisher Scientific, 
Waltham, Massachusetts) supplemented with 1x penicillin/streptomycin (WISENT, 
Saint-Bruno, Quebec, Canada). One million splenocytes were then added to individual 
wells of a sterile 48-well plate and were incubated with either 35 μg NP-OVA, 25 μg 
mMOGtag, or 27 μg haMOGtag for one hour at 37 °C 5% CO2. OTII or 2D2 T cells were 
CFSE (Thermo Fisher Scientific, Waltham, Massachusetts) labelled as described in (278) 
and 4 x105 T cells were added to the Ag loaded splenocytes. After three days of co-
culture, CFSE labeling of Ag-specific T cells was analyzed by flow cytometry. For the in 
vivo assays, T cells were CFSE labelled as listed above and transferred into mice, also 
listed above. 
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2.4.10 ELISpots and ELISA 
 96-well plates were coated overnight at 4°C with 0.5 μg MOG1-125. Wells were 
blocked with 1% (wt/vol) BSA in PBS, then incubated with serial diluted bone marrow or 
LN cells at 37°C in 5% CO2. Spots were detected using a goat alkaline phosphatase-
conjugated anti-mouse IgM or IgG antibody (MABTECH, Nacka Strand, Sweden) and 5-
bromo-4-chloro-3-indolyl-phosphate substrate (Sigma-Aldrich, St. Louis, Missouri) and 
counted under a Leica M80 dissection microscope. To detect circulating antibodies 
against MOG1-125, 96-well plates were incubated with MOG1-125 and blocked with BSA 
as written above. Blood was extracted from mice using a cardiac puncture into preloaded 
syringes with 0.5 M EDTA and spun at 4500 x g for 15 minutes. Plasma was extracted 
and incubated with the 96-well plate for one hour at room temperature. Plates were 
incubated with anti-IgM or IgG antibodies and then the alkaline phosphatase yellow 
(pNPP; Sigma-Aldrich, St. Louis, Missouri) substrate. OD405 was measured using an 
Eon microplate spectrophotometer (BioTek, Winooski, Vermont). 
2.4.11 Statistical analyses 
 PRISM software (GraphPad Software, La Jolla, California) was used to analyze 
flow cytometry and histology data. For statistical comparisons, a Student’s T-test was 
used for single comparisons and a one-way ANOVA followed by a T test with 
Bonferroni correction was used for multiple comparisons. 
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Chapter 3  
3 Autoreactive T cells preferentially drive differentiation of 
short-lived memory B cells at the expense of germinal center 
maintenance. 
 B cell fate decisions within a GC are critical to determining the outcome of the 
immune response to a given Ag. Here, I characterize GC kinetics and B cell fate choices 
in response to the autoAg MOG, and compare them to the response to a standard model 
of foreign Ag (NP-haptenated ovalbumin, NPOVA). Both Ags generated productive 
primary responses, as evidenced by GC development, circulating Ag-specific antibodies, 
and differentiation of memory B cells. However, in the MOG response the status of the 
cognate T cell partner drove preferential B cell differentiation to a memory phenotype at 
the expense of GC maintenance, resulting in a small ongoing GC. Indeed, placing the 
same NP-specific B cells under the control of either OVA or MOG-specific T cells, I 
identified that preferential memory B cell differentiation over GC maintenance was 
instructed by the MOG-specific T cell. Furthermore, the MOG-specific T cell could not 
efficiently expand the early low-affinity plasmablast response although plasma cell 
differentiation occurred similarly within the GC under the control of either T cell. The 
collapse of MOG-driven GCs, but not plasmablast expansion, could be partially reversed 
by hyperactivating MOG-specific T cells with a high-affinity Ag suggesting low T cell 
Ag-affinity limits the MOG-driven GC response. Despite this, TFH cells exhibited no 
observed differences in the expression of cytokines or surface receptors previously 
identified as controlling memory B cell differentiation in the different model systems. 
Interestingly, memory B cells formed in the MOG GC were short-lived leading to the 
failure of secondary challenges with Ag to induce GC responses. The short-lived nature 
of memory B cells was not programmed by the autoreactive T cell. Overall these results 
highlight properties of B and T cells that contribute to B cell fate choices in GC responses 
and how these are relevant to an autoimmune response. 
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3.1 Introduction 
 Tailoring the immune response to a given Ag is a crucial function of the immune 
system, as the quality and nature of the response impacts the success of pathogen 
clearance as well as subsequent long-lived immunity. This is further complicated in cases 
where the response directly targets or cross reacts with an autoAg. Nearly all naturally 
occurring immune responses incorporate both B and T cell recognition of the Ag, and 
collaboration between B and T cells specific for said Ag produces a GC response (94, 
279, 280). Throughout the GC response, B cell survival, proliferation, and differentiation 
to either antibody-producing plasma cells or memory B cells is dependent upon, and 
informed by, direct interactions with T cells specific for the same Ag (cognate 
interactions) (58). However, the signals that drive differential fate choices made by B 
cells responding to different Ags and how they are influenced by features of the Ag itself 
are not well understood.  
 Interactions with cognate T cells are critical during two distinct phases of the 
developing B cell response. The first phase occurs shortly after exposure to a new Ag, but 
prior to GC formation. During this phase, cognate B-T interactions are essential to the 
initiation of Ag-stimulated B cell proliferation and also to driving B cell differentiation 
along three distinct pathways: 1st, short-lived plasmablasts that produce low-affinity 
largely IgM antibodies; 2nd, early (mostly) IgM memory B cells; and 3rd, GC B cells 
that reenter the follicle to initiate a new GC (281). The second phase of B-T cell 
interactions occurs within the mature GC itself. GC B cells undergo clonal expansion and 
SHM largely within the DZ, before migrating to the LZ to compete for survival signals 
supplied through interactions with specialized cognate TFH cells (58). Evidence also 
suggests that TFH cells provide signals that, in addition to maintaining the GC by 
selecting GC B cells for survival and additional rounds of proliferation and mutation in 
the DZ, further influence GC B cell differentiation into memory B cells or plasma cells. 
GC-derived plasma cells and long-lived plasma cells produce the high-affinity, class-
switched antibodies critical to pathogen clearance and long-term immunity; while 
different subpopulations of GC-derived memory B cells are able to rapidly differentiate 
into plasma cells or re-initiate the GC upon re-exposure to Ag.  
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 Several TFH-derived signals have been identified that can, through genetic 
deletion or antibody blockade, influence B cell differentiation. These include the 
cytokines IL-4 and IL-21 (177, 233) and receptors PD-1 and ICOS (218, 223). It is 
possible that differential expression of these factors is the mechanism by which the 
immune system tailors the B cell response to different Ags, but this has not been 
explored. B cell receptor affinity for Ag is known to influence B cell fate choice, with 
higher-affinity being linked to preferential plasma cell differentiation (248), but how or if 
an Ag can influence the cognate T cell partner or the signal it provides to B cells is not 
known.  
 Recent advances in understanding GC development and the cognate B-T 
interactions that drive them have benefited from model Ag systems in which B and T 
cells specific for the Ag can be identified and their activation and differentiation tracked 
over the course of the response. For example, we and others have transferred fluorescent 
protein-marked ovalbumin (OVA)-specific T cells isolated from OTII mice and 
nitrophenyl hapten (NP)-specific B cells from B1-8 mice to non-fluorescent protein-
marked mice to track both cell types in the developing GC following immunization with 
NPOVA (78, 106). Similar models based on other (mostly) foreign-Ags produce GCs 
with similar kinetics and patterns of B cell differentiation. A model system based on an 
autoAg may provide a tool with which to dissect the mechanisms by which the immune 
system itself controls differential outcomes, without relying on external blockade or 
deletion of candidate factors. Yet comparable models that examine the development of 
the autoimmune GC remain under explored.  
 MOG is a well characterized autoAg associated with anti-myelin autoimmunity of 
the CNS, both in human MS and the well-characterized animal model EAE. In MS, anti-
myelin B cells and antibodies show evidence of SHM, indicating that they are GC-
derived (72, 282). Currently, the most common way to induce MOG autoimmunity in 
C57Bl/6 mice is to immunize with the MOG35-55 peptide that corresponds to the CD4
+ T 
cell epitope, a method that excludes B cell targeting of the MOG protein (240). However, 
as I have showed earlier (Chapter 2), immunization with a larger peptide corresponding 
with the MOG-extracellular domain does indeed result in GC development incorporating 
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anti-MOG B cells (240, 283). Therefore, using the tools assembled and developed in 
Chapter 2, we can use our MOG-based model Ag system in an analogous manner to the 
NPOVA system described above for investigation of differential B cell fate choice under 
the control of notably different Ags. 
 Here, I demonstrate that the GC develops very differently in response to MOG 
compared to the well characterized NPOVA system. In comparison to the NPOVA 
response, B cell fate choice in the MOG GC response was heavily biased against plasma 
cells. Further, while the initial stages of the MOG GC developed normally, it was not 
sustained and instead collapsed early, producing a large number of memory-phenotype B 
cells. By manipulating the T cell controlling the same B cell response, I determined that, 
while plasma cell differentiation was largely independent of T cell influence, 
immunoglobulin class-switching, GC maintenance, and B cell differentiation into a 
memory-phenotype were largely under the control of the T cell partner. By manipulating 
the Ag itself, I, for the first time, found the T cell affinity for Ag impacts B cell fate 
choice. Finally, we determined that memory-phenotype B cells derived from the MOG 
GC are not long-lived, resulting in a failed memory response to secondary-challenge. 
Finally, the short-lived nature of MOG-specific memory B cells is not due to education 
by the autoimmune T cell. 
 
3.2 Results 
3.2.1 Immunization with MOG autoAg results in an atypical, unsustained 
GC response 
 In order to identify and track responding B and T cells throughout an immune 
response to two different Ags, GFP+ B cells (either NP-specific B1-8+ Jκ-/- (284, 285) or 
MOG-specific IgHMOG (256)) and RFP+ T cells (either OVA-specific OTII (265) or 
MOG-specific 2D2 (264)) were isolated from transgenic mice and transferred into wild 
type C57Bl/6, non-fluorescent protein-marked recipients (Figure 3.1A). Two days post-
transfer, mice were immunized in the footpad with the appropriate Ag (NPOVA for 
recipients of B1-8 B cells and OTII T cells, or mMOGtag for recipients of IgH
MOG B cells 
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and 2D2 T cells) in CFA. Lymph nodes were harvested for histological analysis 5d post-
immunization, representing the outcomes of early, pre-GC cognate interactions between 
responding B and T cells, or 10d post-immunization, representing a mature GC time 
point.  
 While virtually no transferred fluorescent cells could be observed in LNs from 
unimmunized mice (data not shown), large numbers of fluorescent B and T cells derived 
from the original transferred populations were readily evident at the 5d time point in both 
Ag systems (Figure 3.1B, top and 3.1C). Consistent with previous observations (78), PD-
1+ RFP+ TFH cells were distributed throughout the follicle and GC in both model systems, 
although the density of RFP+ T cells was significantly lower in mMOGtag-immunized 
mice (Figure 3.1B, 3.1C, 3.1E).  
 Very large numbers of GFP+ CD138+ cells, representing the early short-lived 
plasmablast response, were evident outside of the follicles and within medullary cords of 
NPOVA- but not mMOGtag-immunized mice (Figure 3.1D). By 10d post immunization 
fewer, but equivalent numbers of plasma cells were within medullary cords in both model 
systems. 
 Within B cell follicles, dense clusters of GFP+ cells (Figure 3.1B and 3.1C) that 
were also IgDlo, Ki67+, and Bcl-6+ (Figure 3.1A and 3.1E) were evident in both systems 
5d post-immunization, indicating that early pre-GC B-T interactions were sufficient to 
drive GC B cell differentiation and establishment of a new GC. However, by 10d post-
immunization, the GC in the MOG Ag system had largely disappeared, while this time 
point corresponded with the full development of a mature and organized GC in the 
NPOVA system (Figure 3.1B, bottom and 3.1C). Small clusters of Ki67+ and Bcl-6+ cells 
could still be observed in follicles of mMOGtag-immunized mice, however these were 
much smaller and less dense than those observed in NPOVA mice (Figure 3.1E). Instead, 
greater numbers of individual GFP+ cells were scattered throughout the follicle (Figure 
3.1B and 3.1C). Very few individual GFP+ cells were evident in the follicle in the 
NPOVA system, and virtually all remained confined in the GC. 
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Figure 3.1. Differential GC development in the NPOVA and MOG model Ag systems. 
(A) Fluorescent protein-marked B and CD4+ T cells specific for NPOVA or MOG were 
isolated and transferred into wild type, non-fluorescent protein-marked recipients. Two 
days post-transfer, mice were immunized with either NPOVA or mMOGtag in CFA in the 
footpad. Draining popliteal LNs were harvested for histology d5 and d10 post-
immunization, representing the early and mature GCs. (B) Immunofluorescence of LNs 
from NPOVA and mMOGtag immunized mice to visualize RFP
+ T cells and GFP+ B cells 
derived from transferred Ag-specific cells. Sections were also stained for IgD to outline B 
cell follicles. Scale bars represent 100 µm. (C) The density of GFP+ or RFP+ cells in the 
GC or follicle was quantified. Each data point represents the average value across one 
histological section for a single mouse. * p<0.05, **p<0.01, ***p<0.001. A Student’s T-
test was used for single comparisons. (D) Higher magnification of the regions of interest 
outlined by the dashed lines in panel B showing CD138 staining for plasma cells. (E) 
Higher magnification of the regions of interest outlined by the solid white line in panel B 
were further examined for Ki67, Bcl6, and PD-1 expression. Data is representative of 1 
of 2 experiments. 
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3.2.2 Preferential differentiation of B cells with a memory phenotype in 
response to MOG autoAg 
 The developing GC response was analyzed by flow cytometry in a separate, 
identical experiment. Consistent with our histological observations, the early CD19int 
CD138+ plasma cell response was nearly absent in mMOGtag-immunized mice compared 
to a very large response in the NPOVA system (Figure 3.2A-3.2C). This was true of both 
the GFP+ response derived from transferred, Ag-specific B cells and the endogenous 
GFP- response (Figure 3.2C bottom), confirming that this is a feature of the anti-MOG 
response. 
 While Ag-specific GFP+ CD95hi CD38lo GC B cells were evident in both the 
NPOVA and MOG systems at the d5 time point, they made up a significantly smaller 
proportion of the total GFP+ B cell population in the MOG system (Figure 3.2A-3.2C), 
and most dramatically at the d10 time point, consistent with the collapse of the GC 
response observed by histology. A similar collapse of the endogenous, GFP- GC was also 
observed in mMOGtag immunized mice (Figure 3.2C bottom). The proportional loss of 
GFP+ Ag-specific GC B cells and plasma cells in the MOG response was offset by a large 
increase in the proportion of CD95lo CD38hi cells, a phenotype shared by naïve and 
memory B cells (Figure 3.2C, top right).  
 Evaluation of immunoglobulin class-switching in the GC B cell population 8d 
post immunization, prior to complete collapse of the MOG GC, revealed that the ratio of 
IgG1 to IgM-expressing GC B cells was significantly higher in NPOVA-immunized mice 
(Figure 3.2E). Nevertheless, and despite the bias against plasma cell development (Figure 
3.2A and 3.2C), mMOGtag-immunized mice were still capable of mounting an Ag-
specific antibody response, albeit smaller than observed to NPOVA. Indeed, by ELISpot 
the number of anti-MOG IgM and IgG producing cells was significantly lower in LN’s 
14d post immunization compared to anti-NP producing cells (Figure 3.2D, middle). 
Similar analysis of bone marrow revealed a reduction in anti-MOG IgM, but not IgG-
producing cells (Figure 3.2D, right). This was reflected by reduced levels of circulating 
anti-MOG compared to anti-NP IgM but not IgG, as measured by ELISA of serum from 
the same mice (Figure 3.2D, left). 
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 As the anti-MOG GC response is an autoimmune response, it was possible that 
regulatory processes, such as the induction of Bregs (44), Tregs (286), or TFR cells (187), 
could have contributed to the collapse of the MOG GC response. In a separate 
experiment, there was no difference between the MOG and NPOVA systems in IL-10 
production by GFP+ or GFP- B cells, a measure of Breg cells, or by T cells (Figure 3.2F). 
Neither were there any differences in the proportion of Treg or TFR cells. Therefore, an 
enhanced regulatory response was not responsible for the failed GC in the MOG system. 
It has also been suggested that administration of PTX, which is often used in conjunction 
with MOG-immunization to induce EAE, could modify regulatory responses and by 
extension, potentially affect the GC (287). However, I found that PTX administration did 
not rescue the MOG GC (Figure 3.3A) and had no effect on circulating antibody titers 
(Figure 3.3B). 
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Figure 3.2. Early collapse of the MOG GC to a memory B cell phenotype. 
(A-C and F) Fluorescent protein-marked B and CD4+ T cells specific for NPOVA or 
MOG were transferred into non-fluorescent protein-marked C57Bl/6 mice that were then 
immunized with NPOVA or mMOGtag. Draining LNs were harvested for analysis by 
flow cytometry d5 and d10 post-immunization. (A) Representative gating of GFP+ cells 
for plasma cells (PC), GC B cells, and memory/naive B cells (M/N). (B) Shown is the 
absolute number of GFP+ cells per LN. (C) Quantification from panel A showing size of 
each cell subset (as defined in panel A, gating shown above each plot) derived from the 
transferred GFP+ B cells (top row) or from endogenous GFP- cells (bottom row). Data is 
expressed as the percentage of all GFP+ cells for Plasma cells, or percentage of all GFP+ 
B cells (CD19+ CD138-) for GC and Memory/Naïve B cells. One representative of two 
separate experiments is shown. Of note, the difference between GFP- plasma cells at d5 
was not seen using a non-parametric test. (D) C57Bl/6 mice were immunized with either 
NPOVA or mMOGtag in CFA. Day 14 post-immunization, draining popliteal LNs and 
bone marrow were taken for ELISpot analysis of NP- or MOG-specific IgM or IgG. 
Blood serum from the same mice was assayed by ELISA for circulating anti-NP or -
MOG IgM or IgG antibodies. Data is representative of 1 of 2 experiments. Of note, no 
statistically significant difference is seen in the number of IgM plasma cells in the bone 
marrow when using a non-parametric test. (E) The ratio of IgG1 expressing cells over 
IgM expressing GC B cells d8 post-immunization is shown. Data is representative of 1 of 
2 experiments. (of note, there was no statistically significant difference between the 
groups when using a non-parametric test). (F) The percentage of all T cells expressing 
IL-10 (top) or FoxP3 (top middle), the percentage of Bcl6+ PD-1high expressing FoxP3 
(middle), and the percentage of B cells expressing IL-10 for GFP+ cells (bottom middle) 
and GFP- cells (bottom) are shown d10 post-immunization. Data is based on one 
experiment. In all graphs, each data point represents an individual mouse. * p<0.05, 
**p<0.01, ***p<0.001. A Student’s T-test was used for single comparisons. 
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Figure 3.3. Administration of pertussis toxin does not save the MOG-induced GC from 
collapse 
(A and B) Fluorescent protein-marked MOG-specific B and CD4+ T cells were 
transferred into non-fluorescent protein-marked C57Bl/6 mice that were then immunized 
with mMOGtag. On days 0 and 2, mice were injected i.p. with either PBS or PTX. 
Draining LNs were harvested for analysis by flow cytometry d10 post-immunization. (A) 
Shown is the absolute number of GFP+ cells per LN (left) and each cell subset derived 
from the transferred GFP+ B cells is expressed as the percentage of all GFP+ cells for 
Plasma cells, or percentage of all GFP+ B cells (CD19+ CD138-) for GC and 
Memory/Naïve B cells. (B) Blood serum from the same mice was assayed by ELISA for 
circulating anti-mMOGtag IgM or IgG antibodies. Data is based on one experiment. In all 
graphs, each data point represents an individual mouse. A Student’s T-test was used for 
single comparisons. 
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3.2.3 Ag-specific GFP+ CD95lo CD38hi B cells are Ag experienced 
 To confirm that the GFP+ CD95lo CD38hi B cells observed above derive from 
previously activated and proliferating cells, bromodeoxyuridine (BrdU) was injected d4, 
d5, and d6 post-immunization to label proliferating cells. On d10 post-immunization, 
LNs were harvested for flow cytometry analysis. In this way, only cells that were actively 
proliferating during the labeling period (note that only a proportion of actively 
proliferating cells would be labeled, due to the short half-life of free BrdU in mice), but 
had then become quiescent would retain BrdU labeling (126). Indeed, neither non-
proliferating endogenous GFP- CD95lo CD38hi follicular B cells (Figure 3.4A), nor 
proliferative GFP+ CD95hi CD38lo GC B cells (data not shown) stained with BrdU. In 
contrast, a proportion of GFP+ CD95lo CD38hi memory/naïve B cells were BrdU+ in both 
model systems, confirming that some of them derived from previously activated cells. 
Nonetheless, a relatively smaller portion of MOG-specific memory-phenotype B cells 
had labelled with BrdU, making it unclear how many of these cell had actually expanded 
due to mMOGtag-immunization.  
 To more precisely establish whether GFP+ CD95lo CD38hi B cells in the MOG 
system had indeed derived from previously activated cells, GFP+ IgHMOG B cells were 
isolated and labeled with Cell Tracker Yellow (CTY) prior to transfer along with either 
OVA or MOG-specific T cells. The CTY dye was used to monitor proliferation as the 
fluorescent signal from this dye halves whenever cells proliferate. Furthermore, this dye 
was used in combination with fluorescently labelled mMOGtag protein to identify 
mMOGtag-specific B cells. Recipients expressing an irrelevant transgenic TCR 
(SMARTA) were used as recipients to limit the endogenous T cell response. Control 
mice were left unimmunized or, to measure Ag-non-specific expansion, recipients of 
OVA-specific T cells were immunized with OVA to generate a GC response to an 
irrelevant Ag. Compared to unimmunized mice at the same time point, immunization 
with OVA protein resulted in a small, non-significant increase in GFP+ cells in draining 
LNs d10 post-immunization and, as expected, they did not participate in the GC response 
(Figure 3.4B, top). Immunization of mice with mMOGtag that received MOG-specific T 
cells however, resulted in an increase in GFP+ cells. Consistent with above (Figure 3.2C), 
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the majority had a CD95lo CD38hi naïve/memory B cell phenotype, but some CD95hi 
CD38lo GC B cells were still evident. Approximately 90% of these GFP+ GC B cells 
bound fluorescently-labelled mMOGtag antigen (Figure 3.4B, bottom), and all had fully 
diluted out the CTY dye (data not shown). Among the GFP+ CD95lo CD38hi 
naïve/memory B cell population, ~50% bound mMOGtag Ag (Figure 3.4B, bottom). 
Further, a proportion of these cells had at least partly diluted CTY, indicating that they 
derived from proliferating cells (Figure 3.4C, left). While some non-specific expansion 
and CTY dilution was observed in the OVA-immunized mice, compared to expanded 
GFP+ memory B cells in MOG-immunized mice, they had a higher mean fluorescence 
intensity (MFI) for CTY, indicating that immunization with OVA did not induce the 
same extent of proliferation (Figure 3.4C, middle). Furthermore, CTY dilution was 
concentrated in the mMOGtag-binding population in MOG-immunized but not OVA-
immunized mice, indicating that expansion of the CD95lo CD38hi had been driven by Ag 
(Figure 3.4C, right). 
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Figure 3.4. Memory-phenotype B cells generated in response to MOG are Ag-
experienced 
(A) Fluorescent protein-marked OVA or MOG-specific B and T cells were transferred 
into non-fluorescent protein-marked SMARTA recipient mice and immunized with 
NPOVA or mMOGtag, respectively. Mice were injected i.p. with BrdU d4, d5, and d6 
post-immunization and BrdU incorporation in the GFP+ or GFP- memory/naïve B cell 
populations was assessed by flow cytometry d10 post-immunization. Each graph 
represents a separate experiment and the data points in the mMOG graph were pooled 
from two separate experiments. (B and C) IgHMOG GFP+ B cells were labelled with CTY 
then transferred into SMARTA recipient mice along 2D2 or OTII T cells. Mice were then 
immunized with either mMOGtag, OVA (for those that received OTII T cells), or given no 
immunization and the GC response was assessed by flow cytometry d10 post-
immunization. (B) Data is expressed as the absolute number of GFP+ cells, as the 
percentage of all GFP+ B cells (CD19+ CD138-) for GC and Memory/Naïve B cells (top 
panels), or as the percentage of all GFP+ GC or Memory/Naïve B cell that are mMOGtag
+ 
(bottom panels). Of note, the difference in the percentage of GFP+ B cells as GC B cells 
between the OVA and MOG groups was not seen in a non-parametric ANOVA. (C) Data 
is expressed as the percentage of GFP+ Memory/Naïve B cells that are CTYlow/neg (left) 
(of note, one data point in the ‘none’ group was identified as an outlier; furthermore, a 
statistically significant difference is seen between the ‘none’ group and MOG group 
when using a non-parametric ANOVA), the MFI CTY of CTYlow/neg Memory/Naïve B 
cells (middle), or the percentage of CTYlow/neg Memory/Naïve B cells that are MOGtag
+ 
(right). Data is based on one experiment. In all graphs, each data point represents an 
individual mouse. *p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for 
single comparisons and a one-way ANOVA was used for multiple comparisons. 
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3.2.4 T cells partially control the outcome of the germinal center response 
to MOG 
 To begin to decipher the role for the cognate T cell partner in instructing 
differential B cell fate choice and the failure of GC maintenance in the MOG vs NPOVA 
systems, we took advantage of the modular nature of the hapten Ag system to place NP-
specific B1-8+ Jκ-/- B cells under control of either OVA-specific OTII T cells (NPOVA) 
or MOG-specific 2D2 T cells (NPMOG). Fluorescent protein-marked NP-specific B cells 
were transferred to non-fluorescent protein-marked SMARTA recipients and either OVA 
or MOG-specific T cells were transferred at the same time. Recipients were immunized 
2d later with NPOVA for mice that received OTII T cells or NPMOG for those that 
received 2D2 T cells and LNs were harvested d5 or d10 post-immunization for analysis 
by flow cytometry or, in a separate experiment, histology. 
 Five days post-immunization, there was no significant difference in the number of 
GFP+ cells, but short-lived plasmablasts made up a smaller proportion of the NP-specific 
GFP+ response under control of MOG-specific T cells compared to OVA specific T cells 
(Figure 3.5A). However, similar results were not seen at the d10 time point suggesting 
plasma cell numbers had fully recovered by d10. A large population of GC B cells was 
evident d5 post-immunization by flow cytometry (Figure 3.5A) and large GCs were seen 
by histology (Figure 3.5B and 3.5C) in both systems, indicating that OVA and MOG-
specific T cells are capable of supporting the early formation of a GC. However, by d10 
post-immunization there was evidence that the NPMOG GC had begun to collapse, as 
reflected by the significant drop in numbers of GFP+ cells and that GC B cells made up a 
smaller proportion of the total Ag-specific population compared to the NPOVA response 
(Figure 3.5A), and GCs were less dense (Figure 3.5B and 3.5C). This was balanced by a 
significant increase in the proportion of Ag-specific B cells with a memory/naïve CD38hi 
CD95lo phenotype (Figure 3.5A). Furthermore, the immunoglobulin class-switching on 
GC B cells was also significantly reduced under the control of MOG-specific T cells 
(Figure 3.5D). Therefore, ongoing maintenance rather than initiation of the GC, as well 
as the immunoglobulin class-switching, are in part controlled by the T cell partner of the 
cognate B-T pairing. 
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Figure 3.5. MOG-specific T cells induce early GC collapse to a memory B cell 
phenotype. 
Fluorescent protein-marked NP-specific B cells and either OVA or MOG-specific CD4+ 
T cells were transferred into non-fluorescent protein-marked SMARTA recipients that 
were then immunized with either NPOVA or NPMOG. Draining popliteal LNs were 
harvested for analysis by flow cytometry or, in a separate experiment, histology at d5 and 
d10 post-immunization. (A) The absolute numbers of GFP+ cells and size of the given 
cell subset is shown as a percentage of all GFP+ cells (Plasma cells) or all GFP+ B cells 
(GC B cells and Memory/Naïve B cells). The d5 and d10 time points were assessed in 
separate experiments, data shown is representative of 2 to 3 individual experiments. Of 
note, no statistically significant difference is seen in the proportion of GFP+ plasma cells 
between groups at the d5 time point when using a non-parametric test. Furthermore one 
of the data points at the d10 time point in the NPOVA group was identified as an outlier. 
(B) Representative histological sections from NPOVA or NPMOG-immunized mice to 
visualize NP-specific GFP+ B cells and either RFP+ OVA-specific or MOG-specific T 
cells, respectively. Sections were stained for IgD to outline B cell follicles. Data is 
representative of one experiment. Scale bars represent 100 µm. (C) The density of GFP+ 
or RFP+ cells in the GC was quantified from histological images. (D) The ratio of IgG1- 
over IgM-expressing GC B cells d5 and d10 post-immunization is shown. Of note, 
differences in class-switching were not seen when using a non-parametric test. Each data 
point represents an individual mouse. *p<0.05, **p<0.01, ***p<0.001. A Student’s T-test 
was used for single comparisons. 
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3.2.5 Low T cell Ag-affinity limits the MOG GC response 
 A common feature of autoimmune TCRs, including TCRs that recognize the 
MOG35-55 peptide, is that they tend to bind peptide:MHC with relatively low-affinity 
(288, 289). Additionally, many are also polyreactive including the MOG35-55-specific 
2D2 TCR that also recognizes the NF-M18-30 peptide with higher-affinity than it does 
MOG35-55 (261, 262). I took advantage of polyreactivity of the 2D2 TCR to determine if 
TCR affinity for Ag influences B cell fate choice and maintenance of the GC response by 
using our modified haMOGtag Ag that incorporates the NF-M18-30 epitope.  
 Fluorescent protein-marked MOG-specific B and T cells were transferred to 
SMARTA recipients which were then immunized with either mMOGtag or haMOGtag. 
Lymph nodes were harvested d5 or d10 post-immunization for analysis by flow 
cytometry. No differences in plasma cell differentiation were observed at either time 
point (Figure 3.6A). However, consistent with the hypothesis that the TCR affinity of the 
T cell partner in the cognate pair influences GC maintenance vs B cell differentiation, 
partial recovery of the GC with a corresponding decrease in the proportion of memory-
phenotype B cells was observed 10d post-immunization with haMOGtag. In contrast to 
our observations where NP-specific B cells were placed under control of two different T 
cells (Figure 3.5), T cells responding to haMOGtag did not affect immunoglobulin class-
switching in the GC (Figure 3.6B), suggesting that these outcomes are controlled 
separately or that they represent a gradient of potential outcomes influenced by different 
levels of T cell activation and signal production. 
 In the cyclic re-entry model of the GC response (280), GC B cells undergo 
repeated rounds of proliferation and SHM, largely in the DZ, followed by migration to 
the LZ to receive survival and differentiation signals, primarily from TFH cells. We 
hypothesized that the collapse of the MOG GC was due to the inability of TFH cells to 
drive LZ B cells to maintain GC status and reenter the DZ, instead resulting in 
differentiation to a memory phenotype. To test this, proliferation of GC B cells was 
analyzed by BrdU uptake, along with the expression of CXCR4 as a marker of DZ GC B 
cells. Consistent with our hypothesis, BrdU labeling of GC B cells was significantly 
higher in mice immunized with NPOVA and haMOGtag compared to mMOGtag, and more 
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GC B cells were of the CXCR4+ DZ phenotype in mice immunized with NPOVA, while 
haMOGtag-induced GCs were intermediate (Figure 3.6C). 
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Figure 3.6. Increasing T cell Ag-affinity partly rescues the MOG GC from early collapse. 
(A and B) Fluorescent protein-marked MOG-specific B and T cells were transferred into 
non-fluorescent protein-marked SMARTA recipients that were then immunized with 
mMOGtag or haMOGtag. Draining popliteal LNs were harvested for analysis by flow 
cytometry at d5 and d10 post-immunization. The d5 and d10 time points were assessed in 
separate experiments, data shown is the combination of two separate experiments. (A) 
The absolute numbers of GFP+ cells and size of the given cell subset at both d5 and d10 
post-immunization is shown as a percentage of all GFP+ cells (Plasma cells) or all GFP+ 
B cells (GC B cells and Memory/Naïve B cells). Of note, no statistically significant 
difference is seen in the number of GFP+ cells per LN at the d5 time point when using a 
non-parametric test. Additionally, one data point in the d10 MOG group comparing the 
percentage GC B cells amongst GFP+ B cells was identified as an outlier. (B) The ratio of 
IgG1- over IgM-expressing cells was determined for GC B cells. (C) Fluorescent protein-
marked Ag-specific B and T cells were transferred into non-fluorescent protein-marked 
SMARTA recipients that were then immunized with NPOVA, mMOGtag, or haMOGtag. 
Mice were injected i.p. with BrdU 7d post-immunization, and draining popliteal and 
inguinal LNs were harvested for analysis by flow cytometry 12hrs later. The percentage 
of GFP+ GC B cells that are BrdU+ (left) or CXCR4+ (right) is shown. Of note, no 
statistically significant differences between the haMOG and MOG groups when using a 
non-parametric test. Data is based on one experiment. Each data point represents an 
individual mouse. * p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for 
single comparisons and a one-way ANOVA was used for multiple comparisons. 
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3.2.6 Levels of T cell activation do not explain the differential B cell 
response between the different model systems 
 In an attempt to understand the underlying mechanism behind the differential 
outcome of the GC response in the different model Ag systems, Ag-specific TFH cells 
(CXCR5+ PD-1hi RFP+) were isolated by FACS from LNs of mice 10d post-
immunization with NPOVA, mMOGtag, or haMOGtag (Figure 3.7A and 3.7B). Messenger 
RNA was isolated for quantitative digital droplet PCR analysis of the expression of genes 
with a known role in providing T cell help and differentiation signals to GC B cells. 
Surprisingly, little difference was observed in mRNA expression levels of the canonical 
TFH cytokines IL-4 and IL-21 (Figure 3.7C – note that the small difference in IL-4 
expression was not consistent across experiments). Again, there was no difference in the 
expression of IL-10 (Figure 3.7C, top). Neither were there differences in the mRNA 
expression of the surface receptors CD40L, ICOS, PD-1, CD28 and CTLA-4 (Figure 
3.7C, middle). Equivalent surface expression of ICOS and PD-1 by Ag-specific TFH cells 
was confirmed in a separate experiment by flow cytometry (Figure 3.7D). Interestingly, 
the master regulator of regulatory T cells, FoxP3, mRNA was expressed at significantly 
higher levels by TFH cells from haMOGtag-immunized mice (Figure 3.7C bottom), a 
finding confirmed by flow cytometry (Figure 3.7D). The significance of this observation 
is not clear, as an increased ratio of TFR cells would seem to counter the larger GC 
response in haMOGtag vs mMOGtag-immunized mice. Nevertheless, this finding was 
consistent across three separate ddPCR and flow cytometry experiments. Thus, 
differences in gene expression by TFH cells cannot explain why B cells in the NPOVA, 
mMOGtag, and haMOGtag induced GCs make different fate decisions. 
 I consistently observed that the absolute number of TFH cells was greater in the 
NPOVA vs MOG systems (Figure 3.7B, and also reflected in Figure 3.1C) and that 
haMOGtag immunization produced intermediate numbers of TFH cells (Figure 3.7B). This 
resulted in an identical GC B cell:TFH cell ratio across model Ag systems (one example 
presented in Figure 3.7E). To determine if the size of the GC response was simply linked 
to the size of the T cell response to a given Ag, different numbers of 2D2 T cells were 
transferred along with equal numbers of MOG-specific B cells into SMARTA recipient 
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mice. While immunization with mMOGtag resulted in a significantly larger Ag-specific T 
cell response in mice that received more cells, there was no similar increase in the 
number of TFH cells, nor was there an alteration in the GC response (Figure 3.7F). 
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Figure 3.7. TFH cell phenotype is not altered by Ag. 
(A-C) RFP+ OVA or MOG-specific T cells were transferred along with non-fluorescent 
protein-marked NP or MOG-specific B cells into non-fluorescent protein-marked 
SMARTA recipient mice that were then immunized with NPOVA, mMOGtag, or 
haMOGtag in CFA. Draining popliteal and inguinal LNs were harvested 10d later and TFH 
cells (CD4+ CD19- RFP+ CXCR5+ PD-1hi) were sorted by FACS sorted for subsequent 
analysis of gene expression by digital droplet PCR. One representative of two 
independent experiments is shown. (A) An example of gating for CXCR5+ PD-1hi TFH 
cells is shown. (B) The absolute number of TFH cells per LN is shown (left panel), along 
with size of the TFH population as a percentage of total RFP
+ T cells (right panel). Of 
note, no statistically significant differences are seen between the NPOVA and haMOG 
groups in the left graph or between any groups on the right graph when using a non-
parametric test. (C) Digital droplet PCR analysis of mRNA levels (copies per cell) for the 
listed gene. Of note, between the NPOVA and MOG groups, no statistically significant 
difference is seen in IL-4 copies and a statistically significant difference is seen in CD28 
copies when using a non-parametric test. (D-E) Fluorescent protein-marked Ag-specific 
B and T cells were transferred into non-fluorescent protein-marked SMARTA recipients 
that were then immunized with NPOVA, mMOGtag, or haMOGtag. Draining popliteal and 
inguinal LNs were harvested d8 post-immunization for analysis by FACS. (D) MFI for 
ICOS and PD-1 on RFP+ CXCR5+ PD-1hi TFH cells (top two panels) and the percent of 
TFH cells (Bcl6
+ PD-1hi) that were FoxP3+ (bottom panel) are shown. Data is based on 
one experiment. (E) Ratio of GC B cells to TFH cells in the different Ag systems. (F) 
Fluorescent protein-marked MOG-specific B cells and different numbers of MOG-
specific T cells (0.5, 2, or 8 x 106 2D2 T cells) were transferred into non-fluorescent 
protein-marked SMARTA recipients that were then immunized with mMOGtag. Draining 
popliteal LNs were harvested 10d post immunization for FACS analysis. The absolute 
number of RFP+ T cells per LN (top left panel) and RFP+ TFH cells per LN is shown 
(bottom left panel). The percentage of the GFP+ B cells with a GC B cell (top right panel) 
or memory B cell (bottom right panel) phenotype is shown. Data is based on one 
experiment. Each data point represents an individual mouse. * p<0.05, **p<0.01. A one-
way ANOVA was used for multiple comparisons. 
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3.2.7 The MOG-induced GC does not generate effective B cell memory 
 The primary function of memory B cells is to respond to secondary immune 
challenge (100). To determine if CD38hi CD95lo memory phenotype B cells generated 
from the MOG GC are responsive to Ag challenge, we performed an experiment that 
isolates the primary and secondary responses within the same mouse (Figure 3.8A). B 
and T cells specific for NPOVA protein were transferred into groups of SMARTA 
recipients and MOG-specific cells were transferred into a third group of SMARTA mice. 
Recipients were then immunized in the left footpad only with NPOVA or mMOGtag 
depending on the cells transferred into them. Then 34 days later, mice were immunized in 
the right footpad with NPOVA or PBS if they had originally been immunized with 
NPOVA, or again immunized with mMOGtag. Left and right draining LNs were analyzed 
separately by flow cytometry 5d post-secondary challenge. Control mice immunized with 
NPOVA in CFA in the left footpad but “challenged” with PBS alone showed an ongoing 
primary (but small in absolute terms - Figure 3.8B, top) GFP+ GC response in the left but 
not right draining LNs (Figure 3.8B, middle bottom). This confirmed that the lymphatics 
on the left and right sides of the animal were indeed separate allowing for separate 
analysis of the primary and secondary immune responses within the same animal. As 
expected, memory phenotype B cells made up the vast majority of GFP+ cells on the right 
side, confirming that memory B cells generated in the primary GC properly circulate and 
home to lymphatic tissues (Figure 3.8B, bottom). As expected, secondary-challenge with 
NPOVA resulted in generation of plasmablasts (Figure 3.8B, middle top) and initiation of 
a GC response on the right side. This contrasted starkly with the secondary challenge 
response in mMOGtag-immunized mice. Consistent with previous observations, the 
primary GC response on the left side in mMOGtag-immunized mice had disappeared, 
along with evidence of plasma cells at the d39 time point, leaving GFP+ cells with 
exclusively a CD38hi CD95lo phenotype. Despite the clear presence of memory-
phenotype GFP+ cells in the right LN, secondary-challenge with mMOGtag Ag did not 
produce a new GC response or plasma cells.  
 Recently, subsets of memory B cells have been identified based on differential 
expression of PD-L2 and CD80 (290). Double negative memory cells are associated with 
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the establishment of a new GC (135). Nevertheless, CD38hi CD95lo GFP+ B cells in 
mMOGtag-immunized mice were almost entirely double negative, while a significant 
proportion of memory cells in NPOVA immunized mice expressed PD-L2 and/or CD80 
(Figure 3.10A). Immunoglobulin class-switching remained reduced on GFP+ memory 
cells in the MOG system compared to the NPOVA system (Figure 3.10B), and 
significantly fewer IgG-producing long-lived plasma cells were recovered from the bone 
marrow (Figure 3.10C).  
 In the above experiment, it is possible that the B cell memory response in MOG-
immunized mice failed due to the lack of T cells capable of responding to secondary 
challenge. Therefore, we performed a separate experiment where new naïve MOG-
specific T cells were transferred 2d prior to secondary-challenge with mMOGtag (groups 
iv and v, Figure 3.8C). Transfer of new naïve T cells did not result in an appreciable 
secondary GC response suggesting the secondary GC response was not limited by a lack 
of T cell help (Figure 3.8D). Nevertheless, the large majority of the very-rare GC B cells 
induced by secondary immunization bound mMOGtag, as expected (Figure 3.9A, top). 
Interestingly, only ~12% of memory-phenotype B cells in either LN were MOG-specific 
at this late time point (Figure 3.9A, bottom), which is a considerable reduction from the 
~50% observed d10 post-immunization (Figure 3.4B). This raised the possibility that the 
memory B cell response in the MOG system fails due to the selective loss of MOG-
specific memory B cells over time. Therefore, we repeated the experiment using the 
NPOVA and mMOGtag systems, but performed secondary-challenge d19 post-
immunization (Figure 3.9B). At this intermediate time point, the GC response to 
secondary-challenge in LNs on the right side were equivalent between the NPOVA and 
MOG systems (groups vi and vii, respectively. Figure 3.9C) although, as with the 
primary response (Figure 3.2C), the plasma cell response was significantly lower with 
mMOGtag challenge (Figure 3.9C). As expected, the large majority of GC B cells bound 
appropriate Ag (NP and MOG, respectively) in the secondary-response (Figure 3.9D). 
Importantly, ~60% of memory-phenotype B cells in either LN in the MOG-system bound 
mMOGtag, which is similar to the proportion of MOG-specific memory B cells d10 post-
immunization (Figure 3.4B), and considerably greater than observed d39 post-primary 
immunization (Figure 3.9A). While this percentage of Ag-binding cells was lower than 
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observed in the NPOVA system (Figure 3.9D), it suggests that a threshold number of Ag-
binding cells are required to respond to Ag and that, over time, MOG-binding cells are 
lost and B cell memory fails.  
 To test whether MOG-specific memory B cells could respond in small numbers, 
GFP+ Ag-specific CD38hi CD95lo memory phenotype cells were sorted by FACS from 
mMOGtag or NPOVA immunized mice. Ten days post-immunization, a small number of 
naïve/memory-phenotype B cells, 7.5 x 103, were transferred to new SMARTA recipients 
along with naive T cells specific for the relevant Ag. Following secondary-challenge, 
small numbers of GFP+ NP-specific cells were recovered, the majority of which were 
plasma cells or GC B cells (Figure 3.10D). In contrast, MOG-specific cells were either 
completely undetectable or exclusively of the CD38hi CD95lo phenotype, indicating that 
they had not responded to secondary-challenge. This suggests that NP-specific memory-
phenotype B cells could respond in small numbers; however, MOG-specific memory-
phenotype B cells could not. 
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Figure 3.8. Memory B cells produced by the MOG-induced GC response are 
unresponsive during secondary immune responses. 
(A and B) Fluorescent protein-marked Ag-specific B and T cells were transferred into 
non-fluorescent protein-marked SMARTA recipients that were then immunized in their 
left footpad with either NPOVA or mMOGtag in CFA. Thirty-four days post-
immunization, mice were immunized in their right footpad with NPOVA, PBS, or 
mMOGtag in CFA in the right footpad, as shown. (B and D) The primary response in the 
left draining popliteal and inguinal LNs and secondary response in the right LNs were 
analyzed separately by flow cytometry 5d post-secondary challenge. The absolute 
numbers of GFP+ cells and size of the given Ag-specific subsets as a percentage of the 
total GFP+ cells (Plasma cells) or GFP+ B cells (GC and Memory/Naïve B cells) is shown 
for the left and right sides separately. (B) No statistically significant differences are seen 
between the NPOVA-NPOVA and MOG-MOG groups on the left f.p. for the GC B cells 
and memory B cell subsets using a non-parametric test. Furthermore, on the right f.p. 
there were no differences between the NPOVA-NPOVA and MOG-MOG groups by 
absolute numbers, and between the NPOVA-NPOVA and NPOVA-PBS groups for GC B 
cells, plasma cells, or memory B cells when using a non-parametric test. (C and D) 
Fluorescent protein-marked MOG-specific B and T cells were transferred into non-
fluorescent protein-marked SMARTA recipients that were then immunized in their left 
footpad with mMOGtag in CFA. Thirty-two days post-immunization 5 x 10
5 naïve 2D2 T 
cells were transferred then d34 post-immunization, mice were immunized in their right 
footpad with PBS or mMOGtag in CFA, as shown. Of note, a statistically significant 
difference between the MOG-PBS and MOG-MOG groups in the proportion of GFP+ B 
cells as GC B cells is seen when using a non-parametric test. Data shown is based on one 
experiment. Each data point represents an individual mouse. * p<0.05, **p<0.01, 
***p<0.001. A Student’s T-test was used for single comparisons and a one-way ANOVA 
was used for multiple comparisons. 
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Figure 3.9. MOG-specific memory B cells are responsive but they are short-lived.  
(A) Is from the experiment described in Figure 3.8C. (A and D) The proportion of GFP+ 
B cells (GC and Memory/Naïve B cells) that are Ag-specific is shown for the left and 
right sides separately. (B-D) Fluorescent protein-marked Ag-specific B and T cells were 
transferred into non-fluorescent protein-marked SMARTA recipients that were then 
immunized with either NPOVA or mMOGtag in CFA in their left footpad. Seventeen days 
post-immunization 5 x 105 naïve Ag-specific T cells were transferred then d19 post-
immunization, mice were immunized in their right footpad with NPOVA or mMOGtag in 
CFA, as shown. (C) The primary response in the left draining popliteal and inguinal LNs 
and secondary response in the right LNs were analyzed separately by flow cytometry 5d 
post-secondary challenge. The absolute numbers of GFP+ cells and size of the given Ag-
specific subsets as a percentage of the total GFP+ cells (Plasma cells) or GFP+ B cells 
(GC and Memory/Naïve B cells) is shown for the left and right sides separately. Of note, 
no statistically significant difference is seen between the NPOVA-NPOVA and MOG-
MOG groups in the left f.p. for absolute numbers of GFP+ cells when using a non-
parametric test. Data shown is based on one experiment. Each data point represents an 
individual mouse. * p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for 
single comparisons and a one-way ANOVA was used for multiple comparisons. 
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Figure 3.10. Characterization of MOG-specific memory B cells and their functionality. 
(A) Fluorescent protein-marked NPOVA or MOG-specific B and T cells were transferred 
into non-fluorescent protein-marked SMARTA recipients that were then immunized in 
their left footpad with either NPOVA or mMOGtag in CFA, respectively. Thirty-four days 
post-immunization, mice were immunized in their right footpad with NPOVA, PBS, or 
mMOGtag in CFA in the right footpad, as shown in Figure 3.7A. Representative staining 
and quantification for CD80 and PD-L2 on NPOVA and MOG GFP+ memory/naïve B 
cell subsets. Groups shown are for the NPOVA-NPOVA and MOG-MOG groups. (B) 
The ratio of IgG1 B expressing cells over IgM expressing B cells amongst GFP+ 
memory/naïve B cells is shown. (C) At the same time, bone marrow was harvested for 
ELISpot quantification of NP- or MOG-specific IgG producing plasma cells. (D) 
Fluorescent protein-marked NPOVA or MOG-specific B and T cells were transferred 
into non-fluorescent protein-marked SMARTA recipients that were then immunized with 
NPOVA or mMOGtag in CFA, respectively. Draining popliteal and inguinal LNs were 
harvested d10 post-immunization and CD19+ CD4- CD138- CD38hi CD95lo GFP+ 
memory/naïve B cells were sorted. Seventy five hundred NP or MOG-specific B cells 
were transferred along with 5 x 105 naïve OVA or MOG specific T cells into new non-
fluorescent protein-marked SMARTA recipient mice. These were immunized with 
NPOVA or mMOGtag and 5d later draining popliteal and inguinal LNs were analyzed by 
flow cytometry. The absolute numbers of GFP+ cells per LN (shown on the left) and size 
of the given Ag-specific subsets as a percentage of the total GFP+ cells (Plasma cells) or 
GFP+ B cells (GC and Memory/Naïve B cells) is shown on the right. Of note, no 
difference is seen between the NPOVA and MOG groups when using a non-parametric 
test. Data shown is based on one experiment. Each data point represents an individual 
mouse. *p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for single 
comparisons. 
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3.2.8 Memory B cell responsiveness is not programmed by the MOG-
specific T cell 
 To determine if the failure of MOG-specific B cell memory was due to education 
from MOG-specific T cells, an experiment was performed to determine if MOG-specific 
T cells could instruct short-lived memory into NP-specific memory B cells. Nitrophenyl-
specific B cells were transferred along with either OVA or MOG-specific T cells into 
SMARTA recipient mice. Mice were then immunized with NPOVA, if they receive 
OVA-specific T cells, or NPMOG, if they received MOG-specific T cells, in the left 
footpad only. Thirty-two days later, naive T cells specific for the opposite Ag (mice that 
originally received OVA-specific T cells had a new transfer of MOG-specific T cells or 
vice versa) were transferred; then mice were challenged with Ag in the right footpad 2d 
later such that the NP-conjugated protein matched with the cells of the secondary transfer 
(Figure 3.11A). This was done to eliminate any potential confounding factors associated 
with differences in the generation of T cell memory or regulatory cells from the primary 
immune response. Left and right draining LNs were analyzed separately by flow 
cytometry d5 post-secondary challenge. Analysis of the primary response in the left LN 
revealed that, as at d10 (Figure 3.5), the NP-specific B cell response under control of 
MOG-specific T cells was heavily biased to memory-phenotype cells at the expense of 
GC B cells (Figure 3.11B). The presence of IgG-producing long-lived plasma cells in the 
bone marrow was also reduced (Figure 3.11C). In contrast, and as opposed to the MOG-
specific B cells in the previous experiment (Figure 3.10A), there was no difference in the 
proportion of CD80 PDL2 double negative memory NP-specific B cells under the control 
of either T cell (Figure 3.11D), nor was there a defect in immunoglobulin class-switching 
of memory cells (Figure 3.11E). Also, analysis of the right LN clearly demonstrated that 
NP-specific B cells educated by MOG-specific T cells in the primary response were able 
to respond to secondary-challenge (Figure 3.11B). Overall, this confirmed that the failure 
of MOG-specific memory B cells was not due to T cell education, but, rather was 
something intrinsic to the B cell or its environment. 
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Figure 3.11. Autoimmune T cells do not induce short-lived memory in MOG-specific B 
cells during the GC response. 
(A) Fluorescent protein-marked NP-specific B cells and OVA or MOG-specific T cells 
were transferred into non-fluorescent protein-marked SMARTA recipients that were then 
immunized in their left footpad with either NPOVA or NPMOG. Thirty-two days post-
immunization, naïve T cells of the reciprocal specificity were transferred to these 
recipient mice, as shown, followed two days later by immunization with that Ag in the 
right footpad. (B) The primary response in the left draining popliteal and inguinal LNs 
and secondary response in the right LNs were analyzed separately by flow cytometry d5 
post-challenge. The absolute numbers of GFP+ cells and size of the given Ag-specific 
subsets as a percentage of the total GFP+ cells (Plasma cells) or GFP+ B cells (GC and 
Memory/Naïve B cells) is shown for the left and right sides separately. Of note, a 
statistically significant difference is seen between the groups in the left f.p. when using a 
non-parametric test. (C-E) Groups shown are based upon what they were immunized with 
for the primary immunization. (C) At the same time, bone marrow was harvested for 
ELISpot quantification of NP-specific IgM or IgG producing plasma cells (the Ag used to 
coat plates was based on the primary immunogen). (D) Memory/naïve phenotype GFP+ B 
cells were analyzed for expression of CD80 and PD-L2. Of note, no statistically 
significant differences between groups are seen when using a non-parametric test. (E) 
The ratio of IgG1 over IgM expressing B cells amongst GFP+ memory/naïve B cells is 
shown. Data shown is based on one experiment. Each data point represents an individual 
mouse. *p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for single 
comparisons. 
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3.3 Discussion 
 Here, I manipulated Ag model systems as a novel approach to investigate how the 
immune system controls B cell fate choice and differentiation to produce different GC 
outcomes tailored to the specific Ag in an autoimmune setting. The response to NPOVA 
and other NP-haptenated proteins is well characterized (126, 291), and in many ways is 
considered to represent the default response to a foreign-Ag. Myself and others have 
shown that the anti-NP GC consistently forms 4-5d after exposure to Ag, peaks ~2 wks 
post exposure, and remains active for several weeks after that (78, 135). I show here that, 
while the GC response to MOG develops with similar kinetics, it is not sustained and 
instead dissipates early. This should not be interpreted as a failed GC response, however, 
as it still produces measurable levels of circulating, class switched anti-MOG antibody. 
Further, subcutaneous immunization with MOG protein is a well-established method to 
induce the anti-myelin autoimmune model EAE. In my hands, mice immunized with 
mMOGtag develop a robust disease with evidence that GC-derived anti-MOG B cells 
contribute to both disease severity and chronic disease course (240, 283). Therefore, 
although short-lived, the MOG GC is productive.  
 The GC response is sustained by interactions between GC B cells and TFH cells, 
predominantly in the LZ of the GC. The outcome of these interactions can select B cells 
to maintain their GC status and cycle back into the DZ for additional rounds of cell 
division, mutation, and return to the LZ for selection (58). Alternatively, GC B cells can 
be driven to memory or plasma cells fates (292). The first major finding of this study is 
that, in the MOG GC response, early failure of the GC is associated with preferential 
differentiation to a memory phenotype at the expense of maintaining the GC. Indeed, 
within the small GC B cell population in the collapsing MOG response there is a clear 
bias to a LZ phenotype, suggesting that B cells are not being selected to return to the DZ 
for proliferation. A similar bias to memory cell differentiation is seen for B cells 
defective in CXCR4, which is required for proper DZ B cell homing (108). By histology, 
this manifests as a small, less-organized GC with a large number of individual GFP+ cells 
distributed throughout the follicle. In the GC response to a foreign-Ag, memory B cell 
differentiation has been shown to occur predominantly in the early stages, shortly after 
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GC formation, with plasma cell differentiation preferentially occurring later in the 
response (126). Therefore, it is possible that the early dissolution of the MOG GC to 
generate memory B cells represents an extreme acceleration of this same process.  
 It is clear from my observations that the status of the cognate T cell partner 
strongly influences the dichotomy between GC maintenance and memory B cell 
differentiation, along with immunoglobulin class-switching. Indeed, MOG-reactive T 
cells induced a similar GC outcome when paired with NP-specific B cells and enhanced 
T cell activation via high-affinity Ag partly rescued the MOG GC from collapse and 
reduced memory B cell differentiation. In this case, immunoglobulin class-switching was 
not impacted, suggesting that there is a gradient to the GC parameters that are influenced 
by T cell status. Interestingly, while BCR affinity has previously been linked to plasma 
cell differentiation (128, 248) (see below), this is the first report that I am aware of that 
demonstrates that TCR affinity for Ag can impact B cell fate choice.  
 It is not clear what signals the cognate T cell partners use to drive differential GC 
maintenance vs memory B cell differentiation in the two model systems. Previously 
identified T cell signals that influence GC formation and memory differentiation include 
ICOS and PD-1 (218, 223). TFH-produced cytokines, IL-21, IL4, and IL-10 have also 
been shown to be required for proper GC development (175, 177, 233). Nevertheless, I 
did not find evidence that these are differentially expressed by TFH cells in the NPOVA 
and MOG systems. Therefore, the immune system may employ other signals to modulate 
GC outcome in response to different Ags. The size of the TFH cell pool itself may be one 
of these “signals”, as we consistently observed a direct correlation between the number of 
TFH and GC B cells in our different model systems. An attempt to modulate this by 
increasing the total T cell response was not successful, suggesting that other factors limit 
the size of the TFH cell niche in an Ag-dependent way. Indeed, maintenance of the PD-1
hi 
phenotype on TFH cells is dependent on their ongoing cognate interactions with B cells 
(78, 293). Therefore, it is difficult to separate cause and effect with regards to the GC B 
cell:TFH cell ratio. 
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 While the balance between GC maintenance and memory B cell differentiation, 
along with immunoglobulin class-switching, were heavily influenced by the status of the 
cognate T cell partner, plasma cell differentiation and memory B cell unresponsiveness 
were not. Plasma cell differentiation has been linked to BCR affinity (128, 248). Further, 
plasma cells preferentially differentiate later in the GC response compared to memory 
cells (126). It is possible that the MOG GC doesn’t last long enough to produce BCRs 
with sufficiently high-affinity to promote plasma cell differentiation. The accumulation 
of somatic mutations in anti-MOG B cells and BCR affinity for Ag will need to be 
explored in future studies. However, this would not explain the almost complete absence 
of early, short lived plasmablasts that typically derive from pre-GC interactions. The 
starting affinity for Ag in the Ig-heavy chain knockin (IgHMOG) B cells is clearly 
sufficient to allow for B cell activation to proliferate and initiate the GC. Additional 
investigation will be required to determine if (potentially) low BCR affinity accounts for 
reduced plasma cell formation, or if the few (but productive) plasma cells that do form in 
the MOG GC response represent clones that attained a threshold affinity that allowed for 
their differentiation.  
 Finally, it is clear from our studies that, despite the preference for differentiation 
to memory phenotype B cells in the MOG system, this differentiation may not be 
complete as the cells are not long-lived, resulting in a failure to respond to secondary-
challenge. Our Ag-binding studies demonstrate that the primary GC response is indeed 
driven by specific Ag, as virtually all GC B cells bind mMOGtag. Among naïve/memory 
phenotype cells, the proportion that bound specific Ag was lower in the MOG compared 
to NPOVA systems, which may be in part explained by the properties of the IgHMOG 
mouse. The heavy chain knock-in for the IgHMOG mouse combines with endogenous light 
chains resulting in ~30% of cells being specific for MOG, while the B1.8 heavy chain 
paired exclusively with the lambda light chain in a kappa chain-deficient mice results in 
~90% of cells binding NP (294). Nevertheless, the large majority of proliferated memory-
phenotype B cells bound to MOG Ag at the d10 time point, confirming that they derived 
from the Ag-response. However, over time there was a selective loss of these MOG-
binding cells. Intriguingly, capacity to bind MOG Ag also appeared to be lost among the 
rare remnants of the MOG GC at later time points (compare Figure 3.3B to 3.7H) and 
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therefore, there may be an active selection against MOG-binding not observed in the 
NPOVA system. Further study will be required to determine if this is the case.  
 In conclusion, I showed here that different Ags can drive GC responses with very 
different outcomes. Further, I identify GC maintenance vs memory B cell differentiation 
as a fate decision dichotomy that is regulated independently from plasma cell 
differentiation, and that the status of the cognate T cell partner heavily influences the 
former, but not the latter. Finally, I show that, despite a preference for memory B cell 
formation in the MOG system, differentiation may not be complete as the Ag-specific 
cells are not long-lived. My findings have implications both for our fundamental 
understanding of how B cell fate choice is regulated in the GC response, and for our 
understanding of how autoimmune B cells participate in autoimmune responses, and anti-
myelin responses in particular. 
 
3.4 Materials and Methods 
3.4.1 Mice 
 C57Bl/6, 2D2 TCR-transgenic (264), SMARTA TCR-transgenic (4694; 
Tg(TcrLCMV)327Sdz/JDvsJ), and OTII TCR-transgenic mice (4194; 
Tg(TcraTcrb)425Cbn/J) were purchased from Jackson Laboratories, Bar Harbor, Maine. 
B1-8 mice (285) with a homozygous deletion of the Jκ locus (284) were a generous gift 
from Dr. Ann Haberman. IgHMOG MOG-specific BCR knock-in mice (256) were 
received as a gift from Dr. H Wekerle. Mice expressing fluorescent proteins within all 
nucleated cells, either dsRed (RFP; 6051; Tg(CAG-DsRedpMST)1Nagy/J) under control 
of the β-Actin promoter or eGFP via the ubiquitin promoter (4353; 
Tg(UBCGFP)30Scha/J) were obtained from the Jackson Laboratory. Mice were housed 
in a specific pathogen-free barrier at West Valley Barrier. All animal protocols (2011-
047) were approved by the Western University Animal Use Subcommittee. 
107 
 
 
3.4.2 Antibodies for histology/flow cytometry 
 The following antibodies were purchased from BD Biosciences, Franklin Lakes, 
New Jersey: anti-Bcl6 A647 or v450 (K112-91), anti-CD138 BV421 or biotin (281-2), 
anti-CXCR5 APC (2G8), anti-CD19 BV711 (1D3), anti-CD4 v450 (RM4-5), anti-CD62L 
A700 (Mel14), anti-CD95 PE-Cy7 (Jo2), anti-IgG1 APC (A85-1), anti-B220 PE-Cy7 
(RA3-6B2), Streptavidin v450 or APC-Cy7, and anti-CD80 PE (16-10A1). The following 
antibodies were purchased from Thermo Fisher Scientific, Waltham, Massachusetts: anti-
BrdU A647 (MoBU-1), anti-IgM A568 (polyclonal), anti-CXCR4 PE (2B11), 
Streptavidin A568, anti-Ki67 unconjugated. The following antibodies were purchased 
from eBioscience, Waltham, Massachusetts: anti-PD-1 biotin (RMP1-30), anti-CD38 PE 
or PE-Cy5 (90), anti-CD4 PE-Cy5 (RM4-5), anti-FoxP3 eF660 (FJK-16s), anti-IgD 
eF450 (11-26c), anti-IgG1 PerCP-eF710 (M1-14D12), Streptavidin APC, anti-ICOS 
biotin (C398.4A), and anti-PD-L2 biotin (TY25). The following antibodies were 
purchased from BioLegend, San Diego, California: anti-His Tag purified (J099B12), anti-
PD-1 PE-Cy7 (RMP1-30), anti-rabbit IgG Dylight 649 (polyclonal), anti-IL10 A647 
(JES5-16E3), anti-CD4 A647 (RM4-5), and anti-CD4 A700 (RM4-5). 
3.4.3 MOG production and purification 
 mMOGtag and haMOGtag proteins were produced and purified as described in 
Chapter 2. The final equimolar concentrations were 5 mg/mL for mMOGtag and 5.394 
mg/mL for haMOGtag with no detectable impurities as determined by SDS-PAGE. 
3.4.4 Adoptive transfer of B and T cells and immunization 
 Naïve Ag-specific T cells were isolated from RFP+ 2D2 and OTII mice and naïve 
Ag-specific B cells were isolated from GFP+ IgHMOG and B1-8 Jκ-/- mice as previously 
described (78). Briefly, LNs and spleens of RFP+ Ag-specific T cell and GFP+ Ag-
specific B cell mice were dissociated and B and T cells were isolated using EasySep 
Negative selection Mouse B and T cell Enrichment Kits (StemCell Technologies, 
Vancouver, Canada). Unless otherwise stated, 5 × 105 RFP+ T cells and either 1 x106 
GFP+ B1-8 Jκ-/- or 5 × 106 GFP+ IgHMOG B cells (to account for the fact that only 20% are 
MOG-specific (240)) were transferred i.v into C57Bl/6 or SMARTA recipients 2d prior 
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to immunization. In experiments using CellTrace Yellow (ThermoFisher), 5x106 B cells 
were labelled according to the manufacturer’s protocol prior to transfer. Mice were 
immunized in the footpad with equimolar amounts of the given Ag (125 μg mMOGtag, 
175 μg NPOVA, 125 μg NPMOGtag (both at a 1:25 protein:NP ratio), 135 μg haMOGtag) 
in CFA (of note, unless otherwise stated mice were not injected with PTX, in the scenario 
where PTX is used, 250 ng were injected on days 0 and 2 post-immunization). Unless 
otherwise stated, draining popliteal LNs were harvested at the indicated time points for 
analysis. In experiments using BrdU, 1.5 mg of BrdU was injected i.p at the specified 
time points. 
3.4.5 Flow cytometry 
 Draining popliteal LNs were harvested from mice for flow cytometry analysis as 
previously described (240). Briefly, LN cell suspensions were stained with A647 
conjugated mMOGtag (conjugated using Alexa Fluor 647 antibody labelling kit, 
ThermoFisher) or NP30PE (Biosearch Technologies) then blocked with an anti-Fcγ 
receptor, CD16/32 2.4G2 (BD biosciences), in PBS containing 2% FBS before further 
incubation with the indicated antibodies. Dead cells were excluded by staining with either 
the Fixable Viability Dye eFluor506 (eBioscience), propidium iodide (Thermoscientific), 
or 7-AAD (Biolegend). Flow cytometry was performed on a BD Immunocytometry 
Systems LSRII cytometer and analyzed with FlowJo software (Tree Star, Ashland, 
Oregon). For cytokine staining, 2 x 106 freshly isolated cells were stimulated with cell 
activation cocktail with brefeldin A (Biolegend) for 4 hrs at 37°C then stained as listed 
above. For intracellular stains of IL-10, FoxP3 or Bcl6, cells were fixed and 
permeabilized with Cytofix / Cytoperm solution (BD Bioscience) after cell surface 
staining. Fixed cells were then intracellularly stained for IL-10, FoxP3, and Bcl6 at 4°C 
overnight. For BrdU staining, cells were fixed in 2% PFA then permeabilized in 0.1% 
Tween 20 for two nights at 4°C. The DNA within the fixed cells was degraded using 
DNase I (Sigma-Aldrich, St. Louis, Missouri) then stained with anti-BrdU antibody. Cell 
sorting was performed using a BD FACS ARIAIII where cells were sorted into 100% 
FBS. 
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3.4.6 Immunofluorescent histology 
 Tissues were prepared for histology as previously described (240). Briefly, whole 
popliteal LNs were fixed in periodate–lysine–paraformaldehyde (PLP), subsequently 
passed through sucrose gradients to protect from freezing artifacts and then frozen in 
OCT (TissueTek, Torrance, California) media. Serial cryostat sections (7 μm) were 
blocked in PBS containing 1% Bovine Serum Albumin, 0.1% Tween-20 and 10% rat 
serum before proceeding with staining. Sections were mounted with ProLong Gold 
Antifade Reagent (Invitrogen, Carlsbad, California). Tiled images of whole LN sections 
(20×) were imaged using DM5500B fluorescence microscope (Leica, Wetzlar, Germany). 
3.4.7 Digital Droplet PCR (ddPCR) 
 T follicular helper and naïve T cells were sorted by flow and RNA was extracted 
from cells using a RNeasy Plus Micro Kit (QIAGEN, Hilden, Germany) and immediately 
converted into cDNA using a Superscript VILO cDNA Synthesis Kit (Invitrogen). 
ddPCR reactions were set up using ddPCR EvaGreen 2x Supermix (Bio-Rad, Hercules, 
California) and the following primers: IL-4 Sense – 5' 
AGATGGATGTGCCAAACGTCCTCA 3', IL-4 Antisense – 5' 
AATATGCGAAGCACCTTGGAAGCC 3', IL-10 Sense – 5' 
GGTTGCCAAGCCTTATCGGA 3', IL-10 Antisense – 5' 
ACCTGCTCCACTGCCTTGCT 3', IL-21 Sense – 5' 
TGAAAGCCTGTGGAAGTGCAAACC 3', IL-21 Antisense – 5' 
AGCAGATTCATCACAGGACACCCA 3', CD40L Sense – 5' 
GTGAGGAGATGAGAAGGCAA 3', CD40L Antisense – 5' 
CACTGTAGAACGGATGCTGC 3', ICOS Sense – 5' TGACCCACCTCCTTTTCAAG 
3', ICOS Antisense – 5' TTAGGGTCATGCACACTGGA 3', PD-1 Sense – 5' 
CGTCCCTCAGTCAAGAGGAG 3', PD-1 Antisense – 5' 
GTCCCTAGAAGTGCCCAACA 3', CD28 Sense – 5' TGACACTCAGGCTGCTGTTC 
3', CD28 Antisense – 5' TTCCTTTGCGAGAAGGTTGT 3', CTLA4 Sense – 5' 
GCTTCCTAGATTACCCCTTCTGC 3', CTLA4 Antisense – 5' 
CGGGCATGGTTCTGGATCA 3', FoxP3 Sense – 5' 
CCCAGGAAAGACAGCAACCTT 3', FoxP3 Antisense – 5' 
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TTCTCACAACCAGGCCACTTG 3'. ddPCR reactions were run on a QX200 Droplet 
Digital PCR System (Bio-Rad) and analyzed using Quantasoft software (Bio-Rad). Gene 
expression was normalized to the number of sorted cells and expressed as mRNA copies 
per cell. 
3.4.8 ELISpots and ELISA 
 96-well plates were coated overnight at 4°C with 0.5 μg NPOVA, NPMOGtag, or 
mMOGtag. Wells were blocked with 1% (wt/vol) BSA in PBS, then incubated with serial 
diluted bone marrow or lymph node cells at 37°C in 5% CO2. Spots were detected using a 
goat alkaline phosphatase-conjugated anti-mouse IgM or IgG antibody (MABTECH, 
Nacka Strand, Sweden) and 5-bromo-4-chloro-3-indolyl-phosphate substrate (Sigma-
Aldrich) and counted under a Leica M80 dissection microscope. To detect circulating 
antibodies using an ELISA, 96-well plates were incubated with Ag and blocked with 
BSA as written above. Blood was extracted from mice using a cardiac puncture and spun 
at 4500 x g for 15 minutes. Serum plasma was extracted and incubated with the 96-well 
plate for one hour at room temperature. Plates were incubated with anti-IgM or IgG 
antibodies and then the alkaline phosphatase yellow (pNPP; Sigma-Aldrich) substrate. 
OD405 was measured using an Eon microplate spectrophotometer (BioTek, Winooski, 
Vermont). 
3.4.9 Image and statistical analyses 
 Histology images were analyzed using ImageJ software to quantify the density of 
B and T cells in germinal centers (Bcl6+ IgD-) and B cell follicles (IgD+ cells excluding 
five cells deep worth of the outermost perimeter of the B cell follicle near the capsule). 
PRISM software (GraphPad Software, La Jolla, California) was used to analyze flow 
cytometry and histology data. For statistical comparisons, a Student’s T-test was used for 
single comparisons and a one-way ANOVA followed by a T test with Bonferroni 
correction was used for multiple comparisons. Additionally, data sets were also analyzed 
using non-parametric a Mann-Whitney test for single comparisons and a Kruskal-Wallis 
test with a Dunn’s correction for multiple comparisons. Unless otherwise stated, the 
results were the same with each test. Outliers were identified using ROUT method. 
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Chapter 4  
4 Reporters for in vivo and in vitro monitoring of NFκB and 
NFAT signaling 
 The development of a high-affinity class-switched B cell response is absolutely 
dependent on cognate interactions between B and T cells. Signals are exchanged between 
B and T cells during these interactions that inform B cell fate choices however, the 
precise timing of signal exchange has never been established. This is important as 
cognate interactions can differ substantially in duration over the course of the immune 
response and between individual B-T pairings making it difficult to establish how long 
and short B-T interactions may uniquely contribute to the immune response. Studying the 
relationship between intracellular signaling and interaction duration is complicated by the 
lack of tools available for visualizing intracellular signaling in individual cells in living 
tissue. To address this issue, I sought to generate reporters that were capable of 
visualizing signaling by monitoring the activity of two key transcription factors: p65 
(NFκB) and NFAT1. These proteins integrate signaling through multiple different 
receptors involved with B and T cell activation. To monitor p65 and NFAT1 activity, two 
fluorescent reporters were constructed using a histone 2 B-GFP fusion protein, which will 
label the nuclei of cells, coupled to the expression of the mCherry fluorescent protein 
linked to the N-terminus of the p65 or NFAT1 proteins. In vitro stimulation of 
macrophage cell lines transfected with these reporters revealed that mCherry labelled p65 
or NFAT1 were excluded from the nucleus in the steady state but could be induced to 
translocate into the nucleus when stimulated. Using the CRISPR/Cas9 genomic editing 
system, these reporters were adapted for insertion of the mCherry labelled p65 or NFAT1 
constructs into the NFAT1 or p65 loci to allow expression from their endogenous loci. 
Although I was not successful in editing the p65 locus, initial experiments editing the 
NFAT1 locus in vitro were successful. However, this was not successfully translated into 
making reporter mice carrying the reporter. I am now adapting the reporter to be inserted 
into the Rosa26 locus and single cell zygote injections will be used to generate a reporter 
mouse controlled by Cre recombinase expression.  
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4.1 Introduction 
 Communication between immune cells is essential in shaping an immune 
response and can determine if a pathogen infection persists or if it is successfully cleared. 
A critical component of immunity is the B cell response that is coordinated by 
communication between B and T cells specific for the same Ag through direct physical 
interactions that occur at the pre-GC phase and throughout the GC response (78, 206). 
Interactions between B and T cells are coordinated through cytokines and the engagement 
of multiple cell surface receptors that initiate intracellular signaling (295). The induction 
of cellular signaling is responsible for informing cells to become activated, differentiate, 
or undergo cell death and, thus, determines the output of the immune response. As a 
result, B and T cell interactions are essential for the duration of a GC response. Yet, the 
duration of interactions formed between B and T cells varies considerably over the course 
of the immune response, where pre-GC interactions are longer than those that occur in 
the GC, and between individual B-T pairings at each time point (78, 106). Indeed, in our 
lab we have seen at the pre-GC phase, B-T interactions occurring in MOG immunized 
mice are significantly shorter than those that occur in NPOVA immunized mice (Parham 
KA et al. in progress). Thus, B-T cell interaction length may contribute to the different 
fate choices seen in these two systems. However, it is difficult to address this hypothesis 
because we still do not understand the basics of how signaling kinetics and interaction 
kinetics are related to one another. Additionally, as GC B-T interactions are shorter than 
pre-GC interactions, it is not clear whether the kinetics of signal exchange change over 
the course of the response. 
 Traditional methods of monitoring intracellular signaling, such as western blots, 
rely on pooling millions of cells and analyzing in bulk and are therefore inappropriate for 
analyzing individual events amongst a variable pool of cells. Furthermore, fate decisions 
are made at the single cell level and thus can only be studied by analyzing individual cells 
(296). Direct imaging of cells during their interactions using two-photon intravital 
microscopy solves this problem, however this technology requires fluorescent reporters 
(297). This is problematic as most fluorescent activation reporters currently rely on de 
novo expression of a fluorescent protein driven by a promoter which requires time to 
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transcribe, translate, and fold the fluorescent protein (298, 299). This results in a delay 
between the time of signal initiation and the time of visible reporter activity making it 
impossible to determine the kinetics of activation using transcription-based reporters 
(298, 299). Commercially available fluorescent Ca2+ signaling reporters, that fluoresce 
when binding to intracellular Ca2+ (300), allow real-time visualization of signaling and 
could address this issue (301). However, these reporters are not retained in cells over long 
periods of time and can be diluted out of cells as they proliferate making their use 
impractical in rapidly expanding immune responses (302). Ideally, an activation reporter 
should continuously provide instantaneous information about cellular signaling. 
 Designing a reporter that provides real-time signaling information is possible by 
taking advantage of how immune signaling becomes integrated: through the activation of 
transcription factors. Signaling cascades initiated at the cell membrane rely on a wide 
variety of adaptor proteins and signaling enzymes to initiate intracellular signaling. These 
signaling pathways tend to converge on a much more limited number of common 
transcription factors. In this way, the signals from various surface receptors can be 
integrated to refine the signal that is transmitted to the nucleus to alter the expression of 
specific genes. Nuclear factor of activated T cells and NFκB are two key transcription 
factors that are downstream of receptors involved in both B and T cell activation (195, 
303). Both are maintained in the cytosol and upon activation translocate into the nucleus 
where they can initiate gene transcription (196, 304). Thus, by monitoring the cellular 
location of NFκB and NFAT, we can obtain real-time evidence of ongoing signaling that 
is relevant to cellular immune activation.  
 The NFAT family consists of 5 related proteins where NFAT1, NFAT2, and 
NFAT4 are expressed in B and T cells (305). Of these, NFAT1 and NFAT2 have 
considerable overlap in function where deletion of either gene alone leads to subtle 
changes in B and T cell responses (306-308) and double deletion leads to accelerated 
differentiation of B cells and the inability of T cells to function (309). As both of NFAT 
proteins are expressed in and affect B and T cells across an immune response, either 
could act as a potential reporter of B and T cell activation. Of these two proteins, I 
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focused on NFAT1 as fusion proteins using NFAT1 have been described previously 
(310).  
 The NFκB family includes 5 proteins: p65, Rel-B, c-Rel, p105/p50, and p100/52 
that form homo- or heterodimers in order to be transcriptionally active (304). Only the 
p65, RelB, and c-Rel proteins have C-terminal transactivation domains that promote 
transcription whereas the p50 and p52 proteins do not directly promote transcription but 
rather competitively inhibit NFκB binding sites and are not associated cellular activation 
(304). Amongst the NFκB proteins that have transactivation potential and could act as 
reporters for activation, the Rel-B gene is only expressed transiently in B cells during the 
GC response and thus would not act as good reporter of B cell activity (311). In contrast, 
c-Rel and p65 are both expressed in mature B cells and the GC (312). Thus, either could 
act as a reporter of activation. However, fusion proteins of p65 have already been 
described making p65 a more appealing target (313).  
 Here, I describe the generation of fluorescent reporters based on the NFAT1 and 
p65 proteins. This was accomplished by making fusion proteins of the NFAT1 and p65 
proteins where the N-terminus of each is fused to the mCherry fluorescent protein. The 
fluorescently tagged reporters were then combined with a nuclear marker, Histone 2 B-
GFP (H2B-GFP), for accurate quantification of nuclear versus cytoplasmic localization. 
These reporters proved to be functional and useful for quantifying intracellular signaling. 
However, when attempting to generate reporter mice using the CRISPR/Cas9 system by 
inserting my reporter constructs into the endogenous p65 or NFAT1 loci, I was unable to 
generate any founder mice. Therefore, I have generated a new version of the reporter that 
has been adapted for insertion into the Rosa26 locus and will be used to generate an 
NFAT1 reporter mouse whose expression of the reporter will be under the control of Cre 
recombinase. Overall, this reporter mouse will extend what is currently possible with 
intravital two-photon microcopy by allowing us to see signaling in real-time within 
immune cells in vivo. 
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4.2 Results 
4.2.1 Fusion of p65 or NFAT1 to fluorescent proteins generates functional 
reporters capable of monitoring their nuclear and cytoplasmic 
localization 
 To construct the p65 and NFAT1 reporters, cDNA sequences for mouse p65 or 
NFAT1 were cloned into the pEGFP-N1 vector along with the DNA sequence encoding 
the mCherry fluorescent protein. The mCherry gene was inserted upstream of the p65 or 
NFAT1 sequences creating N-terminal fusions. To unambiguously determine whether p65 
or NFAT1 are in the nucleus, the mCherry fusion proteins were combined with a nuclear 
marker, histone 2 B (H2B) fused to the N-terminus of GFP (H2B-GFP). By using a 
nuclear marker, the nucleus can be identified with GFP and the ratio of nuclear vs 
cytosolic mCherry can be calculated with certainty. As only 1 protein can be expressed 
from a single mRNA transcript, and the H2B-GFP and mCherry fusion proteins must be 
expressed as separate proteins, a T2A site was incorporated between into the fusion 
proteins allowing both proteins to be expressed separately from a single mRNA transcript 
at a 1:1 ratio (314). Altogether, the reporters were constructed such that the H2B-GFP 
gene was followed by a T2A site allowing for expression of a second mCherry-p65 
fusion protein (H2B-GFP-T2A-mCh-p65) or a mCherry-NFAT1 fusion protein (H2B-
GFP-T2A-mCh-NFAT1) as shown in Figure 4.1A. 
 To determine whether the T2A site separates the two fusion proteins into 
functional reporters, RAW267.4 macrophages were transfected with either the H2B-GFP-
T2A-mCh-p65 or the H2B-GFP-T2A-mCh-NFAT1 vectors. Cells were stimulated with 
lipopolysaccharide (LPS) (known to induce p65 signaling (315)) or phorbol 12-myristate 
13-acetate (PMA) + ionomycin (known to induce NFAT signaling (316)), respectively. 
Cells were then fixed at 0, 10, 20, 40, or 60 min time intervals and imaged by fluorescent 
microscopy. For both the p65 and NFAT1 reporters, the T2A site effectively split the 
H2B-GFP fusion protein from the mCherry fusion proteins as seen by the separation of 
green and red fluorescence in unstimulated cells (Figure 4.1C and 4.1E). In addition to 
the H2B-GFP protein properly localizing to the nucleus, the H2B-GFP protein was seen 
to effectively monitor proliferation through the visualization of chromosomes condensing 
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during mitosis, a feature and advantage of H2B-GFP over other nuclear markers (317) 
further confirming that this protein was functional (Figure 4.1B). The p65 and NFAT1 
fusion proteins were also seen to be functional as the stimulation of RAW267.4 
macrophages resulted in p65 and NFAT1 translocating from the cytoplasm to nucleus as 
seen by GFP and mCherry co-localization (Figure 4.1C and 4.1E) and a shift in the ratio 
of mCherry in the cytoplasm to mCherry in the nucleus (Figure 4.1D and 4.1F). Together, 
these results confirm that the p65 and NFAT1 reporters are functional and capable of 
providing quantitative information on cytoplasmic to nuclear translocations. 
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Figure 4.1. Reporters capable of monitoring the cytoplasmic and nuclear localization of 
the p65 and NFAT1 proteins. 
(A) Schematics of the H2B-GFP-T2A-mCh-p65 or NFAT1 constructs that were inserted 
into the pEGFP-N1 vector using the indicated restriction sites. (B-F) RAW macrophage 
were transfected with H2B-GFP-T2A-mCherry-p65 then stimulated with 1 µg/ml LPS 
(B-D) or transfected with H2B-GFP-T2A-mCherry-NFAT1 then stimulated with 1 µg/ml 
ionomycin and 0.25 µg/ml PMA (E and F) for the indicated periods of time. Cells were 
then fixed and imaged in bright field, GFP, and mCherry channels. (B) Shown are two 
images of RAW macrophage undergoing proliferation as seen by the condensation of 
chromosomes visualized by H2B-GFP. (C and E) Representative images of unstimulated 
and stimulated RAW macrophage are shown. (D and F) Quantification of average 
mCherry MFI in the nucleus (defined by GFP fluorescence) over the average mCherry 
MFI in the cytoplasm where each data point represents a single cell. Data shown is 
representative of three individual experiments. For panel D: n=31 for time 0, n=38 for 
time 10, n=30 for time 20, n=22 for time 40, n=28 for time 60. For panel F: n=71 for time 
0, n=66 for time 10, n=97 for time 20, n=55 for time 40, n=57 for time 60. **p<0.01, 
****p<0.0001. A one-way ANOVA comparing time 0 to the other time points was used 
for multiple comparisons. 
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4.2.2 Using the CRISPR/Cas9 system to generate a reporter knock-in at the 
p65 locus in vitro 
 The purpose for constructing these reporters is to visually monitor signaling 
within primary B and T cells during immune responses. However, the forms described 
above are based upon overexpression of the p65 and NFAT1 proteins. This is problematic 
as the overexpression of p65 protein is known to affect the biology of cells (318, 319). To 
avoid problems associated with overexpression, the p65 reporter was adapted to insert the 
H2B-GFP-T2A-mCh construct into the genome of mouse cells ahead of the p65 gene in 
the p65 locus to be expressed off of the endogenous promoter. To insert DNA into the 
genome in a site directed fashion, arms of homology that consist of DNA segments that 
are homologous to the DNA in either direction of the insertion site direct the homologous 
recombination pathway to insert the DNA contained between the arms of homology into 
the genome (320). Based on this, a DNA donor vector containing two ~1 kbp arms of 
homology corresponding to the DNA sequence of the p65 locus upstream and 
downstream of the ATG start codon was constructed. In between the two arms of 
homology, the H2B-GFP-T2A-mCh reporter was inserted upstream of the p65 gene 
resulting in a fusion of the fluorescent reporters to the N-terminus of the p65 protein 
(Figure 4.2A). 
 As DNA donor vectors do not incorporate into DNA in a site directed fashion 
unless the homologous recombination DNA repair pathway is induced, the CRISPR/Cas9 
system was used to create targeted DNA damage at the p65 locus to enhance 
incorporation efficiency. The Cas9 enzyme is a RNA guided DNA endonuclease that can 
be used to induce double stranded DNA breaks at any site in the genome that has been 
targeted by a RNA guide (321). As homologous recombination is one of the pathways 
used to repair double stranded DNA damage (322), the CRISPR/Cas9 system can be used 
to promote recombination of a DNA donor vector into the genome. To target the p65 
locus using the CRISPR/Cas9 system, a guide RNA was designed based on available 
tools (323) (Figure 4.2B) and incorporated into the pX330 vector that expresses the Cas9 
enzyme as well as the associated guide RNA. 
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 To test the efficacy of the CRISPR/Cas9 system to facilitate incorporation of the 
p65 DNA donor vector into the genome of cells, J774 macrophages were transfected with 
the p65 DNA donor vector along with its associated pX330 vector. Two days post-
transfection, cells were either fixed for fluorescent microscopy or their genomic DNA 
was isolated for genotyping. Insertion of the p65 reporter in the p65 locus was not 
detected in wild type J774 macrophage however, insertion of the reporter was detected in 
transfected cells although this was not consistent across repeat experiments (no band was 
observed in 2 of 4 experiments) (Figure 4.2C).  
 By microscopy, a small proportion of observed cells were fluorescent, indication 
that they had incorporated the p65 donor vector (Figure 4.2D). Due to the low 
incorporation rate, further characterization of the functionality of the p65 reporter was not 
possible. Although not shown here, several guide RNAs were tested. However, none of 
these guide RNAs proved to be efficient in facilitating insertion into the p65 locus. Thus, 
although the p65 reporter can insert into the p65 locus, it does not occur efficiently. 
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Figure 4.2. CRISPR/Cas9-mediated editing of the p65 locus. 
(A) Targeting strategy for inserting the H2B-GFP-T2A-mCherry construct into exon 1 of 
the p65 locus. Shown is the DNA donor vector consisting of two ~1 kbp arms of 
homology, corresponding to the sequence around the ATG start codon in the p65 locus, 
surrounding the H2B-GFP-T2A-mCherry DNA construct. Upon recombination with the 
p65 locus, transcription begins at a new start codon at the start of the H2B gene and 
continues through to the p65 gene. (B) Diagram showing the CRISPR/Cas9 cut site. The 
guide RNA is shown in orange including the nucleotide sequence used to target the p65 
locus, the location of the double stranded break is shown in red, the site of translation 
initiation is shown in yellow, and in black is the protospacer associated motif that is 
required CRISPR mediated cutting (324). (C and D) J774 macrophage were transfected 
with the p65 DNA donor vector and a pX330 vector containing the Cas9 gene and 
sequence encoding the guide RNA specific for the p65 locus. Two days post-transfection, 
DNA was isolated to detect incorporation of the p65 vector into the p65 locus by PCR 
(C), or cells were fixed and imaged in the GFP and mCherry channels (D). (C) To detect 
site-specific incorporation into the p65 locus two primers were used, one specific for the 
p65 locus and the other specific for the mCherry gene. The negative control is pure p65 
donor vector DNA, the positive control is pure p65 donor vector DNA with ~2 kbp arms 
of homology, WT is untransfected J774 macrophage, and p65 is J774 macrophage 
transfected with the p65 donor vector and pX330 vector (Representative of 2 of 4 
experiments). 
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4.2.3 The CRISPR/Cas9 system can be used to generate a reporter knock-in 
at the NFAT1 locus in vitro 
 Similar to the approach described above, the NFAT1 reporter was adapted for 
incorporation into the NFAT1 locus such that ~1 kbp arms of homology derived from the 
sequence surrounding the ATG start codon in the NFAT1 locus were cloned around the 
H2B-GFP-T2A-mCh reporter (Figure 4.3A). Additionally, a guide RNA was designed to 
target the NFAT1 locus to facilitate homologous recombination and was cloned into the 
pX330 vector (Figure 4.3B). 
 To test whether the CRISPR/Cas9 system can facilitate insertion of the NFAT1 
reporter into the NFAT1 locus, J774 macrophages were transfected with NFAT1 DNA 
donor vector and associated pX330 vector and cultured for two days. After two days, the 
cells were processed for genotyping or fixed for microscopy. Incorporation of the DNA 
donor vector into transfected cells was observed by genotyping as a 2 kbp band was 
present in transfected J774 macrophage but not wild type controls (Figure 4.3C). 
Additionally, by microscopy many cells were observed to be fluorescent and this was 
above background levels of incorporation in cells transfected with donor alone (data not 
shown).  
 To determine whether the reporter remains functional when expressed from the 
endogenous NFAT1 promoter, J774 macrophages were transfected as indicated above. 
Two days post-transfection, the cells were imaged over time in a live cell fluorescent 
microscope after the addition of PMA and ionomycin. At time 0, NFAT1 reporter cells 
had the proper distribution of H2B-GFP in the nucleus and mCh-NFAT1 in the 
cytoplasm (Figure 4.3D). Over time mCh-NFAT1 began to accumulate in the nucleus 
resulting in a shift of mCherry fluorescence in the cytoplasm to the nucleus confirming 
that the knock-in at the endogenous locus was still responsive (Figure 4.3D and 4.3E). Of 
note, nuclear accumulation did not occur unless the cells were stimulated with ionomycin 
as unstimulated or LPS stimulation did not result in nuclear accumulation of NFAT1 
(Figure 4.3F, bottom) using a protocol that induced robust p65 translocation (Figure 4.3F, 
top).  
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Figure 4.3. CRISPR/Cas9 mediated editing of the NFAT1 locus 
(A) Targeting strategy for inserting the H2B-GFP-T2A-mCherry construct into exon 1 of 
the NFAT1 locus. Shown is the DNA donor vector consisting of two ~1 kbp arms of 
homology, corresponding to the sequence around the ATG start codon in the NFAT1 
locus, surrounds the H2B-GFP-T2A-mCherry DNA construct. Upon recombination with 
NFAT1 locus, transcription begins at a new start codon at the start of the H2B gene and 
continues through to the NFAT1 gene. (B) Diagram showing the CRISPR/Cas9 cut site. 
The guide RNA shown in orange is used to target the NFAT1 locus, the location of the 
double stranded break is shown in red, the site of translation initiation is shown in yellow, 
and in black is the protospacer associated motif. (C-E) J774 macrophage were transfected 
with the NFAT1 DNA donor vector and a pX330 vector containing the Cas9 gene and 
sequence for the guide RNA for the NFAT1 locus. Two days post-transfection, DNA was 
isolated to detect incorporation of the NFAT1 vector by PCR (C), or live cells were 
imaged in the GFP and mCherry channels (D and E). (C) To detect site-specific 
incorporation into the NFAT1 locus two primers were used, one specific for the NFAT1 
locus and the other specific for the mCherry gene. The negative control is pure NFAT1 
donor vector DNA, the positive control is pure NFAT1 donor vector DNA with ~2 kbp 
arms of homology, WT is untransfected J774 macrophage, and NFAT1 is J774 
macrophage transfected with the NFAT1 donor vector and pX330 vector (representative 
of 3 of 4 experiments). (D and E) Transfected cells were stimulated with 1 µg/ml 
ionomycin and 0.25 µg/ml PMA then imaged once every minute for 21 mins. (D) GFP 
and mCherry fluorescence is shown at the 10 min time point. (E) Quantification of 
average mCherry MFI in the nucleus (defined by GFP fluorescence) over the average 
mCherry MFI in the cytoplasm at each time point is shown. Data is from a combination 
of two independent experiments. A one-way ANOVA was used to compare values at 
each time point to time 0, errors bars are SEM, n=7, *p<0.05. (F) J774 macrophage were 
transfected with pEGFP-N1 H2B-GFP-T2A-mCh-p65 (top panel) or NFAT1 DNA donor 
vector and a pX330 vector containing the Cas9 gene and sequence for the guide RNA for 
the NFAT1 locus (bottom panel). Two days post-transfection, live cells were imaged in 
the GFP and mCherry channels after stimulation with 1 µg/ml LPS over the course of an 
hour (D and E). Representative cells are shown for two individual experiments. 
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4.2.4 Generating knock-in mice using the CRISPR/Cas9 system 
 Having confirmed that the NFAT1 locus can be modified to generate a functional 
reporter, I sought to use the CRISPR/Cas9 system to genetically modify mouse zygotes, a 
prerequisite to making a reporter mouse. To determine whether mouse zygotes could be 
edited to incorporate the NFAT1 reporter, single C57Bl/6 mouse zygotes were given 
nuclear microinjections with guide RNA, DNA donor vector, and Cas9 mRNA and 
grown in vitro into blastocysts. Individual blastocysts were then processed for 
genotyping. 
 The PCR protocol was first validated to be capable of detecting small amounts of 
DNA by detecting the NFAT1 locus in wild type blastocysts and confirmed not to 
produce false positives when using primers specific for the NFAT1 reporter (Figure 
4.4A). Then, 65 viable blastocysts were genotyped as an initial measure of incorporation 
frequency. Unfortunately, there was no evidence of incorporation of the reporter in any of 
the blastocysts, suggesting that this approach to insert a large segment of DNA is not 
reliable enough to proceed with generating mice (Figure 4.4B). Indeed, in a second 
attempt where live blastocysts were implanted to produce pups, no positive mice were 
identified by genotyping (data not shown). 
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Figure 4.4. Insertion of the NFAT1 reporter into C57Bl/6 blastocysts. 
(A) A protocol for detecting DNA from blastocysts was tested on 10 wild type C57Bl/6 
blastocysts using a nested PCR approach. Primers specific for either the NFAT1 locus 
(left) or specific for a site specific incorporation of our reporter (right) were used. (B) 
Incorporation of the NFAT1 reporter into blastocysts injected with the NFAT1 CRISPR 
components was assessed using PCR (38 of 65 shown).  
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4.2.5 An overexpression-based NFAT1 reporter 
 As inserting the NFAT1 reporter into the endogenous locus was not viable, I 
attempted an alternative approach where a transcriptionally inactive reporter, thus unable 
to affect the biology of the cell, would be overexpressed in cells. This was accomplished 
by taking advantage of the structure of the NFAT1 protein. The NFAT1 protein has an N-
terminal transactivation domain followed by a regulatory domain that contains the 
nuclear localization sequence as well as phosphorylation sites that regulate the 
availability of the nuclear localization sequence (325). Following this is the Rel-
homology domain that is responsible for DNA binding and the final domain is the C 
terminal domain. Of key significance, the regulatory domain of NFAT1 is entirely 
separate from its DNA binding domain. Thus, it is possible to express the regulatory 
domain of NFAT1, which is responsible for dictating NFAT1 import and export from the 
nucleus, without its DNA binding domain that would be required for this protein to act as 
a transcription factor. 
 To construct this reporter, amino acids 1-399 from NFAT1, corresponding to the 
N-terminal transactivation domain and regulatory domains, were used in place of the full 
length NFAT1 protein. The NFAT11-399 gene was then combined with mCherry, the H2B-
GFP gene, and T2A site in a pEGFP-N1 vector (Figure 4.5A). To test whether this form 
of the reporter was functional, J774 macrophages were transfected with the NFAT11-399 
reporter and then stimulated with PMA and ionomycin for 20 mins prior to fixation for 
fluorescent microscopy. Transfected cells that were unstimulated had no evidence of 
nuclear accumulation of the NFAT11-399 reporter whereas the reporter accumulated in the 
nucleus of stimulated cells confirming the reporter was functional (Figure 4.5B).  
 To adapt the reporter for insertion into the mouse genome, I took advantage of a 
commonly targeted locus known as the Rosa26 locus. This locus constitutively expresses 
a non-coding RNA, with no known function, uniformly across the body (326). Genes of 
interest can be expressed from this locus by inserting them into the intron between exon 1 
and 2 of this locus along with a gene trap (327). A gene trap involves the usage of a 
splice acceptor site to ‘steal’ the splice donor site from the previous exon, preventing the 
second exon from being spliced into the mRNA transcript, resulting in your gene of 
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interest becoming the next exon. To take advantage of this system, the NFAT1-399 reporter 
was inserted into the ROSA26TV vector, a plasmid that already contains the splice 
acceptor site and arms of homology required for insertion into the Rosa26 locus (Figure 
4.5C). Additionally, this plasmid also has a neomycin resistance gene flanked by loxP 
sites ahead of the NFAT1 reporter such that expression through the construct will result 
in the production of the neomycin resistance protein before production of the NFAT1 
reporter. This organization of genes is useful as the expression of the NFAT1 reporter is 
inducible in this system through the expression Cre recombinase in cells. When Cre 
recombinase is expressed, it will use the LoxP sites to remove the neomycin resistance 
gene (328) resulting in the first start codon to then reside at the start of the NFAT1 
reporter construct. Thus, this construct not only expresses the NFAT1 reporter, but can do 
so in a cell-specific manner depending on Cre recombinase expression. 
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Figure 4.5. Construction of an NFAT1 reporter that can be overexpressed. 
(A) Schematic of the NFAT11-399-mCherry-T2A-H2B-GFP construct that was inserted 
into the pEGFP-N1 vector using the indicated restriction sites. (B) J774 macrophages 
were transfected with NFAT11-399-mCherry-T2A-H2B-GFP and then stimulated with 
PMA + ionomycin for 20 mins prior to fixation for fluorescent microscopy. Cells were 
imaged in the GFP and mCherry channels. Shown are representative images. (C) Shown 
is a diagram outlining the targeting strategy for inserting the NFAT11-399-mCherry-T2A-
H2B-GFP construct into the Rosa26 locus. A donor vector consisting of two arms of 
homology, corresponding to the intron sequence in between exon 1 and 2 of the Rosa26 
locus, surrounds the DNA construct. The DNA construct contains a splice acceptor (SA) 
site, that upon recombination into the locus, interrupts splicing between exon 1 and 2 of 
the Rosa26 locus and instead leads to the reporter construct being incorporated into the 
mRNA transcript. Ahead of the NFAT1 reporter, a neomycin resistance gene flanked by 
LoxP sites is expressed and prevents expression of the NFAT1 reporter. Using Cre-LoxP 
mediated recombination, the neomycin gene can be removed allowing expression of the 
NFAT1 reporter. 
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4.3 Discussion 
 Our understanding of how intracellular signaling induced through B and T cell 
interactions contributes to B cell fate choices is limited by the inability to visualize 
signaling as it occurs in vivo. Here, I address this issue by constructing fluorescent 
reporters capable of monitoring NFκB and NFAT signaling in vivo, in real-time, and in 
individual cells using reporters compatible with intravital imaging. Despite the reporters 
being functional, I was unable to generate reporter mice using a knock-in approach to 
modify the p65 and NFAT1 loci. Nonetheless, insertion into the Rosa26 locus holds 
potential for generating an NFAT1 reporter mouse. This will be accomplished through 
either conventional knock-in methods (320) or aided using the CRISPR/Cas9 system 
(329). 
 As the generation of new mouse strains is never guaranteed, additional options 
can be explored in the case where a mouse cannot be made. This is easier for the NFAT1 
reporter as I have made a form of this reporter that can be overexpressed in cells. Indeed, 
the use of a retroviral vector to introduce a transcriptionally inactive NFAT1 reporter into 
cells has already been used with success (310, 330). One major limitation to retroviral 
vectors however, is that they do not readily transduce quiescent cells such as naïve B and 
T cells (310, 330, 331). This problem can be overcome through in vitro activation of cells 
and transducing the cells as they begin to proliferate. However, in the context of studying 
foreign or autoAg driven GCs, in vitro activation of B and T cells would pose several 
problems: First, it is not clear whether in vitro activated cells would behave similarly to 
cells activated exclusively in vivo. Second, in vitro activation may allow autoreactive B 
and T cells to subvert regulatory pathways that would normally suppress their activation 
(332, 333). Lastly, although in vitro activation of T cells is well established (334), in vitro 
expansion of B cells is relatively new and is likely to affect the phenotype of the cultured 
B cells (335). Thus, to study naive B and T cell responses, a reporter mouse is needed and 
may require the use of methods that are less than ideal for generating a transgenic mouse. 
Transgenic mice can be generated by injecting zygotes with linear DNA that incorporates 
at random into the genome where the linear DNA contains your gene of interest as well 
as a promoter to drive its expression (336). This method is quite robust for generating 
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founder mice, although, it suffers from several problems: 1st, variable expression of the 
transgene; 2nd, loss or gain of function mutations in genes already in the genome as a 
result of transgene insertion; and 3rd, insertion of multiple copies of the transgene. The 
combination of these problems makes it difficult to be confident that the founder mice 
generated are truly correct as these factors could act as confounding factors in 
interpreting the data acquired by studies using mice with incorrect transgenes. Thus, 
although there are alternative methods available for generating a useable NFAT1 
reporter, these methods have significant limitations. 
 Ideally these studies would be conducted using both the NFAT1 and p65 reporters 
as transcription factors do not work alone. Instead, they work in coordination with other 
transcription factors influencing their activity (337) and the NFAT1 and p65 proteins are 
no exception to this (338-340). For example, NFAT1 induces an anergic transcriptional 
program unless it is complemented by other transcription factors (341, 342). 
Additionally, as particular transcription factors are preferentially activated by certain 
pathways (see Chapter 1.8.2), the usage of multiple reporters of activation would 
integrate a greater range of signaling allowing us to more confidently determine whether 
signals are being exchanged. I was able to construct a reporter of NFAT1 activity by 
taking advantage of the monomeric nature and structure of the NFAT1 protein (325) to 
express a transcriptionally inactive reporter. A similar approach is not possible with p65 
or the other NFκB proteins as the same domain is responsible for regulating 
cytoplasmic:nuclear shuttling and DNA binding making these functions inseparable 
(343). Indeed, even if the p65 protein was mutated to abolish its capacity to bind DNA 
and act as a transcription factor (344), the transgene would create a dominant negative 
mutation. Cytoplasmic and nuclear shuttling of NFκB proteins requires them to form 
dimers (304), and given that NFκB proteins form homo- and heterodimers, inactive forms 
of p65 would inactivate any other NFκB proteins they dimerized with. Thus, a reporter of 
NFκB activity requires modification of the endogenous locus. 
 The major factor limiting the generation of a p65 reporter mouse was the low 
incorporation rate of my p65 donor DNA. In the time since we had completed the 
injections, the field of genomic modifications using the CRISPR/Cas9 system has moved 
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forward generating several technologies that could have aided my approach. Although I 
will not provide an exhaustive list of new methods, the following represent easily 
adaptable methods that could be employed in the future. The first is the use of single 
stranded DNA donor vectors over double stranded DNA. For some applications, single 
stranded DNA donor vectors have been able to achieve high levels of incorporation 
relative to double stranded DNA vectors (345). Second, the stability of the guide RNA 
can also be limiting (321). The stability of RNAs can be increased by incorporating 
chemically modified nucleotides at the ends of the RNA molecules to limit their 
degradation and can have substantial effects on incorporation rates (346). Lastly, 
inhibition of the non-homologous end joining pathway can promote usage of the 
homologous recombination pathway. In this study, I used the SCR7 inhibitor of non-
homologous end joining (347). However, additional small inhibitors of non-homologous 
end joining have been identified and could be used to further promote homologous 
recombination over non-homologous recombination (348). Thus, there are several 
methods that could be used in the future to try to improve incorporation into the p65 
locus. 
 The generation of these reporters is of great interest to us as this will allow us to 
answer many basic questions about the GC response. Throughout the GC response B and 
T cells form interactions that are essential for GC induction and maintenance (78, 204). 
We know that individual interactions can differ substantially in length and this has been 
associated with B cells making different fate choices (112, 117, 161). Nonetheless, we 
still do not understand at a molecular level what makes a long and short interaction 
different. It is for example, unclear whether a short interaction represents a ‘failed’ 
interaction in which signaling in the B or T cell fails to be induced or is a less potent 
version of the longer interaction. Furthermore, although interactions can be quite long at 
the pre-GC phase, interactions within the GC are exclusively short. Thus, it is not clear 
how signaling in B and T cells has changed between these two time points. Beyond 
questions about the basic biology of B and T cell interactions, there are also several 
applications of this reporter in our MOG-induced GC model. At the pre-GC phase, it was 
observed that B and T cells in MOG-immunized mice form substantially shorter 
interactions than those in NPOVA-immunized mice (unpublished observations, Parham 
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KA et al.). Currently, it is not clear whether the short interactions in both systems are 
equivalent or, perhaps, if the short interactions are unique in each Ag model. Indeed, 
using these signaling reporters would give us the first clues for identifying whether the 
developing B cell response is controlled through unique signals being exchanged during 
interactions to different Ag’s or if perhaps, B cell differentiation is controlled by a 
universal code of interaction duration. 
 In conclusion, the reporters developed here will require additional optimization. 
Fortunately, several different avenues are available to address this. By creating 
fluorescent mouse strains capable of monitoring the activity of the NFκB and NFAT 
proteins, an understanding of the molecular events responsible for directing B cell 
differentiation at a cellular level can be defined. This will ultimately give us a more 
precise understanding of B cell differentiation that is not currently possible with bulk 
analysis of B cells. 
 
4.4 Materials and Methods 
4.4.1 Cloning 
 Primers referenced in Table 4.1 (Integrated DNA Technologies, Carolville, Iowa, 
and Sigma, St. Louis, Missouri) were used in PCR reactions using either Pfu polymerase 
(Gbiosciences, St. Louis, Missouri) or Phusion polymerase (Thermo Fisher Scientific, 
Waltham, Massachusetts). PCR products were run through agarose gel electrophoresis 
and bands corresponding to the correct PCR products were purified using either E.Z.N.A. 
Gel Extraction Kit (OMEGA Bio-Tek, Norcross, Georgia) or Gel/ PCR DNA Fragments 
Extraction Kit (Geneaid, New Taipei City, Taiwan) using manufacturers protocols. 
Purified PCRs were digested using combinations of SalI, HindIII, EcoRI, MfeI, NotI, 
XmaI, AscI, SacI, XhoI, and BglII (New England Biolabs, Ipswich, Massachusetts) or 
BbsI (Thermo Fisher Scientific, Waltham, Massachusetts) then purified using Geneclean 
II Kit (MPbiomedicals, Santa Ana, California) according to manufacturers protocol. 
Digested products were then ligated into pEGFP-N1 (Clontech, Mountain View, 
California), pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene 42230), pCAGGS 
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(Belgian Co-Ordinated Collections of Micro-Organisms), or STOP-eGFP-ROSA26TV 
vector (Addgene 11739) using T4 DNA ligase (New England Biolabs, Ipswich, 
Massachusetts).  
 The following plasmids were used for PCR templates: pBABE-H2BGFP 
(Addgene 26790) was used for amplification of H2B-GFP, RelA cFlag pcDNA3 
(Addgene 20012) was used for amplification of the p65 subunit of NFκB, WT NFAT1 
(Addgene 11100) was used for amplification of NFAT1, pmCherryN1 (Clontech, 
Mountain View, California) was used for amplification of mCherry, RP23-30E22 
Bacterial Artificial Chromosome (Invitrogen, Carlsbad, California) containing the p65 
locus was used for amplification of arms of homology for the p65 locus, RP23-135N9 
Bacterial Artificial Chromosome (Invitrogen, Carlsbad, California) containing the 
NFAT1 locus was used for amplification of arms of homology for the NFAT1 locus. 
BACs were purified using NucleoBond Xtra BAC (Clontech, Mountain View, California) 
as listed in manufacturers protocol. 
 In brief, the H2B-GFP-T2A-mCh-p65/NFAT1 reporters were constructed by PCR 
amplifying H2B-GFP and cutting the PCR transcript with BglII and HindIII. This was 
ligated into the pEGFP-N1 vector along with annealed primers corresponding to the T2A 
sequence. The mCherry gene was then PCR amplified and cut with SacI and HindIII. 
This was cloned into the same pEGFP-N1 vector along with PCR amplified NFAT1 (cut 
with HindIII and SalI) or p65 (cut with HindIII and EcoRI). 
 The p65 donor DNA plasmids were constructed by first modifying the pCAGGs 
vector using EcoRI and BglII to incorporate annealed primers encoding a multiple 
cloning site. The left arm of homology for the p65 locus was PCR amplified to make a 
long version (1938 bp) or a short version (961 bp) and cloned into the pCAGGs vector 
using the SalI and MfeI restriction sites. The H2B-GFP-T2A-mCh reporter was PCR 
amplified (cut with MfeI and XhoI) and ligated into the same pCAGGs vector. Finally, 
the right arm of homology for the p65 locus was amplified to make a long version (1942 
bp) or a short version (988 bp) then cut with Xho1 and HindIII before ligation into the 
pCAGGs vector. The NFAT1 donor plasmids were similarly constructed by PCR 
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amplifying the right arm of homology to make a long version (1999 bp) and a short 
version (952 bp) that were cut with NotI and BglII for insertion into the pCAGGs vector. 
Then the H2B-GFP-T2A-mCh reporter was PCR amplified and cut with NotI and XhoI 
for insertion into the same pCAGGs vector. Lastly, the left arm of homology was PCR 
amplified to make a long version (1976 bp) or short version (937 bp) that were cut with 
SalI and XhoI before ligation into the pCAGGs vector. 
 The DNA sequences coding the guide RNAs responsible for targeting the p65 and 
NFAT1 locus where generated by annealing DNA primers and ligating them into pX330 
vectors cut with BbsI. 
 Cloning of the NFAT11-399-mCh-T2A-H2B-GFP construct was accomplished by 
PCR amplifying NFAT11-399 (cut with SacI and HindIII) and mCherry (cut with HindIII 
and AgeI) then ligating them into the pEGFP-N1 vector. Then H2B-GFP (cut with SalI 
and NotI) was ligated into the same vector along with two annealed primers forming the 
T2A site. This reporter construct was then PCR amplified (cut with AscI and NotI) and 
cloned into the STOP-eGFP-ROSA26TV vector along with anneal primers to act as an 
adaptor between the XmaI restriction site and the NotI restriction site. 
 Ligated plasmids were transformed into competent E. coli (DH5α) using standard 
techniques (275). Plasmids were collected from these cells using the High-Speed Plasmid 
Mini Kit (Geneaid, New Taipei City, Taiwan) according to manufacturers protocol. 
Finalized vectors were sent for sequencing (London Regional Genomics Centre, London, 
Ontario) and upon confirmation plasmids were purified using Plasmid Maxiprep kit 
(Geneaid, New Taipei City, Taiwan). 
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Table 4.1. Forward and reverse primers used for cloning 
Primer 
name 
DNA sequence (5' to 3') Product 
size 
H2B-GFP 
fwd 
5'-AAA AAA AGA TCT ATG CCA GAG CCA GCG AAG 
T-3' 
1137 bp 
rev 5'-AAA AAA AAG CTT CTT GTA CAG CTC GTC CAT 
GCC-3' 
 
T2A fwd 5'-AGC TGG AGG GCA GAG GAA GTC TTC TAA CAT 
GCG GTG ACG TGG AGG AGA ATC CCG GCC CTG 
AGC T-3' 
64 bp 
rev 5'-CAG GGC CGG GAT TCT CCT CCA CGT CAC CGC 
ATG TTA GAA GAC TTC CTC TGC CCT CC-3' 
 
mCherry 
fwd 
5'-AAA AAA GAG CTC ATG GTG AGC AAG GGC GAG 
G-3' 
732 bp 
rev 5'-TTT TTT AAG CTT CTT GTA CAG CTC GTC CAT 
GCC-3' 
 
p65 fwd 5'-AAA AAA AAG CTT ATG GAC GAT CTG TTT CCC 
CTC ATC-3' 
1674 bp 
rev 5'-TTT TTT GAA TTC TTA GGA GCT GAT CTG ACT 
CAA AAG AGC AG-3' 
 
NFAT1 fwd 5'-AAA AAA AAG CTT ATG GAC GTC CCG GAG CCG 
CAG C-3' 
2808 bp 
rev 5'-AAA AAA GTC GAC CTA GGT CTG ATT TCG GGA 
GGG AG-3' 
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p65 guide 
RNA fwd 
5'-CAC CGT CCA TGG TCA GGG TCC CGG-3' 24 bp 
rev 5'-AAA CCC GGG ACC CTG ACC ATG GAC-3'  
NFAT1 
guide RNA 
fwd 
5'-CAC CGT CCG GGA CGT CCA TGG CTC G-3' 25 bp 
rev 5'-AAA CCG AGC CAT GGA CGT CCC GGA C-3'  
multiple 
cloning site 
pCAGGs 
fwd 
5'-AAT TCC AAT TGC AGG TTC TCG AGT CGT GTG 
AGC TCA ACT GAG CGG CCG CAT GTC GA-3' 
60 bp 
rev 5'-GAT CTC GAC ATG CGG CCG CTC AGT TGA GCT 
CAC ACG ACT CGA GAA CCT GCA ATT GG-3' 
 
long left 
arm p65 
fwd 
5'-TTT TTT GTC GAC CTA GCC CCT GCT GGT CCA 
GAG CTC-3' 
1968 bp 
short left 
arm p65 
fwd 
5'-TGC CAC CTG GTC GAC GCC AGA GTC CCC ACA 
CTC AAT CTG CA-3' 
985 bp 
rev 5'-GCT TTT CAA TTG GGT CAG GGT CCC GGG AGC 
GGG GCC GGG GT-3' 
 
p65 reporter 
fwd 
5'-AAA AAA CAA TTG ATG CCA GAG CCA GCG AAG 
T-3' 
1900 bp 
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rev 5'-TTT TTT CTC GAG CTT GTA CAG CTC GTC CAT 
GCC GCC GGT GGA G-3' 
 
right arm 
p65 fwd 
5'-GAA CCG CTC GAG ATG GAC GGT GAG GCT GCC 
CTC TGG CTC G-3' 
 
long rev 5'-GAA CCC AAG CTT CTT CCC ACT CCT TAC CCA 
CTG GCA AGT-3' 
1966 bp 
short rev 5'-GAT TAC GCC AAG CTT CAA TCC CTA ATC TGG 
CTC TTA GAC ACA GGG C-3' 
1012 bp 
long left 
arm NFAT1 
fwd 
5'-GAA CGC GTC GAC TGT GGG TCA TGA CTG ACC 
CCT TCG GGT ATG TCA AAA GAC CC-3' 
2000 bp 
short left 
arm NFAT1 
fwd 
5'-TGC CAC CTG GTC GAC TCA GGG AGC ACT GCC 
CAT CTC C-3' 
961 bp 
rev 5'-GAA CCG CTC GAG GGC TCG GAG CGT TCG GGA 
TGC GGG TTC GTA TAG AG-3' 
 
NFAT1 
reporter fwd 
5'-AAA AAA CTC GAG ATG CCA GAG CCA GCG AAG 
T-3' 
1911 bp 
rev 5'-AAG GAA AAA AGC GGC CGC CCT TGT ACA GCT 
CGT CCA TGC CGC CGG TGG AG-3' 
 
right arm 
NFAT1 fwd 
5'-TTT TTT GCG GCC GCA TGG ACG TCC CGG AGC 
CGC A-3' 
 
long rev 5'-TTT TTT AGA TCT CAG CAG GAC AGG AGA AGG 
GAA TGG CC-3' 
2023 bp 
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short rev 5'-GAG GGA AAA AGA TCT ATC TGG AAG CTG CCA 
GCA GGC T-3' 
976 bp 
p65 
genotyping 
fwd 
5'-CAT GGA CGA GCT GTA CAA GCT CGA G-3' 1041 bp 
rev 5'-CCA AAG TAC AGA GTA CTC TAG TGG CCA G-3'  
NFAT1 
locus 
genotyping 
fwd 
5'-ATG GAC GTC CCG GAG CCG CA-3' 985 bp 
NFAT1 
reporter 
genotyping 
fwd 
5'-ACG AGC TGT ACA AGG GCG GCC GC-3' 1008 bp 
NFAT1 
locus rev 
5'-ACC AGA TGC CCG CAA GCC CGC AG-3'  
nested fwd 5'-AGA GGT AGA GGG GCG TGT GC-3' 121 bp 
rev 5'-AAG TCC CCA ACA ACC GGC TC-3'  
NFAT11-399 
fwd 
5'-AAA AAA GAG CTC ATG GAC GTC CCG GAG CCG 
CAG C-3' 
1221 bp 
rev 5'-CAA GGC AAG CTT GAG TGG TGG GAG GGA TGC 
AGT C-3' 
 
mCherry 
fwd 
5'-GAA CCG AAG CTT ATG GTG AGC AAG GGC GAG 
G-3' 
732 bp 
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rev 5'-GAA GCC ACC GGT CTT GTA CAG CTC GTC CAT 
GCC G-3' 
 
T2A fwd 5'-CCG GAG AGG GCA GAG GAA GTC TTC TAA CAT 
GCG GTG ACG TGG AGG AGA ATC CCG GCC CT-3' 
60 bp 
rev 5'-TCG ACA GGG CCG GGA TTC TCC TCC ACG TCA 
CCG CAT GTT AGA AGA CTT CCT CTG CCC TC-3' 
 
H2B-GFP 
fwd 
5'-GAA CGC GTC GAC ATG CCA GAG CCA GCG AAG 
TCT G-3' 
1144 bp 
rev 5'-AAG GAA AAA AGC GGC CGC TTA CTT GTA CAG 
CTC GTC CAT GCC GAG AG-3' 
 
reporter 
ROSA26 
fwd 
5'-GTC GAA GAG CTC GGC GCG CCA TGG ACG TCC 
CGG AGC CGC AGC-3' 
3117 bp 
rev 5'-GTA AGC GCG GCC GCA TTA ATT TAC TTG TAC 
AGC TCG TCC ATG CCG-3' 
 
ROSA26-
TV adaptor 
fwd 
5'-GGC CCA CAC TTG CCT GGT AAG CTG CAC TCT 
GCT C-3' 
38 bp 
rev 5'-CCG GGA GCA GAG TGC AGC TTA CCA GGC AAG 
TGT G-3' 
 
Genotype 
GFP fwd 
5'-GCG AGG GCG ATG CCA CCT ACG GCA-3' 450 bp 
rev 5'-GGG TGT TCT GCT GGT AGT GGT CGG-3'  
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4.4.2 Cell culture and transfections 
 RAW264.7 macrophage or J774 macrophage were cultured in 12-well plates with 
1 ml RPMI Medium 1640 with L-glutamine (WISENT, Saint-Bruno, Quebec) and 10% 
FBS (WISENT, Saint-Bruno, Quebec) at 37°C, 5% CO2. Cells were plated at 5x10
5 cells 
per well and grown on coverslips overnight until approximately 30-50% confluency at 
which point they were transfected with 1 μg of total DNA per well using Fugene HD 
(Promega, Madison, Wisconsin) as listed in manufacturer’s protocol (for CRISPR 
experiments, cells were transfected at a 3:1 ratio of DNA donor plasmid:pX330 vector). 
After 4-5 hours, the media on the transfected cells was replaced by 1 ml of fresh media 
and incubated for 1 day for overexpression experiments and 2 days for CRISPR 
experiments where the media was supplemented with 0.1 µM SCR7 (Xcessbio, San 
Diego, California). For the p65 stimulation experiments, p65 transfected cells were then 
stimulated with LPS from S. enterica (Sigma, St. Louis, Missouri) in 10% FBS RPMI 
and MEM Non-Essential Amino Acids Solution 100x (Thermo Fisher Scientific, 
Waltham, Massachusetts). For NFAT1 stimulation experiments cells were stimulated 
with PMA (Tocris Biosciences, Bristol, United Kingdom) and ionomycin (Sigma, St. 
Louis, Missouri) in 1 mL serum free RPMI with MEM non-essential amino acids after a 
PBS wash. 
4.4.3 Fixed and live cell microscopy 
 Cells were fixed onto coverslips after a PBS wash using a 20 minute incubation in 
4% PFA (Electron Microscopy Sciences, Hatfield, Pennsylvania). Fixed cells were then 
washed again with PBS and mounted onto glass slides using PermaFluor Mountant 
(Thermo Fisher Scientific, Waltham, Massachusetts). These slides were then imaged 
using a DM5500B fluorescence microscope (Leica microsystems, Concord, ON, Canada) 
with a 40x objective lens in the Bright Field, GFP, and mCherry filters. 
 For live cell experiments, coverslips with transfected macrophage (described in 
4.4.2) were transferred to a Leiden chamber in a Leica DM16000B microscope equipped 
with a 37°C heated stage perfused with 5% CO2, a 40x objective, photometrics Evolve-
512 delta EM-CCD camera, Chroma Sedat Quad filter set, and the Leica Application 
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Suite X software platform (Leica microsystems, Concord, ON, Canada). The locations of 
2-3 reporter positive cells were tracked using the mark-and-find feature then the Leiden 
chamber was opened to add PMA + ionomycin to a final concentration of 0.25 µg/ml 
PMA and 1 µg/ml ionomycin in serum free RPMI. Cells were then imaged once every 
minute for 22 minutes in the GFP and mCherry channels. 
4.4.4 Genotyping of CRISPR transfected cells and mouse pups 
 Two days post-transfection, J774 macrophage were scraped off the bottom of 12-
well plates then centrifuged at 1500 rpm for 8 minutes at 4°C. The pellet was then 
suspended in permeabilization buffer (50 mM Tris, 50 mM KCl, 2.5 mM EDTA, 0.45% 
Igepal, 0.45% Tween-20 (Bioshop, Burlington, Ontario), and 0.15 mg/ml proteinase K 
(Biobasic, Markham, Ontario)) and incubated overnight at 55°C then frozen at -20°C 
until needed. To set up the genotyping reactions, Phusion polymerase (Thermo Fisher 
Scientific, Waltham, Massachusetts) was used with 2% DMSO and either 1 µl of 
genomic DNA or 0.5 µg of purified donor DNA plasmids were used as templates. The 
cycler conditions used were: 98°C for 3 mins then 45 cycles of (0.5 mins 98°C, 0.5 mins 
62°C, and 3 mins 72°C) followed by 10 mins 72°C. Finished PCR reactions were then 
loaded onto a 1% agarose gel. For the genotyping of mouse pups, small tail snips were 
used instead of transfected cells. 
4.4.5 Guide RNA design 
 Suitable guide RNAs were identified for both the p65 and NFAT1 loci using the 
CRISPR design tool provided at (http://crispr.mit.edu/) which is described in (323). 
Guide RNAs were selected based on specificity where the p65 guide RNA had a score of 
82 and the NFAT1 guide RNA had a score of 94. 
4.4.6 Nuclear injections 
 The protocol for nuclear injections was based on (349). In brief, 4 week old 
C57Bl/6 females were injected with pregnant mare serum gonadotrophin (Sigma, St. 
Louis, Missouri) and two days later mice were injected with human chorionic 
gonadotrophin (Sigma, St. Louis, Missouri) then mated with male C57Bl/6 mice. Single 
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embryos were then collected from female mice, washed, then cultured briefly in M2 
media (Millipore, Burlington, Massachusetts) at 37°C and 5% CO2. An injection mixture 
of 100 ng/µl Cas9 mRNA (TriLink Biotechnologies), 50 ng/µl guide RNA (Integrated 
DNA Technologies, Carolville, Iowa), and 200 ng/µl donor DNA was mixed at a 1:3:3 
ratio with M2 media supplemented with Cytochalasin B 10 µg/ml (Sigma, St. Louis, 
Missouri) and M2 media supplemented with 10% (wt/vol) Polyvinylpyrrolidone 360 kDa 
(Sigma, St. Louis, Missouri). Zygotes were then injected with this mixture and cultured 
in KOSM media (Millipore, Burlington, Massachusetts) supplemented with 0.1 µM 
SCR7 until the two cell stage for transfers into pseudopregnant females to generate whole 
mice, or cultured to the blastocyst stage for genotyping. 
4.4.7 Blastocyst genotyping 
 To isolate DNA from blastocysts a DNeasy blood and tissue kit (Qiagen, Hilden, 
Germany) was used. To detect blastocysts DNA, an initial set of primers specific for the 
NFAT1 locus or specific for a site-specific insertion of the NFAT1 reporter was used in 
combination with Q5 high-fidelity polymerase (New England Biolabs, Ipswich, 
Massachusetts) according to the manufacturer’s protocol. Then, 1 µl of the PCR was used 
to seed a second PCR reaction using two primers that formed a nested PCR within the 
first set of primers. Again the PCR reaction was conducted with Q5 high-fidelity 
polymerase according to the manufacturer’s protocol. Once complete, the PCRs were run 
on a 2% agarose gel. 
4.4.8 Image analysis 
 Tiled images from microscopy were analyzed using the ImageJ program. The cell 
counter add-on for this program was used to quantify the number of cells in a tiled image 
that displayed a nuclear translocation of a transcription factor where a nuclear 
translocation was defined as visible fluorescence in the area defined by the nuclear 
marker. The nuclear to cytoplasmic fluorescence ratio was calculated by measuring the 
fluorescence in the nuclei of cells defined by the nuclear marker and dividing this by the 
fluorescence measured in a representative portion of cytoplasm near the nucleus. 
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4.4.9 Statistical analysis 
 Prism software (Graphpad, La Jolla, California) was used to graph the data and 
for calculation of statistical significance. A student’s T test was used to compare two 
groups, while multiple comparisons were compared using an ANOVA followed by a T 
test with a Bonferroni correction. 
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Chapter 5  
5 Overall discussion and future directions 
 In this thesis, I describe factors that influence the initiation and progression of 
GCs directed against the autoAg MOG. The hypothesis that the MOG-induced GC would 
be short-lived and less productive than foreign-Ag driven GCs is addressed. 
5.1 Summary of the major findings of this thesis 
 In Chapter 2 of this thesis, I developed a novel protein expression system to 
express large amounts of mMOGtag protein. I show that the mMOGtag expression system 
is amenable to manipulation through the generation of haMOGtag, which alters T cell Ag-
affinity and induces accelerated proliferation of MOG-specific T cells. Both mMOGtag 
and haMOGtag were confirmed to be capable of inducing EAE incorporating autoreactive 
B and T cells confirming that these Ags can induce GC responses in the context of 
relevant autoimmune disease. In Chapter 3, I used the tools developed in Chapter 2 to 
determine factors that influence B cell differentiation in the context of autoimmune GC 
responses. I found that immunization with MOG protein results in a short-lived GC that 
produces few plasma cells relative to the model foreign-Ag, NPOVA. Instead, the MOG-
induced immune response produces predominantly memory B cells; however, these cells 
are short-lived. I then showed that the collapse of the MOG-induced GC response is 
instructed by the autoreactive T cell and could be attributed to their low-affinity for Ag. 
However, the short-lived nature of MOG-specific memory B cells was not under T cell 
control. Despite evidence of T cells contributing to B cell fate choices in these Ag-
models, I saw no evidence that TFH cells are differentially expressing molecules 
associated with B cell differentiation. Instead, TFH cells differed only in absolute number, 
a property that appears to be instructed by the Ag itself. Increases in TFH cell numbers 
were also associated with an expansion of DZ B cells suggesting that absolute TFH cell 
numbers influence the fate decision between staying in the GC and memory B cell 
differentiation. Altogether, the MOG-induced autoreactive GC response is limited by 
properties of the MOG-autoAg including low T cell Ag-affinity. One hypothesis that 
could link the fate choices B cells make in immune responses to the properties of Ags, is 
149 
 
 
that Ag-properties influence how signals are exchanged during B and T cell interactions. 
This hypothesis was addressed in Chapter 4 by developing a tool to investigate the 
kinetics of signal exchange between B and T cells during their interactions. I showed that 
I can monitor the activation status of cells by monitoring the cytoplasmic to nuclear 
translocations of the NFAT1 and p65 proteins. The reporter of NFAT1 activity was 
successfully adapted for insertion into the endogenous NFAT1 locus using the 
CRISPR/Cas9 system; however, this did not translate into successful generation of a 
reporter mouse. The NFAT1 reporter has since been adapted for insertion into the Rosa26 
locus and this construct should generate a functional reporter mouse. 
5.2 A model of the autoreactive germinal center 
 Overall, the results of this thesis reinforce the current models of GC initiation and 
progression but also extend them. One of the key findings in Chapter 3 was that MOG-
induced GCs are biased towards centrocytes over centroblasts as a result of not 
maintaining a DZ in the GC. Indeed, the lack of a DZ in the MOG-induced GC response 
can potentially explain why I do not see efficient plasma cell production and why there is 
preferential memory differentiation. In particular, differentiation into plasma cells is 
favored in B cells that acquire a high-affinity BCR, where the acquisition of a high-
affinity BCR is facilitated by SHM, whereas memory B cell differentiation is favored by 
low-affinity BCRs (58, 108, 128, 152). As SHM occurs in the DZ of the GC (108), it 
seems likely that the lack of selection of centrocytes to enter the DZ of the MOG-induced 
GC would contribute to preferential memory B cell differentiation although, further 
analysis of SHM in the MOG-induced GC would be required to validate this. 
 I also showed that when immunizing with haMOGtag instead of mMOGtag, which 
incorporates a high-affinity T cell epitope, MOG-specific B cells favored staying in the 
GC over memory B cell differentiation and this was associated with an expansion in the 
DZ of the GC and increased proliferation. This result is also supported by the cyclic re-
entry model of the LZ and DZ of the GC and by studies looking at how Ag-presentation 
affects B cell differentiation. In particular, several reports have shown that when 
additional Ag is targeted towards a population of GC B cells, that population is 
preferentially selected to enter the DZ of the GC over memory B cell differentiation (112, 
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127). This is similar to my experiments with haMOGtag, where manipulation of T cell 
Ag-affinity promoted the transition of GC B cells to enter the DZ, opposed to Ag-avidity 
that was used in the studies mentioned above. One key difference between our model and 
the studies mentioned above, is that in my experiments all GC B cells are presenting a 
higher-affinity Ag whereas in their experiments they are targeting Ag towards a small 
population of GC B cells within the GC. Thus, in their studies they are manipulating the 
competitiveness of a specific population of GC B cells whereas in my experiments I am 
manipulating the whole GC, as all GC B cells would present the exact same Ag. Indeed, 
my results would suggest that B cell fate choices are influenced by not only competition 
between B cells for Ag, but also that presentation of higher-affinity Ags can affect B cell 
fate choices across the entire GC. 
 While I was able to show that T cell Ag-affinity affected the balance between 
memory B cells and GC B cells, manipulation of T cell Ag-affinity in our MOG system 
did not affect plasma cell generation unlike the manipulation of Ag-avidity in other 
studies (112, 127). However, it should be noted that, although haMOGtag does contain a 
higher-affinity peptide than mMOGtag, the affinity of this peptide is still much lower than 
the affinity of many foreign Ag-derived peptides typically used in such studies (261, 
350). Furthermore, the NF-M18-30 peptide used in haMOGtag has a relatively low affinity 
for MHC class II molecules resulting in incomplete presentation of this peptide (351). 
Thus, it is likely that haMOGtag only partially enhanced T cell Ag-affinity in B-T 
interactions, perhaps explaining its modest effects. Consistent with this, in our 
experiments using NPOVA and NPMOG, where there is a substantial difference in T cell 
affinity, the results were more striking. Relative to NPOVA, NPMOG was characterized 
by reduced early plasmablast expansion and reduced long-lived plasma cell generation. 
Based on these results and the results of others (112), it seems likely that there is a 
continuum where low levels of T cell help promotes memory B cell differentiation, while 
intermediate levels of T cell help promotes GC maintenance and T cells imparting the 
highest level of help promote plasma cell expansion. 
 An unexpected finding in this thesis was that TFH cells in the NPOVA, mMOGtag, 
and haMOGtag responses had the same expression of cytokines and surface receptors 
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known to influence B cell fate choices, despite clear evidence of B cells making different 
fate decisions. The only major difference between these Ags, was the absolute number of 
TFH cells that each Ag could induce. It is possible however, that the differing numbers of 
TFH cells may alone be sufficient to change B cell fate choices. In all of the experiments 
conducted in this study, the ratio of GC B cells to TFH cells remained the same, a finding 
also supported by the results of others (170, 352), suggesting that the absolute numbers of 
TFH cells by itself may determine the size of the GC B cell response. Furthermore, based 
upon the experiments in this thesis and the results of others (170), Ag can be a limiting 
factor in GCs by controlling the maintenance of TFH cells (170). In particular, Ag-
presentation by GC B cells is required for TFH cells to maintain PD-1 expression. This is 
important because PD-1 signaling is required to suppress the expression of the CXCR3 
chemokine receptor that normally directs TFH cells to leave the GC environment (180). 
Thus, it seems likely that a combination of Ag-affinity and Ag-avidity may influence the 
number of TFH cells that can be maintained in the GC, which in turn may determine the 
number of GC B cells that can be supported. Nonetheless, it should be noted that Ag-
affinity can also affect the initial differentiation of pre-TFH cells (353, 354) and thus, 
increased initial differentiation of pre-TFH cells could contribute to my findings. 
 Based upon the literature cited above, there are general rules established for how 
B cell differentiation is instructed during GC responses: first, low BCR-affinity promotes 
memory differentiation over GC B cell or plasma cell differentiation and high-BCR  
affinity promotes plasma cell differentiation over GC B cell or memory B cell 
differentiation; second, the acquisition of a high-affinity BCR is dependent on acquiring 
high-affinity mutations through SHM that is largely influenced by the time GC B cells 
stay within the DZ of the GC; lastly, presentation of larger amounts of Ag leads to 
preferential plasma cell expansion and increased LZ to DZ transitions leading to better 
GC retention of particular B cell clones in increased DZ dwell time. I have contributed to 
these rules by expanding the last point. In particular, I have shown that in addition to the 
absolute amount of Ag being presented, it is important to consider the cumulative 
affinities of those Ags as this functions similarly to the presentation of more Ag. 
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 Altogether, these results suggest a model where the absolute number of TFH cells 
controls LZ to DZ transitions. In particular, when TFH cells are limited, TFH cell help 
would also be limited making it difficult for GC B cells to gain access to the DZ of the 
GC (112). However, when TFH cells are in abundance, TFH cell help would be expected to 
be plentiful resulting in many B cells being selected to enter the DZ of the GC. As 
discussed above, how T cell Ag-affinity and the absolute number of TFH cells would 
affect plasma cell differentiation is less clear. The decision to become a plasma cell is B 
cell intrinsic (128). However, T cells can influence plasmablast proliferation (128, 156) 
and influence the long-term production of plasma cells indirectly by maintaining GCs 
over a longer period of time (126). Thus, the absolute number of TFH cells may influence 
plasmablast proliferation or the accumulation of plasma cells over time; however, 
additional experiments will be required to determine how this occurs. Putting all of these 
ideas together, a model was generated and is summarized and described in Figure 5.1. In 
the next sections I will address unresolved questions and the significance of this research. 
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Figure 5.1. A model of how T cell antigen-affinity affects germinal center progression 
Based on the results of this thesis, the initiation of GC responses is similar regardless of 
the T cell controlling the GC. However, for low-affinity Ags, the low number of TFH cells 
is limiting leading to fewer B cells acquiring sufficient T cell help. This leads to 
inefficient plasma cell expansion and failure of centrocytes to be selected to enter the DZ 
of the GC. Furthermore, this leads to B cells accumulating and persisting in the LZ of the 
GC leading to preferential memory B cell differentiation. Limited interactions between B 
and T cells also limits the maintenance of TFH cells, resulting in TFH cells losing their PD-
1high phenotype and leaving the GC. Then at the mature GC time point, an equilibrium is 
reached between the small number of GC B cells and TFH cells allowing the maintenance 
of a small GC response. In contrast, high-affinity Ags maintain themselves over longer 
periods of time by maintaining a larger TFH cell pool that can support plasma cell 
differentiation and LZ to DZ transitions in the GC. 
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5.3 Future directions 
5.3.1 Somatic hypermutation in the MOG-induced germinal center 
 One of the main functions of the GC, in particular the DZ of the GC, is to drive 
SHM (58). Differences in SHM between the NPOVA and MOG GC responses could 
potentially partially explain the collapse of MOG-induced GCs and inefficient plasma 
cell differentiation. However, SHM was not addressed in this thesis. Studying SHM is 
complicated by the need to sequence individual BCRs of GC B cells to identify mutations 
in their BCRs. These mutations also need to be mapped, cloned, and expressed to test 
how each mutation contributes to the affinity of the antibody/BCR. Mutations and their 
affinities have been mapped for the NP system using B1-8 mice, indeed, the NP-system 
has been used extensively for the study of SHM (355). In this study, we could not 
conduct similar research as mutations in the IgHMOG BCR have not been mapped, which 
requires a significant amount of work and was beyond what could be accomplished in 
this thesis. Nonetheless, preliminary experiments to determine how autoreactive T cells 
affect SHM could make use of the NPOVA and NPMOG systems, as the tools for 
analyzing the NP response are already available (274).  
 This avenue of research would be of interest in the future as this could help 
solidify the GC model I suggested above. In particular, I would expect that the MOG-
induced GC would be characterized by low SHM and that SHM would be restored upon 
immunizing with haMOGtag, as haMOGtag could support a sizable DZ. Presumably, 
centroblasts would have a sufficiently longer DZ dwell time to permit efficient induction 
of SHM (112). It should be noted however, that in some scenarios excessive TFH cell 
support can inhibit SHM as a result of excessive selection of centrocytes for entry into 
the DZ of the GC making it difficult to specifically expand high-affinity B cell clones 
(356). Thus, it possible that additional T cell help would not promote SHM. Nonetheless, 
based upon the results of Chapter 3, immunization with haMOGtag approached but did not 
exceed the DZ proportions of the NPOVA GC, which effectively supports SHM and the 
selection of high-affinity GC B cells (123), suggesting that immunization with haMOGtag 
would not represent excessive T cell help. 
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 Another unresolved finding of this thesis is that although MOG-specific GCs start 
as being predominantly MOG-specific, over time MOG-specificity appears to decrease, 
something that is not seen with the NPOVA system. A similar phenomenon has been 
described before where GC B cells undergo SHM to mutate their autoreactive BCRs to 
become non-autoreactive (104, 357-359). In these scenarios, autoreactive B cells first 
mutate their BCR to decrease their affinity for epitopes on the endogenously expressed 
autoAg, then mutate their BCRs towards any foreign-epitopes on the immunizing-Ag. Of 
key significance, as this process had been described to be dependent on the endogenous 
expression of the autoAg, we can test whether this process is occurring in our 
autoreactive GCs by taking advantage of MOG deficient mice (351), thereby eliminating 
the endogenous Ag. 
 Another scenario where using MOG-deficient mice would be useful is in 
understanding why MOG-specific memory B cells have a short life-span. In Figure 3.9, I 
showed that autoreactive T cells were not responsible for programming unstable B cell 
memory suggesting that the reduced life-span of autoreactive memory B cells was due to 
some factor intrinsic to the autoreactive B cell or its environment. Using MOG-deficient 
mice, we could determine whether endogenously expressed MOG, available in tissues 
such as the deep cervical LNs (69, 70), is leading to activation-induced cell death of 
MOG-reactive B cells as I would expect MOG-specific memory to be more stable in a 
setting where no endogenous MOG is available. Additionally, if the MOG-deficient 
background was crossed onto the IgHMOG mouse to generate MOG-specific B cells that 
pass through immune tolerance unaffected, we could assess whether the reduced life-span 
of MOG-specific memory B cells is as a result of anergy induced during development 
(30). Indeed, we cannot be sure at this time that MOG-specific B cells do not start in an 
anergic state and that being drawn into an immune response would reverse anergy in 
these cells. 
5.3.2 T cell antigen-affinity and the germinal center 
 In Chapter 3 of this thesis, there were unaddressed confounding factors 
influencing the interpretation of how T cell Ag-affinity affects the GC: 1st, Many of my 
experiments make use of two different T cells that differ in autoreactivity making it 
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unclear whether autoreactivity or low T cell Ag-affinity was affecting my results; 2nd, in 
my experiments using haMOGtag the differences in affinity were not substantial and lead 
to only modest changes in the GC response. Thus, to more firmly establish how T cell 
Ag-affinity affects the GC response, I would need to make use of an Ag-model system 
that eliminates autoimmunity and has a greater range of T cell Ag-affinities that can be 
manipulated. Both of these issues could be addressed using the NPOVA system using 
B1-8 B cells and OTII T cells. The NP-based system is useful as NP can be attached to 
any protein allowing for the B cell side of the immune response to be standardized to any 
protein (360). The OTII T cell is also useful as it recognizes the OVA323-339 peptide with 
a high-affinity (250) and it is easier to design mutated peptides (known as altered peptide 
ligands) that lower T cell Ag-affinity than it is to increase T cell Ag-affinity. Indeed, 
several altered peptide ligands of the OVA323-339 peptide have been described making it 
possible to clone and express a series of OVA proteins exhibiting a gradient of T cell Ag-
affinities (250, 251). Overall, this system would not only provide more precise control of 
T cell Ag-affinity, but it will also eliminate the confounding factor of autoreactivity. 
Nonetheless, these results could also be validated using the haMOGtag system if done on 
a MOG-deficient background to eliminate autoreactivity in IgHMOG B cells, 2D2 T cells, 
and eliminate endogenous MOG-expression in the recipient environment. 
5.3.3 Signal exchange and interaction duration of B and T cell conjugates 
 As I elaborated on in Chapter 4 of this thesis, there are several basic aspects of the 
B and T cell interaction that are still not understood. In particular, it is not known what 
the kinetics of signal exchange between B and T cells is during their interactions. This is 
important as interactions can differ substantially in duration (78). Thus, it is not clear 
whether signals can be effectively exchanged within a short-interaction or that signals 
continue to be exchanged during long-interactions. This question requires the usage of 
reporters such as the ones I had attempted to make in Chapter 4 of this thesis, which 
would allow for real-time quantification of signaling in B and T cells as they interact in 
living tissue. Indeed, if these reporter mice are successfully generated in the future, they 
will be used to answer these questions. 
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 Beyond understanding the basic rules that govern B cell differentiation during B 
and T cell interactions, these results are also likely relevant to the GC responses I have 
characterized in this thesis. A promising explanation for how Ag-properties influence B 
cell fate choices is that Ag-properties affect signal exchange between B and T cells 
during their interactions. Indeed, the Kerfoot laboratory has found that during the pre-GC 
phase of the immune response, B and T cells form shorter interactions in response to 
MOG relative to NPOVA (Figure 5.2A). Furthermore, when we immunize with 
NPMOG, we get an intermediate phenotype consistent with the intermediate phenotype I 
saw in Chapter 3. Consistent with our results, others have seen that increased interaction 
duration promotes GC B cell differentiation over memory B cell differentiation and 
promotes ASC differentiation over GC B cell differentiation (112, 127). Thus, interaction 
length may play a key role in determining B cell differentiation to these different Ags. 
The maintenance of physical interactions between B and T cells is dependent on the 
expression of SLAM proteins and ICAMs (160). Preliminary evidence suggests that 
SLAM and ICAM-1 are upregulated on B cells when immunizing with NPOVA; 
however, this fails to occur on MOG specific B cells and NPMOG immunization results 
in an intermediate phenotype (Figure 5.2B). Thus, differential expression of ICAM-1 
molecules and SLAM receptors that modify cellular adhesion may be responsible for the 
differences in interaction length that we have seen. Further work will need to characterize 
explicitly how Ag-properties influence the upregulation of these molecules on B cells, 
whether these differences in receptor expression on B cells are truly determining 
interaction length, and by extension, influencing how B cells are differentiating. 
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Figure 5.2. Pre-GC B and T cell interactions are influenced by properties of immunizing 
Ags. 
(A and B) Fluorescent protein-marked Ag-specific B and T cells were transferred into 
non-fluorescent protein-marked SMARTA recipient mice then immunized with the 
indicated Ag two days post-transfer. Two days post-immunization, the popliteal LN was 
exposed for intravital two-photon microscopy to track Ag-specific B and T cell 
interactions over time (A) or LNs were processed for flow cytometry analysis (B). (B) N 
is IgD- CD19+ GFP- B cells, Ag is IgD- CD19+ GFP+ B cells. *p<0.05, **p<0.01, 
****p<0.0001. Data courtesy of Dr. Parham. 
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5.4 B cells in MS and EAE 
 In addition to acquiring a better understanding of the basic biology of GC 
responses, the results of this thesis have important implications to the autoimmune 
disease MS and its animal model EAE. In particular, there is the idea that myelin-specific 
B cells are activated in the deep cervical LNs and that these cells are fueling a myelin-
specific B cell response in the CNS (68-70). Nonetheless, despite evidence of myelin-
specific GCs occurring in MS (62), no other study beyond the work in this thesis has 
characterized a myelin-specific GC. Indeed, the short-lived nature of myelin-specific GCs 
is likely to have several implications in how we look at MS. 
 Currently, the memory B cell subset appears to be a promising candidate for the 
pathogenic subset in MS (5, 361). In this thesis, I found MOG-specific GCs produced 
memory B cells in abundance at the early stages of the GC response; however, these cells 
were short-lived. Given that memory B cells have recently been shown to be potent 
inducers of myelin-specific T cell responses (361), then it would be expected that their 
short life span would represent a major limitation in driving the disease. Indeed, this 
would suggest that myelin-specific B cells would need constant replenishment to 
continue to fuel the autoimmune response and thus, would be therapeutically targetable 
throughout MS.  Consistent with the idea autoreactive GCs require replenishment, MS 
relapses are associated increased numbers of circulating memory TFH cells, that are 
generated during the initiation of GCs and throughout GCs (94), suggesting the induction 
of autoreactive GCs coincides with disease progression (362, 363).  
 One possibility that was not fully addressed in this thesis or in the MS literature in 
general, is that some of the cells that we are defining as memory B cells may actually be 
ABCs. This population is produced from GC responses to most Ags (166) and has a 
tendency to localize to the B cell follicle-T cell zone border where they can interact with 
T cells and promote T helper 17 cell differentiation (148), a T cell subset associated with 
the promotion of MS and EAE (364-367). Indeed, when looking at GC histology, many 
GFP+ B cells can be seen at the B cell follicle-T cell zone interface although presently it 
cannot be definitively determined whether these cells are ABCs. Nonetheless, knowing 
whether ABCs are being generated in GCs would be of interest as this population appears 
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to be expanded in MS patients and also shows evidence of disproportionate 
representation in the cerebral spinal fluid of MS patients relative to peripheral blood 
suggesting these cells actively accumulate in the inflamed CNS (141). 
 Beyond my analysis of GCs and memory B cells, I also found that when 
immunizing with our MOG Ag, I could induce Ag-specific plasma cell responses 
including the generation of long-lived plasma cells that could be detected as late as d39 
post-immunization. This would suggest that even a single GC response directed against a 
myelin autoAg is sufficient to drive an antibody response including the generation of 
long-lived cells that can maintain antibody production over time. Although antibodies are 
not the main driving factor in MS (368), they can exacerbate damage (61-63) and thus, 
should ideally be suppressed. However, if these plasma cells are actually long-lived, then 
halting their production is unlikely to appreciably affect their numbers as it would require 
a great deal of time for the long-lived plasma cells to die off. Altogether, these results 
would suggest that the therapeutic targeting of autoreactive GCs to induce a full collapse 
would quickly lead to the deterioration of myelin-specific memory B cells as these cells 
would not be renewed; however, long-lived plasma cells would persist. 
5.5 Concluding remarks 
 The focus of the research conducted in the Kerfoot laboratory is to understand the 
basic rules governing B cell differentiation and establishing the role of B cells in MS. The 
work in this thesis bridges the gap between these two goals by establishing the rules that 
govern myelin-specific GC development, but also doing this in a model that is relevant to 
CNS autoimmune disease. Indeed, relative to the development of GCs towards foreign-
Ags, the GC response against MOG diverges significantly from the expected trajectory of 
a foreign-Ag resulting in plenty of opportunities to look at factors that influence B cell 
differentiation. This thesis focused predominantly of how T cells contribute to the 
collapse of autoreactive GCs. However, as shown in the above sections, there may also 
be differences between MOG and foreign-Ag specific B cells that may be contributing to 
the differential GC progression I have seen. Furthermore, I do not know how the 
autoreactive origins of the B and T cells I studied or how the expression of endogenous 
autoAg may be contributing to GC progression. Both of these issues will need to be 
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studied in more detail. Thus, the results of this thesis points to several different avenues 
of research on basic B cell biology that will need to be addressed in the future. 
 Additional work is also needed to characterize how myelin-specific B cells 
contribute to EAE. I have shown that MOG-specific B cells can be expanded through 
immunization with MOG and I and others have shown that MOG-specific B cells 
contribute to EAE. Nonetheless, it is still not known how or where MOG-specific B cells 
contribute to EAE. Thus, future research will need to characterize how the subsets of B 
cells produced in MOG-specific GCs, are contributing to EAE. Overall, the research in 
this thesis into the manipulation of B cell responses may be valuable in vaccine design, 
but also for understanding how autoreactive B cell responses initiate and progress. 
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